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Endometrial cancer is the most common gynecologic malignancy in the western world and the 
fourth commonest site after breast, colorectal, and lung cancer.1, 2 It accounts for 1,930 new cases 
and 425 cancer-related deaths in the Netherlands each year.3 Most cases are diagnosed after 
menopause, with the highest incidence around the sixth decade of life.4 Symptoms of endometrial 
cancer appear early in the course, which explains why most women have early-stage disease at 
presentation. In these cases, the disease is commonly confined to the uterus and can usually be 
cured by surgery only. The presence of extra-uterine disease significantly affects recurrence rates 
and survival, emphasizing the importance of identification of sites of disease spread and provision 
of appropriate adjuvant postoperative therapy.5 Pathological examination is the cornerstone 
of diagnosis of endometrial cancer, and different histopathological types of carcinoma can be 
distinguished. The majority of endometrial cancers are low-grade tumors with endometrioid 
histology, which have a good prognosis. Endometrioid endometrial carcinoma (EEC) comprises 
about 80% of all endometrial carcinomas, and typically presents at an early stage, in relatively 
younger women with obesity, hyperlipidemia, and signs of hyperestrogenism (either endogenous 
or exogenous). Recurrent disease is usually local, with the pelvis being the most common site, and 
it is frequently curable with tumor-directed radiotherapy.4, 6
SEROUS ENDOMETRIAL CARCINOMA
Uterine papillary serous carcinoma (UPSC) is a highly aggressive subtype of endometrial cancer 
that represents approximately 10% of all endometrial cancer diagnoses, but is disproportionately 
responsible for up to 50% of all treatment failures and 40% of all endometrial cancer-related 
deaths.7-9 UPSC is histologically similar to serous ovarian carcinoma (SOC) and was first established as 
a distinct subtype of endometrial cancer in 1981.10, 11 UPSC was found to have a distinct microscopic 
appearance, epidemiology, and clinical behavior in comparison with the more common low-risk 
EEC (Table 1).12 UPSC most often presents with metastatic disease at the time of diagnosis, is at high 
risk of recurrence, often arises in lean, older women, and demonstrates no hormonal risk factors.10, 13, 
14 While clinicopathologic risk factors for recurrence and survival have been delineated quite clearly 
for EEC, prognostic factors such as lymphovascular space invasion (LVSI), myometrial invasion, and 
tumor size did not impact on recurrence risk or survival in UPSC patients.8, 9, 15, 16
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Table 1: Contrasting features of endometrioid versus serous endometrial carcinoma.
Feature EEC UPSC
Demographics Younger age (mean age 60 years old)
Obesity
Older age (mean age 70 years old)
Normal BMI 
Risk factors Hyperestrogenism
Obesity
Hyperlipidemia
Pattern of recurrence Local Distant
Precursor lesion Atypical hyperplasia EIC
Histologic grade Low, intermediate, or high High
Molecular changes PTEN gene mutation
KRAS gene mutation
Defective DNA mismatch repair (MSI)
TP53 gene mutation
HER-2/neu gene amplification
Stage at presentation I   (73%)
II  (11%)
III (13%)
IV (3%)
I   (54%)
II  (8%)
III (22%)
IV (16%)
Survival by stage I    (85-90%)
II   (70%)
III  (40-50%)
IV (15-20%)
I   (50-80%)
II  (50%)
III (20%)
IV (5-10%)
EEC: endometrioid endometrial carcinoma; UPSC: uterine papillary serous carcinoma; MSI: microsatellite instability; BMI: body mass 
index; EIC: Endometrial intraepithelial carcinoma. Table adapted from Boruta et al.17
CLINICAL MANAGEMENT OF UPSC
Uterine papillary serous carcinoma not only resembles SOC morphologically, but also in its clinical 
behavior, characterized by high recurrence and mortality rates even in early stages of disease. Due 
to its rarity, most clinicians are unfamiliar with the clinical aspects and management of UPSC. At 
present, no prospective randomized trials have been performed to establish a standard treatment 
approach. The existing data are derived exclusively from relatively small retrospective single and 
multi-institutional studies with limited statistical power and considerable heterogeneity with 
regard to treatment approach. This inevitably causes uncertainty regarding preferred treatment, 
and to date, treatment of UPSC is therefore usually a hybrid of the standard approaches for both 
ovarian and endometrial cancers, incorporating surgery, chemotherapy, and radiotherapy.17-19 
Surgery & Staging
Endometrial cancer is a surgically staged disease, because clinical estimates and preoperative 
imaging of the extent of disease are incorrect in over 20% of cases.20 Therefore, the first introduced 
clinical staging system for endometrial cancer by the International Federation of Obstetricians and 
Gynecologists (FIGO)21 was changed to a surgical staging system in 1988.20, 22 The similar prognosis 
of stage IA and IB patients, the uncertainty of defining endocervical glandular involvement, the 
recognition of the favorable prognosis in patients with only isolated positive peritoneal cytology, 
and the poor prognosis in patients with para-aortic lymph node metastasis, led FIGO to revise the 
1988 staging system in the year 2009 (Table 2).23, 24
Table 2: FIGO staging (2009) for endometrial carcinoma.
Stage I Tumor confined to the uterus
    IA No or less than half myometrial invasion
    IB Invasion equal to or more than half of the myometrium
Stage II Tumor invades cervical stroma, but does not extend beyond the uterus*
Stage III Local and/or regional spread of the tumor
    IIIA Tumor invades the serosa of the corpus uteri and/or adnexa$
    IIIB Vaginal and/or parametrial involvement$
    IIIC Metastases to pelvic and/or para-aortic lymph nodes$ 
Stage IV Tumor invades bladder and/or bowel mucosa, and/or distant metastases
    IVA Tumor invades bladder and/or bowel mucosa
    IVB Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes
*Endocervical glandular involvement only should be considered as Stage I and no longer as Stage II; $Positive peritoneal cytology has 
to be reported separately without changing the stage. Adapted from Creasman et al. and Zaino et al.23, 24
The most important therapy for endometrial cancer patients is surgery. The standard surgical 
procedure includes total hysterectomy including the uterine cervix, and bilateral salpingo-
oophorectomy. To date, there is no worldwide consensus whether pelvic and/or para-aortic 
lymphadenectomy should be performed as part of the staging procedure.25-27 According to 
the Dutch guideline, pelvic and/or para-aortic lymphadenectomy should not be performed in 
patients with EEC and no suspicion of extra-uterine disease. Primary surgery alone is curative in 
most endometrial cancer patients in whom disease appears to be confined to the uterus on final 
histopathological examination, as is common in EEC patients. Only 8-13% of the EEC patients have 
cervical involvement, and about 3-7% will have extra-uterine disease  at the time of diagnosis.28, 29
However, this surgical staging approach routinely used in EEC patients may not be adequate in 
patients with UPSC. Typically, 55-87% of UPSC patients have metastatic disease at the time of 
diagnosis16, 30-32, and approximately 40-70% of clinical Stage I UPSC patients are therefore upstaged 
at the time of surgical staging.31-33 Since the clinical behavior and trans-peritoneal spread of UPSC 
resembles that of SOC, the same surgical management was suggested. This comprehensive surgical 
staging includes total hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic and para-
aortic lymph node sampling, omentectomy or omental biopsy, and biopsy of any suspect lesions. 
Various studies have recently emerged showing first data on a favorable impact on survival in 
comprehensively staged UPSC patients compared to patients treated by a more conservative 
surgical approach.30, 31, 34-37 Selectively performing a comprehensive staging procedure in UPSC 
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patients, based upon uterine factors such as myometrial invasion or LVSI, seemed not reliable in its 
ability to assess the overall disease status.33, 38, 39 
Furthermore, questions were raised whether to perform complete debulking surgery with 
maximum cytoreduction in all stages of UPSC. The beneficial role of complete cytoreduction has 
already been demonstrated in ovarian cancer patients.40, 41 Since its close clinical resemblance with 
SOC, some investigators have addressed the importance of cytoreductive surgery in UPSC patients. 
Indeed some retrospective studies found a favorable effect of complete cytoreductive surgery on 
survival, mainly in UPSC patients with advanced stage of disease (FIGO stage III – IV).34, 42, 43 However, 
because proper prospective trials are currently lacking, it is still unknown how best to treat patients 
with UPSC. 
Adjuvant treatment
Given the excellent prognosis of early stage low-risk EEC, adjuvant therapy is considered 
unnecessary in most cases. In case of advanced stage EEC, the mainstay of adjuvant post-operative 
treatment is radiotherapy. Alternatively, UPSC patients often present with extra-uterine disease 
and have a poor prognosis with a high recurrence rate, primarily extra-pelvic in nature. As a result, 
this limits the ability of radiotherapy, as a single modality, to be delivered with curative intent in 
UPSC patients. Most studies on radiotherapy as adjuvant treatment modality have focused on 
whole abdominopelvic irradiation (WAPI), whole pelvic radiotherapy (WPRT), and whole abdominal 
radiotherapy (WART). However, diverging results on the effect of radiotherapy on disease-free and 
overall survival have been reported.18, 39, 44, 45 Furthermore, the benefit of vaginal brachytherapy 
in the adjuvant setting for UPSC patients remains controversial.46-48 The high frequency of extra-
uterine disease at the time of presentation, along with treatment failures within the radiation fields, 
and the histological and biological similarities between UPSC and SOC, have led to an increasing 
interest for using chemotherapy as adjuvant treatment modality in UPSC patients. The combination 
of platinum-based chemotherapy with the addition of taxanes has produced promising results, with 
significant improvement of recurrence rates and survival outcome for all stages of UPSC.8, 17, 44, 49-53 
However, the benefit of chemotherapy in an adjuvant setting, relative to solely radiation therapy 
or combined treatment, remains untested in randomized clinical trials in different stages of UPSC 
disease. Therefore, the optimal adjuvant treatment approach for patients remains elusive.
PREOPERATIVE ASSESSMENT IN UPSC PATIENTS
Endometrial biopsy
Women with endometrial cancer often present with abnormal (e.g. postmenopausal, 
perimenopausal, or irregular) vaginal bleeding. Histopathological examination has been the 
cornerstone for the diagnosis of endometrial carcinoma. Endometrial biopsy, performed with an 
endometrial pipelle in the outpatient clinic, is minimally invasive. It is usually the first step for any 
woman presenting with abnormal bleeding and currently the standard of care procedure to obtain 
a preoperative histopathological diagnosis. Dilatation and curettage (D&C) remains the diagnostic 
procedure of choice when endometrial biopsy is not feasible or when biopsy specimens are not 
conclusive for the pathologist.27, 54 UPSC is known mostly to arise from an atrophic endometrium or 
from endometrial polyps.15, 55, 56 False-negative results for both endometrial biopsy and curettage 
have been found to occur when tumors are localized to a polyp or to a small surface area of the 
endometrium.57, 58 Furthermore, preoperative diagnosis of the histological type on biopsies or 
curettage specimen can be challenging, with up to 20% of the diagnoses of histological type being 
altered after surgery.59, 60 In part, this inaccuracy may occur because UPSC is often found admixed 
with other histological subtypes within an uterine specimen.59 
Cervical cytology
Investigators have sought for other minimally invasive preoperative methods to detect uterine cancer 
and to determine high-risk histology or metastatic disease. Already in the 1980’s cytopathologists 
recognized that endometrial cells in cervical cytology were suspicious for endometrial pathology 
in menopausal women.61 However, in asymptomatic women, cervical cytology appeared to be a 
poor screening tool for endometrial carcinoma.62 Although the incidence of cervical cytology with 
atypical or malignant endometrial cells is low among patients with endometrial cancer, abnormal 
cervical cytology was predictive for endometrial pathology and associated with poor prognostic 
factors.61-69 It was noticed that UPSC patients may have atypical or malignant endometrial cells within 
their preoperatively taken cervical cytology more often. Incidence rates have varied though70-73, and 
evidence for an association with poor prognostic factors or survival specifically in UPSC patients is 
lacking.
Serum CA-125
A particularly troublesome feature of UPSC has been the inability to predict extra-uterine spread 
of disease preoperatively based on the primary diagnostic endometrial biopsy or D&C specimen. 
Furthermore, uterine prognostic factors such as LVSI, myometrial invasion, and tumor size were 
invariably not able to predict extra-uterine disease in UPSC patients.9, 15-17 Since its discovery in 
198374, the clinical application of the tumor-associated antigen CA-125 has been widely explored. 
Various studies and prospective trials have demonstrated and validated the clinical utility of serum 
CA-125 in aspects pertaining to ovarian cancer.75-78 The histologic similarities between UPSC and 
SOC and both their propensity for intra-abdominal spread have led investigators to explore the 
potential role of serum CA-125 to evaluate the disease status in women with UPSC. At present, only 
a limited number of studies have addressed this issue and there have been conflicting results as to 
CA-125 and its utility in predicting recurrence.79, 80 In addition, few studies have explored the role 
of preoperative serum CA-125 in predicting extra-uterine disease and clinical outcome specifically 
in women with UPSC. Some found that preoperatively elevated CA-125 was associated with extra-
uterine disease at the time of surgery and that it was predictive for reduced survival81, 82, while 
others reported that the preoperative level of CA-125 was not predictive for complete or suboptimal 
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cytoreduction and survival.83 Further studies are needed to address whether elevated serum CA-
125 may be a true surrogate marker for extra-uterine disease and poor clinical outcome in UPSC 
patients. 
HISTOPATHOLOGY OF UPSC
As mentioned earlier, UPSC has a similar morphology as SOC, its homologue in the ovary, and 
both have a tendency to produce ascites and spread along mucosal and peritoneal surfaces. Since 
UPSC should be treated more aggressively, it must be distinguished histopathologically from 
other subtypes of endometrial carcinoma. Histologically, UPSC demonstrates a complex papillary 
growth pattern, although glandular and solid patterns may also occur, with numerous mitotic 
figures, fibrovascular micro-papillae and large, branching glands lined by papillary tufts composed 
predominantly of cuboidal or hobnail cells. Marked nuclear atypia is always present (Figure 1A and 
1D).10, 11, 84 Psammoma bodies are commonly present within the tumor but are not a prerequisite for 
the diagnosis of UPSC.10, 55 Recent studies have emphasized that UPSC varies widely in appearance, 
including tumors composed largely or exclusively of gaping glands with intraluminal papillary 
proliferations, tumors associated with benign polyps, and mixed tumors in which serous carcinoma 
coexist with endometrioid, clear cell, or undifferentiated patterns.55, 84 There is controversy regarding 
the effect of this mixed versus pure UPSC histology on recurrence risk and survival outcome. It was 
proposed that mixed tumors, even in which only 10% of the carcinoma appeared serous, usually 
behave as aggressively as pure UPSC.10, 19, 36, 55 In contrast, others described a more favorable survival 
outcome for patients with mixed UPSC compared to pure UPSC.18 Further studies are needed to 
elucidate the potential effect of mixed versus pure UPSC histology on recurrence risk and survival 
outcome.
Precursor of UPSC
The widely accepted pathogenic pathway for low-risk EEC starts with long-lasting unopposed 
oestrogen exposure leading to endometrial hyperplasia, which increases the chance of development 
of endometrial hyperplasia with atypia, and eventually of endometrial cancer with endometrioid 
histology. In contrast, at present less is known about the early events in UPSC carcinogenesis. This 
is partly the result of the rarity of UPSC compared to its EEC counterpart, and of the probable rapid 
emergence of UPSC from an apparently normal state with a small window for clinical detection of 
early disease. Histopathologic studies have suggested that the majority of UPSC develop from a 
distinctive lesion termed endometrial intraepithelial carcinoma (EIC), which appears to represent 
malignant transformation of atrophic surface endometrium without myometrial invasion.55, 85, 86 This 
was supported by the observations that EIC was often multicentric, topographically related and 
immediately adjacent to the invasive UPSC (Figure 1B and 1C).85-87 In addition, the transition from 
non-neoplastic endometrium to EIC was invariably abrupt, and the presence of EIC in association 
with UPSC confined to endometrial polyps was found to be suggestive for EIC as an early event in 
the pathogenesis of UPSC. EIC was identified in most uteri containing UPSC, but was rarely found 
in specimens containing other histological subtypes of endometrial cancer.85-87 The uninvolved 
endometrium in uteri containing UPSC was usually atrophic and rarely showed endometrial 
hyperplasia.15, 55, 85, 86 The incidence of EIC specifically in mixed compared to pure UPSC cases is 
currently unknown.
 
Figure 1: Uterine papillary serous carcinoma (UPSC). A) Overview of full-blown UPSC with invasive 
properties and complex papillary growth (level of magnification: 50x). B & C) The distinctive precursor 
lesion endometrial intraepithelial carcinoma (EIC) represents malignant transformation of atrophic surface 
endometrium without myometrial invasion, and is immediately adjacent to the invasive UPSC (level of 
magnification: 200x). D) In detail view of UPSC, with its complex papillary growth, numerous mitotic figures, 
and marked nuclear atypia (level of magnification: 400x).
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ORIGIN OF SEROUS OVARIAN CARCINOMA
Ovarian cancer is the most lethal of all gynecological malignancies.1 Serous ovarian carcinoma 
(SOC), histologically similar to its endometrial counterpart UPSC, is the most common of the ovarian 
epithelial malignancies, accounting for approximately 70-80% of cases.88 The poor prognosis of 
this disease is attributable to its propensity for serosal organ involvement and peritoneal spread, 
resulting in up to 60-80% of patients presenting with advanced stage of disease (FIGO stage II-IV).88, 
89 Attempts at screening and early detection of ovarian cancer, using a combination of transvaginal 
ultrasound, measurement of serum CA-125, and other biomarkers, have largely been unsuccessful.90-92 
Furthermore, early detection is also hindered by uncertainty as to the histologic origin and early 
natural history of this malignancy. The cell of origin of ovarian cancer has long been debated. Until 
recently, the paradigm was that epithelial ovarian cancer arises from the ovarian surface epithelium 
(OSE). OSE is composed of flat, nondescript cells more closely resembling the mesothelium lining 
the peritoneal cavity, with which it is continuous, rather than the various histologic types of ovarian 
carcinoma (serous, endometrioid, and clear cell) that have a Müllerian phenotype. Accordingly, the 
traditional view of ovarian carcinogenesis assumes that ovarian carcinoma originate from the OSE 
(mesothelium), undergoing a process called metaplasia that accounts for a profound morphologic 
transformation. Invagination of the metaplastic OSE into the underlying stroma results in epithelial 
inclusion cysts that eventually undergo malignant transformation.93-96 However, molecular and 
clinicopathologic studies have failed to support this hypothesis, and epithelial inclusion cysts were 
invariably present in both high risk cases and controls.97, 98 In addition, a precursor lesion was never 
identified in the ovary itself. 
SOC originating in the fallopian tube
In the most widely accepted theory for serous ovarian carcinogenesis to date, the fallopian tube 
has recently emerged as an important source for female pelvic serous carcinoma. The Müllerian 
(paramesonephric) tubes are known to develop into the upper part of the vagina, uterus and 
fallopian tubes during early embryogenesis. The lack of an identified ovarian precursor lesion 
and the fact that a bilateral salpingo-oophorectomy needs to be performed to protect female 
BRCA mutation carriers for ovarian cancer99, 100 have led researchers to put forward the fallopian 
tube as a possible source of SOC. The original lining of the fallopian tube consists of Müllerian type 
epithelium and malignant transformation of these cells would logically result in a serous carcinoma 
cell type. Recently, an early form of serous carcinoma in the fallopian tube of female BRCA mutation 
carriers was identified, and this precursor lesion was termed serous tubal intraepithelial carcinoma 
(STIC).101-103 It was hypothesized that cells from these lesions may be dislodged and implant in the 
ovary. However, the incidence of STIC has varied widely, and a spectrum of putative and possibly 
non-obligate precursor lesions have been described in the fallopian tube.101, 104-107 Furthermore, 
the diagnosis and reporting of these lesions may sometimes be problematic with poor diagnostic 
reproducibility104, 108, and most studies were lacking a proper control group to differentiate between 
true premalignant lesions and histological variants of normal tubal epithelium. 
SOC originating in the uterus
The histologic and morphologic properties of ovarian carcinoma show striking similarities to 
those of extra-ovarian tissues that are of Müllerian origin. Interestingly, both tubal ligation and 
hysterectomy have repeatedly shown a protective effect on the incidence of ovarian cancer.109-111 
UPSC has a very close resemblance to SOC, serous fallopian tube cancer, and other types of pelvic 
serous cancers, both morphologically and in clinical behavior. A subset of tubo-ovarian serous 
carcinoma coexist with UPSC of the endometrium. In most cases, multifocal serous carcinomas 
were presumed to originate from a single rather than multiple sites.112-114 In addition, although EIC 
has been described as precursor lesion of UPSC, cases of metastatic disease have been reported 
in patients with only EIC in their uterus, suggesting that EIC may be, in and of itself, a malignant 
lesion and not just a precursor.38, 115, 116 At present, the uterine specimens of SOC patients have never 
been extensively studied for the presence of a precursor lesion to elucidate the possibility of SOC 
primarily originating in the uterus.
A paradigm shift resulting in most ovarian and pelvic serous carcinoma being considered to be 
of fallopian tube or endometrial, rather than ovarian origination could have significant clinical 
implications in the near future.
OUTLINE OF THIS THESIS
In this thesis we investigate a large cohort of UPSC patients, and focus on preoperative markers 
and clinicopathological variables whether these can be used as predictors or prognosticators in 
the clinical management of UPSC. Furthermore, improving care for women with UPSC also requires 
further understanding of the pathogenesis of this endometrial cancer. We focus on different 
histopathological aspects of UPSC, including the incidence of the precursor lesion EIC in both pure 
and mixed UPSC cases. 
In Chapter 2 we review the current literature on the clinical management of UPSC patients, in order 
to gain more insight whether or not a comprehensive staging procedure should be performed, with 
or without maximum cytoreduction, as is currently standard practice in ovarian cancer patients. 
Furthermore, we give an overview of various adjuvant treatment modalities and evaluate the effects 
of radiotherapy and chemotherapy in UPSC patients. 
At present, it remains difficult to predict metastatic disease and survival outcome in UPSC patients 
already in a preoperative setting. Serum CA-125 has already proven its utility as a prognostic marker, 
for monitoring the clinical response to treatment, and for the detection of recurrent disease in 
patients with ovarian cancer. In Chapter 3, we investigate whether serum CA-125 can be used as 
a preoperative tumor marker for the prediction of extra-uterine disease and as prognosticator for 
survival specifically in patients with UPSC. 
Chapter 1 Introduction
2120
Chapter
 1
Furthermore, in Chapter 4 we assess whether cervical cytology can be used as predictor for 
metastatic disease, as prognosticator for survival, and as additional tool in the preoperative work-
up of endometrial cancer patients to suspect a high-risk endometrial carcinoma like UPSC. 
After final histopathological examination of the surgical specimen, UPSC often shows morphologic 
heterogeneity containing an additional histological subtype. In Chapter 5, we set out to investigate 
whether pure versus mixed UPSC histology has an impact on recurrence risk and survival. 
Furthermore, the role of EIC as precursor lesion in the etiology of both pure and mixed UPSC is 
assessed. 
Despite extensive research, never a precursor lesion of SOC has been identified in the ovaries itself. 
Because STIC in the fallopian tube was recently described as a potential precursor lesion for SOC, in 
Chapter 6 we evaluate the fallopian tubes of BRCA mutation carriers at risk for SOC and controls for 
the presence of this precursor lesion.
Since UPSC and SOC are histopathologically identical, show a similar clinical behavior, and the 
fact that hysterectomy and tubal ligation had a vast impact on the incidence of SOC, we study the 
hypothesis of EIC as possible precursor lesion for SOC in Chapter 7. The endometrium of patients 
with SOC is reviewed extensively for the presence of possible premalignant lesions. SOC patients 
with coinciding EIC in their uterine specimens are selected, and immunohistochemistry as well as 
TP53 mutation and DNA ploidy analyses are used to provide first evidence for EIC as lesion of origin 
for SOC.
Finally, in Chapter 8 the results of this thesis are discussed in general, and future studies and 
hypotheses based on the abovementioned studies are proposed.
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ABSTRACT
Uterine papillary serous carcinoma (UPSC) is an aggressive variant of 
endometrial cancer. Owing to its rarity, most clinicians are unfamiliar with 
the clinical aspects and management of UPSC. Furthermore, little prospective 
evidence exists regarding how best to treat this subset of patients. In anticipation 
of prospective clinical trials, this review summarizes the latest results of various 
clinical management options in the different substages of UPSC, with a special 
focus on the effects of cytoreductive surgery, comprehensive surgical staging 
and different adjuvant treatment options in relation to recurrence rate and 
survival outcome.
INTRODUCTION
Endometrial carcinoma is the most common malignancy found in the female genital tract, 
comprising 40,100 new cases in the USA in 2008, and 1800 new cancers and 400 deaths annually 
in The Netherlands.1,101 The majority of endometrial carcinomas (~70–80%) have an endometrioid 
histology. These tumors typically present at an early stage, have an excellent prog nosis and are 
designated as type I tumors.2-4 Type II endometrial carcinomas mainly involve serous and clear-cell 
carcinomas, are poorly diff erentiated, and have a tendency for deep inva sion into the myometrium, 
a high frequency of extra-uterine metastatic spread and a poor prognosis.2,5-7 
Uterine papillary serous carcinoma (UPSC) is the prototypical type II carcinoma. It rep resents only 
3–9% of all endometrial cancers, but accounts for up to 39% of all endometrial cancer deaths and 
is therefore recognized as an unusually aggressive tumor.1,7-10 Owing to its rarity, most clinicians 
are unfamiliar with the clinical aspects and management of UPSC. Furthermore, little prospective 
evidence exists regarding how best to treat this subset of patients. At present, treatment is mainly 
based on outcomes of retrospective analyses that mostly lack size and power. Over the years, 
treatment modalities have varied and staging procedures have undergone drastic changes, from 
clinical to surgical to comprehensive sur gical staging. Therefore, extrapolation of the best treatment 
strategy has been difficult. There is still no consensus on staging procedure and adjuvant therapy, 
and there is an urgent need for evidence-based recommendations on the clinical management 
of UPSC. Few randomized clinical trials exist, and none address substages of UPSC specifically 
in relation to different staging and treatment modalities. We performed a review on the clinical 
aspects of UPSC with a focus on the effects of staging and adjuvant therapy on recurrence rate and 
survival outcome in the different (sub)stages of UPSC.
IMPORTANT CLINICAL ASPECTS OF UPSC
The highly malignant potential of UPSC is indi cated by a 5-year survival rate of only 18–45%, whereas 
the overall 5-year survival rate for all stages of type I endometrioid carcinomas is 70–80%.7,8,10-15 
Traditional survival rates for UPSC vary from 35 to 85% in patients with stage I–II disease, and from 0 
to 25% in patients with stage III–IV disease.12,14,16-18 
Several studies have reported on the meta static properties of UPSC, with a signifi cantly higher 
incidence of pelvic (41.9%) and para-aortic (43.3%) lymph node metastases and omental 
involvement (15–35%) com pared with endometrioid carcinoma of the uterus.19,20 Typically, 55–87% 
of the patients have extra-uterine spreading at the time of diag nosis and approximately 40–70% of 
clinical stage I UPSCs are therefore upstaged at the time of surgical staging.14,19,21-23 In addition, 70–
83% of all recurrences in UPSC patients occur within 2 years and are associated with abdominopelvic 
failure and 34% with distant failure.24,25 
Pathologic review of hysterectomy specimens in UPSC patients often reveals not only pure 
UPSC (60–75%), but also UPSC mixed with other histologies (25–33%), most often comprising 
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an endometrioid or clear cell component.8,26-29 Various stud ies recently showed that mixed UPSC 
resembled pure UPSC in prognosis and behavior, with no differences between the two in depth of 
myometrial invasion, extra-uterine disease or recurrence rate.16,26,29-34 Importantly, even when as little 
as 10% of the tumor was composed of papillary serous histology as determined by the pathologist, 
the patient had the same prognosis and risk for metastases as patients with pure UPSC.6,29,31 These 
findings suggest that UPSC is biologically dominant in a heterogeneous tumor and that a serous 
component, comprising even as little as 10% in a tumor, may dictate tumor progression, metastatic 
potential and survival outcome.
ROLE OF COMPREHENSIVE SURGICAL STAGING IN UPSC PATIENTS
In 1988, the International Federation of Gynecology and Obstetrics (FIGO) changed the clinical 
staging system for endometrial carcinoma to a surgical system. However, this standard surgical 
management used for endometrioid-type carcinoma of the uterus does not appear to be 
adequate in patients with UPSC, indicated by understaging of stage III–IV UPSC patients.16,19,35 
Since UPSC shows a similar behavior and spread pattern as serous papillary carcinoma of the ovary, 
comprehensive surgical staging in UPSC patients was suggested to more reliably predict extra-
uterine spread.16,34,36,37 This comprehensive staging includes total abdominal hysterectomy, bilateral 
salpingo-oophorectomy, pelvic washings, bilateral pel vic and para-aortic lymph node sampling and 
omentectomy or omental biopsy. 
Recently, the possible beneficial role of comprehensive sur gical staging in UPSC patients has 
been shown by a number of studies. Turner et al. described stage I UPSC patients with complete 
comprehensive surgical staging with a significantly better long-term 5-year overall survival 
(OS) of 95% compared with 45% in stage I UPSC patients without surgical staging.38 Geisler et al. 
recommended omental evaluation, since 23.8% of all UPSC patients with negative lymph nodes had 
either omental or peritoneal biopsies that were microscopically positive for meta static disease.19 By 
contrast, Gehrig et al. demonstrated that omental sampling may not be necessary in the routine 
surgical staging of type II carcinoma as the sensitivity of a visually nega tive omentum was 0.89 (p 
< 0.0001) in their retrospective study of 65 patients.39 Other investigators indicated that 21–42% of 
their UPSC patients had evidence of metastatic disease in their sampled omentum or lymph nodes; 
in some cases this was the only evidence of metastasis, which would otherwise be missed when 
no comprehensive staging was performed.19,21,31,35,37 Although comprehensive staging seems to be 
very important and has major implications in the treatment of UPSC patients, some people have 
questioned this practice7,39,40 Goldberg et al. were not able to show that comprehensive surgical 
staging improved the outcome compared with more conservative surgical approaches.28 
Many studies have demonstrated the unusual propensity of UPSC for extra-uterine spread. 
Metastases are often found retro- and intraperitoneally, upper abdominally, and there is a high 
incidence of lymph node and omental involvement.16,21,26,35,37 Therefore, we feel the necessity of 
thorough comprehensive surgical staging in UPSC patients cannot be overemphasized. Considering 
the high rate of surgical upstaging, the atypical meta static spread pattern and the limited staging 
criteria of earlier studies, it seems likely that the poor survival rates commonly associated with stage 
I–II UPSC disease can be at least partially attributed to initially undetected metastatic disease (i.e., 
under staging). Based on these observations, comprehensive surgical staging of all UPSC patients 
can be recommended, regardless of the clinical stage at presentation.
CYTOREDUCTIVE SURGERY IN UPSC TO IMPROVE OVERALL SURVIVAL
The role of optimal cytoreduction, defined as residual disease 1 cm or less in diameter, has already 
been well demonstrated in ovarian cancer.41-43 Authors similarly advocated the impor tance of 
cytoreduction of all visible metastatic tumor in UPSC patients. Recently, some studies have 
investigated the effect of aggressive cytoreductive surgery for the first time specifically in UPSC 
patients.10,12,19,44,45 
In 2001, Bristow et al. investigated the effect of optimal cytoreductive surgery in stage IV UPSC 
patients. These patients had a median survival of 26.2 months compared with 9.6 months for patients 
left with suboptimal residual disease (p < 0.001).8 Furthermore, 57.1% of all optimally cytoreduced 
patients were still alive compared with only 6.7% of patients with suboptimal cytoreduction after 24 
months of follow-up. Memarzadeh et al. showed that stage IIIC–IV UPSC patients with microscopic 
residual disease after optimal cytoreductive surgery had a median survival of 40 months, similar to 
the 43 months for stage IIIA patients who presented only with microscopic disease.35 This was in 
sharp contrast to patients with stage IIIC–IV disease with any degree of residual disease, since their 
survival was only 10 months (p < 0.001). Thomas et al. described that stage IIIC–IV UPSC patients 
with no visible residual disease after optimal cytoreduction had a significantly better median 
survival than those patients with any residual disease left after primary surgery (52 vs 13 months).46 
The 3-year OS of patients with no residual disease was 75%, compared with only 5% for patients 
with residual disease (p < 0.001).
To summarize, there is a growing body of literature suggesting that optimal cytoreductive surgery 
has beneficial consequences associated with improved survival in stage III–IV UPSC patients. 
However, surgical treatment as sole therapy in UPSC patients has been shown to be unacceptable, 
owing to high recurrence rates, mostly in the upper abdomen.24,26,27,47
OVERVIEW OF TREATMENT MODALITIES IN UPSC & THEIR OUTCOME
Since UPSC is characterized by high recurrence rates and a poor prognosis, the majority of UPSC 
patients are offered adju vant therapy, although optimal treatment for different stages of this type 
of cancer has remained elusive. Treatment modalities employed during recent decades include 
pelvic radiation, whole abdominal radiation, vaginal cuff radiation (brachytherapy), different 
chemotherapy (CT) regimens and combinations of these modalities. 
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Role of radiation therapy 
Radiotherapy has been the most commonly used adjuvant treat ment in the management of 
endometrial cancer. Since UPSC has the propensity to spread to and recur in the pelvic area and 
upper abdomen, whole abdominopelvic irradiation (WAPI), whole pel vic radiotherapy (WPRT) and 
whole abdominal radiotherapy (WART) were evaluated as adjuvant treatment. Smith et al. described 
an additional survival benefit of 20–30% in stage I and II UPSC patients with postoperative WAPI 
after cytoreductive surgery.48 Bristow et al. reported a 5-year OS rate of 64–81% in stage I–II UPSC 
patients treated with WPRT, although only 31% for stage III patients.16 Others similarly showed 
improved long-term survival in stage I–II patients using WPRT, reducing pelvic relapses in these 
UPSC patients.12,14 
By contrast, Gallion et al. reported recurrences in seven out of nine stage I UPSC patients treated with 
WPRT, of which six were outside the radiation field.49 In a study by Frank et al., six out of nine UPSC 
patients (stage I–III) recurred after treat ment with WART after a median follow-up of 7.5 months.50 
Markedly, all recurrences were in-field. In addition, Elit et al. found similar recurrence rates in a small 
cohort of stage I UPSC patients with approximately 50% of the recurrences not in-field.51 More 
recently, Slomovitz et al. reported on a large UPSC patient cohort with no significant differences 
in progression-free survival (PFS) and OS between UPSC patients who received adjuvant radiation 
therapy (RT) after surgery com pared with patients who were only observed after cytoreductive 
surgery.18 Huh and colleagues evaluated RT in a large group of stage I UPSC patients and the 5-year 
OS was 66% for the obser vation group compared with 59% in the RT group.52 Mehta et al. reviewed 
reports in which WART was used in stage I–II UPSC patients and concluded that the risk for abdominal 
failure was identical with or without WART treatment, questioning the rationale for WART in these 
patients.53 Furthermore, in a prospective study of the Gynecologic Oncology Group (GOG) using 
WART in stage III–IV UPSC patients, the 3-year OS rate was only 33%.54 The same investigators also 
studied the effect of WART in stage I–II UPSC patients and this revealed a 5-year PFS of only 38%, 
with more than 50% of the recurrences within the radiation field.55 
There have been diverging reports on the effect of adjuvant RT on survival in UPSC patients. 
Reasons for dichotomous find ings may include variation in radiation technique or in radiation 
doses, or not all patient populations used in the studies were correctly surgically staged, leading 
to understaging and worse survival outcome. Either way, adjuvant external radiation was never 
satisfactory concerning disease control and survival. 
Role of brachytherapy 
The benefit of brachytherapy in the adjuvant setting for UPSC patients remains controversial. 
Investigators studying adjuvant RT and systemic CT as treatment modality in UPSC patients have 
found a high rate of recurrence, typically located at the vaginal apex and intra-abdominally. In 
1991, Frank et al. reported on a small cohort of UPSC patients treated with WART with or without 
brachytherapy, in which 50% of the patients who did not receive brachytherapy recurred at the 
vaginal apex.50 In two larger studies, only 6–7% of stage I–II UPSC patients had vaginal recurrences 
after receiving brachytherapy.38,56 Kelly and colleagues showed that none of the 38 stage I UPSC 
patients who received brachytherapy in combination with adjuvant CT recurred at the vaginal cuff, 
whereas 19% of the stage I patients receiving CT only had local recurrences.33 Others have con-
firmed these findings with no recurrences at the vaginal apex when brachytherapy was included 
in the adjuvant therapy set ting, whereas external radiation or systemic CT only resulted in 15–19% 
vaginal failure.6,57-60 
Omission of vaginal brachytherapy was associated with a high rate of vaginal apex recurrences, up 
to approximately 50% in both stage I–II and stage III–IV UPSC patients.38,48,61 Importantly, although 
local vaginal cuff recurrence in type I endometrial car cinomas is often salvageable, various studies 
have reported on unsalvageable tumor progression in UPSC patients at the vaginal apex and most 
patients died of their recurrent disease.33,38 In addition, salvage RT for vaginal cuff recurrence is 
usually more intense and associated with higher toxicity than primary adju vant brachytherapy. Since 
brachytherapy is characterized by a relatively low morbidity and results in improved local control 
and PFS, brachytherapy is recommended to be offered to all UPSC patients in combination with 
other adjuvant treatment modalities. However, in most recent reports OS was never improved using 
brachytherapy, probably owing to extensive interabdominal recur rences and distant metastasis, 
which typically occur in 50–87% of all UPSC patients.24,33,48,53,57,59
Role of chemotherapy 
Owing to histological and biological similarities between UPSC and serous ovarian cancer, and the 
positive effect of adjuvant CT in serous ovarian cancer patients, systemic CT was also inves tigated in 
UPSC patients. Traditionally, as for all histopatho logical types of advanced and recurrent endometrial 
carcinoma, combinations of cisplatin, doxorubicin and cyclophosphamide (CAP) were used. In 1993, 
Rosenberg et al. treated stage I UPSC patients with adjuvant CAP and noticed no recurrences after 
32 months.62 However, others have shown poor response rates of 9–25% in different stages of 
UPSC disease using CAP, with many patients deceased within 2 years.63-66 Combined radia tion and 
CT using CAP was also studied, although only a minor improvement in survival in stage I–IV UPSC 
patients was found compared with patients treated with RT alone.67 Others also studied the effect 
of combination therapy using abdominopel vic radiation and CAP in UPSC patients, but results 
have been disappointing.68,69 Several authors concluded that UPSC was relatively resistant to this 
type of CT, in contrast to its serous ovarian counterparts.63,70,71 Furthermore, significant treatment-
associated toxicity in approximately 70% of patients was observed when using CAP with or without 
external radiation.63,64 
Zanotti et al. and Ramondetta et al. were the first to evaluate the potency of paclitaxel alone or 
in combination with carboplatin in UPSC patients and a response rate of approximately 90% was 
reported in the adjuvant setting with stage I–IV patients.66,72 More recently, various reports showed 
that paclitaxel combined with platinum-based CT was superior in improvement of sur vival in stage 
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I–IV UPSC patients compared with platinum-based only or other therapeutic regimen such as 
CAP.25,29,33,66,73 In a recent Phase II study, women with stage I–IV UPSC were treated with a ‘sandwich’ 
regimen using three cycles of a platinum-based chemotherapeutic agent plus paclitaxel, followed 
by pelvic RT and another three cycles of CT.74 This regimen was very well tolerated and PFS and OS 
were significantly increased for both stage I–II and stage III–IV UPSC patients. By contrast, there 
have been reports in which no significant effect was observed after treat ment of UPSC patients 
with platinum-based CT, with or with out paclitaxel.18,52 However, these studies included stage I–II 
UPSC patients without proper surgical staging, possibly resulting in understaging. This could have 
resulted in underestimation of the survival benefit. 
At present, different reports have shown platinum-based CT in combination with paclitaxel to be 
the most effective adjuvant treat ment modality in stage I–IV UPSC patients, and it significantly and 
favorably impacted upon recurrence rate, PFS and OS.
OPTIMAL MANAGEMENT IN DIFFERENT STAGES OF UPSC 
Despite many proposed treatment strategies, including observa tion only, different radiation and CT 
modalities and combinations of the former, the clinical management of both early- (stage I–II) and 
advanced-stage (stage III–IV) UPSC remains controversial. Synthesizing data from previous reports 
for discerning optimal management in UPSC is challenging for reasons described by Elit et al. and 
Hamilton et al.7,51 Briefly, differences in staging (clinically vs surgically vs comprehensive surgically), 
treatment outcome (based on combinations of stages due to rarity of dis ease), limited follow-up 
time and unclear pathological criteria for the diagnosis of UPSC all make it difficult to distillate 
treatment outcome and survival numbers specified for each substage. 
In this section, we set out to determine the best treatment modality specific for different (sub)stages 
of UPSC. For papers reporting on outcome after adjuvant treatment, we used a date restriction from 
January 2000 until present. Interestingly, owing to relatively high total numbers of stage I UPSC 
patients included in the various studies, we were able to distinguish comprehensively staged 
patients from patients without proper or with incomplete surgical staging in relation to outcome 
after treatment. Patients were considered ‘fully comprehensively staged’ when more than 95% of all 
patients in the study were staged in this manner. Furthermore, since type and dose of radiation and 
CT strongly differed in the various included studies, data on WAPI, WPRT, WART and brachytherapy 
were merged into a single category, RT, whereas data on CT with or without the addition of RT were 
fused into a separate category (CT ± RT). The staging of UPSC patients in all included studies was 
based on the FIGO surgical staging system adopted in 1988. 
Stage IA 
Although evidence for adjuvant platinum-based CT with pacli taxel in advanced-stage UPSC 
patients seems compelling, the benefit for stage I UPSC patients is still unclear. Various investiga-
tors have suggested observation only to be reasonable in stage IA patients after surgery.33,36,40,59 
However, recurrence rates varied from 0 to 21%, and in most cases recurrences were extrapelvic 
and not salvageable. External RT did not prove to be benefi cial in most studies, resulting in identical 
recurrence rates to the observation group.18,33,36,51,73 Adjuvant CT resulted in improved recurrence 
rates with superior PFS and OS compared with obser vation only or RT.33,73,75,76 Our review of the 
literature reveals that the average recurrence rate in the observation group of com prehensively 
staged stage IA UPSC patients was approximately 15%, and decreased by more than 50% when 
these patients were treated with CT with or without RT (Table 1). Observation only and RT were 
associated with a recurrence rate of 14 and 32%, respectively. The beneficial effect of CT seems 
to be reduced in noncomprehensively staged patients compared with observation only (Table 
2). Interestingly, these data show a difference in recur rence rate in CT with or without RT-treated 
patients among the differently staged groups. Despite low numbers of patients in both groups that 
make these findings difficult to interpret, this could possibly correlate with understaging in the 
noncomprehensively staged patient group. 
Stage IB–IC 
Stage IB–IC UPSC patients typically show higher rates of recurrence (up to approximately 50%) when 
only observed or treated with RT compared with stage IA patients.33,36,59,73,77 This marked difference 
suggests that the margin of benefit of systemic adjuvant CT could be even more in stage IB–IC 
UPSC patients. While suggested by some investigators, the high recur rence rates do not seem to 
justify observation only or RT as the sole treatment modality.51,78 Systemic CT with or without RT 
was also evaluated and resulted in decreased recurrence rates and increased PFS and OS.33,58,59,73-76 
After reviewing the litera ture, we found an average recurrence rate of approximately 35% in the 
observation only group for both comprehensively staged and noncomprehensively staged stage 
IB–IC UPSC patients, whereas RT improves the rate of recurrence only to a limited extent (Tables 
1 & 2). By contrast, adjuvant CT with or without RT decreases recurrence rates by 40–70% in (non)
comprehensively staged patients. Interestingly, the rate of recurrence in noncom prehensively 
staged stage IB–IC UPSC patients after CT with or without RT is twice as high compared with 
comprehensively staged patients, possibly correlating with understaging (~21 vs 11%, respectively). 
Independent of the surgical staging procedure, treatment with CT with or without the addition of 
RT resulted in a decrease of approximately 50% in recurrence rate in both stage IA and stage IB–IC 
UPSC patients (~8 and 17%, respectively) (Table 3). In general, the 5-year OS for all stage I UPSC 
patients was improved by CT with or without RT up to 75–100%, whereas observation only or RT 
resulted in a survival of 65–80% and 45–65%, respectively.33,52,59,73 
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Stage II 
Approximately 10% of all women with early-stage UPSC have stage II disease, and recurrence rates 
are generally higher than for stage I patients. Pelvic RT for local control was suggested by some 
investigators, although WART/WPRT proved to be of only minor benefit with recurrence rates of 
25–50%.16,25,53,77 Substantial data were shown recently by Fader et al., in which stage II UPSC patients 
treated with CT with or without RT showed improved recurrence rates down to approximately 10%, 
whereas observation-only and radiation-treated patients had recurrences in approximately 50% 
of the cases.25 Despite low patient numbers in the various studies reviewed, stage II patients on 
average showed a recurrence rate of approxi mately 40% when observed only after surgery, and RT 
decreased the recurrence rate only to a minor extent (Table 3). CT with or without RT resulted in an 
approximately 40% decrease of recurrences, although eventually still more than 20% of all 
stage II UPSC patients had recurrences after optimal treatment (Table 3). Treatment with CT 
with or with out RT resulted in this group of patients demonstrating an improved 5-year OS 
of 70–90%, com pared with 40–60% in both the observation-only and RT groups.12,14,25,74,75 
Stage III & IV 
Advanced-stage UPSC (stage III and IV) has been characterized by extensive metastatic disease, high 
recurrence rates after primary treatment and moder ate response to adjuvant treatment, all resulting 
in a poor prognosis and impaired survival. Reviewed literature revealed low numbers of patients in 
the observation-only and RT groups with a recurrence rate of approximately 70–100% (Table 3). In 
stage III UPSC patients treated with CT with or without RT, a minor improvement of recurrence rate 
could be observed (~55%), whereas hardly any effects were found in stage IV patients treated with 
this modality (Table 3). Unfortunately, CT improved OS rates in advanced-staged UPSC patients only 
to a limited extent. The 5-year OS rates are still dramatic with 20–50% for stage III and 10–40% for 
stage IV UPSC patients, although higher than traditional survival numbers of 0–25%.14,16-18,24,32,57,74,79
Table 3: Recurrences by substage and treatment group, independent of surgical staging procedure.
OBS (N = 280) RT (N = 274) CT +/- RT (N = 426) Total recurrences 
Stage N Recurrence N Recurrence N Recurrence by substage
IA (N = 259)‡ 141 21 (14,9%) 45 14 (31,1%) 73 6 (8,2%) 41 (15,8%)
IB-IC (N = 441)‡ 104 37 (35,6%) 141 45 (31,9%) 196 34 (17,3%) 116 (26,3%)
II (N = 134)* 26 10 (38,5%) 62 21 (33,9%) 46 10 (21,7%) 41 (30,6%)
III (N = 71)∞ 7 5 (71,4%) 17 15 (88,2%) 47 26 (55,3%) 46 (64,8%)
IV (N = 78)# 2 2 (100%) 9 7 (77,7%) 67 53 (79,1%) 62 (79,5%)
OBS: Observation only; RT: Radiation therapy; CT +/- RT: Chemotherapy only or combined with radiation therapy.
‡ Calculated for Stage IA and Stage IB-IC after combining the data from Tables 1 and 2.
* Data adapted from: 17,23,25,26,37,38,46,58,59,75,76,78,80
∞ Data adapted from: 17,23,25,38,46,58,59,75,78,80
# Data adapted from: 9,23,25,33,38,46,58,75,80
CONCLUSION & DISCUSSION
In this article we summarized the latest findings concerning staging procedure, surgical management 
and adjuvant treatment options in relation to recurrence rate and outcome in UPSC patients. It 
now seems advisable to perform a comprehensive sur gical staging procedure in both mixed and 
pure UPSC patients, independent of stage of disease, with a focus on maximum cyto reduction. 
All patients should undergo total abdominal hyster ectomy, bilateral salpingo-oophorectomy, 
collection of peritoneal fluid for cytologic examination, bilateral pelvic and para-aortic lymph node 
sampling and omental sampling. In addition, aggres sive cytoreductive surgery of all tumor tissue 
seems warranted to enhance response to adjuvant therapy. Recent data show major improvements 
in OS and recurrence rates in all stages of UPSC, including stage IA patients, when patients were 
treated with a combination of CT with or without RT with the addition of brachytherapy to decrease 
vaginal recurrences. 
Although the optimal adjuvant treatment for different stages of UPSC remains to be determined 
in prospective randomized clinical trials, our literature review raises some questions regard ing 
the use of RT other than brachytherapy in UPSC patients. Whole abdominal and pelvic radiation 
may not be necessary in either early- or advanced-stage UPSC patients. Most studies are not 
powered to determine whether the addition of pelvic or abdominal radiation to CT resulted in 
improved recurrence rate and survival outcome. Furthermore, recurrences in patients treated with 
postoperative RT are most likely to be distant and result in poor overall prognosis. Our review of the 
literature revealed that RT in most cases does not result in a decrease of recurrences among UPSC 
patients, and thus it seems that RT alone is insufficient as an adjuvant treatment modality. Finally, 
there is some evidence that UPSC is intrinsically less sensitive to irradiation than other histologic 
types.80 UPSC is charac terized by TP53 mutations, and overexpression and mutations in and/or 
loss of functioning p53 protein have been implicated in increased cellular radioresistance.80,81 In 
addition, the gene HER2 is commonly overexpressed by UPSC and HER2 over expression in breast 
cancer has been correlated with decreased radiosensitivity.82 This could be consistent with the low 
effi cacy for WART, WPRT and WAPI observed in the adjuvant setting for UPSC patients. Therefore, we 
suggest that external RT should not be used as the single curative treatment modal ity. This will also 
spare patients the morbidity associated with treatment using a large radiation field. 
Unlike ovarian cancer, UPSC has been demonstrated to be relatively chemoresistant. The effect of 
CAP CT on the outcome of patients with UPSC has been controversial, and the results of platinum-
based CT as sole treatment have been disappoint ing.50,61,63,64,67 The addition of paclitaxel to platinum-
based CT produced promising results, with significant improve ment of recurrence rates and survival 
outcome for all stages of UPSC.15,66,71 Our literature review suggests that a combina tion of platinum-
based CT with paclitaxel decreases recurrence rates by 25–70% depending on stage of disease, and 
improves 5-year OS outcome up to approximately 50% in stage III UPSC patients and up to 70–100% 
in patients with stage I–II disease. Importantly, paclitaxel is very well tolerated, with acceptable 
tox icity, and it has been shown to retain some activity in patients heavily pretreated with other 
chemotherapeutic regimens.66,71,83 
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Since UPSC typically shows recurrences intra-abdominally and more importantly at the vaginal apex, 
the relevance of brachy therapy has become more and more accepted. Although brachy therapy has 
never been used as the single adjuvant treatment modality in UPSC patients, it is possible that a large 
propor tion of the recurrences at the vaginal apex could be overcome by brachytherapy. We have to 
consider though that brachytherapy does not improve OS in most studies, mainly owing to distant 
metastases. However, the decrease in vaginal recurrences resulted in enhanced local control and in 
improved PFS. 
A particularly troublesome feature of UPSC has been the inabil ity to predict extra-uterine spread 
based on the primary tumor pathology. Myometrial invasion and tumor grade have been shown to 
be of no prognostic value.11,21,26,37 This highlights the importance of comprehensive surgical staging 
to prevent under staging, since up to approximately 70% of all UPSC patients are upstaged during 
primary surgery. 
Specific recommendations regarding management of the diff erent substages of UPSC have varied 
widely owing to its low incidence, the variety of surgical interventions and the wide vari ety of 
postoperative adjuvant therapies. Some authors have rec ommended clinical follow-up only after 
surgery, particularly in stage IA patients.16,33,84,85 In addition, Kwon et al. showed that in stage IA–IB 
UPSC patients, after complete surgical staging without further adjuvant treatment, only one out of 22 
patients recurred.78 By contrast, others have recommended aggressive adjuvant therapy using both 
postoperative CT and RT.38,62,67,68 Tables 1 & 2 suggest that stage IA UPSC patients still have a relatively 
high recurrence rate (up to 15%) and worse survival when observed only or treated solely with RT. 
Our review reveals that stage IA–IV UPSC patients could all potentially benefit from comprehensive 
surgical staging with maximum cytoreduction, followed by platinum-based CT combined with 
paclitaxel with optional brachytherapy. 
A novel approach to the treatment of UPSC patients is the use of neoadjuvant CT (NACT) prior to 
surgery and adjuvant CT. Data have been accumulated using NACT in advanced stages of epithe lial 
ovarian cancer and recently NACT prior to primary staging surgery of UPSC patients was investigated 
in a limited number of studies with promising results: the use of NACT resulted in a high rate (80%) of 
optimal interval debulking surgery of patients with transperitoneal spread of disease.86 Furthermore, 
reduc tion of residual disease prior to surgery was correlated with better survival outcome and 
improved quality of life by reduction of complications.86,87 Further research will be necessary to 
validate the possibly beneficial role of NACT prior to primary surgery in the treatment of UPSC 
patients. 
There are several limitations of this review, mostly inherent to the retrospective design of the majority 
of included studies and the rarity of UPSC. Furthermore, single-institution or cooperative group trials 
typically included all endometrial cancer histologies or analyzed combined substages of UPSC, leaving 
subset analysis of UPSC inadequate to distinguish between arms of therapy or between different 
substages of disease. Among the reviewed studies, there was a large variation in staging procedure 
(clini cally vs surgically vs comprehensively surgical) and a wide variety of (combined) adjuvant 
treatment modalities. Treatment groups were often not matched for various variables, including age, 
and there were major differences in median follow-up time. These limitations make the results of the 
various studies somewhat hard to interpret, and without proper prospective randomized trials, no 
definite conclusions can be drawn.
EXPERT COMMENTARY 
At present, comprehensive surgical staging with maximal cytoreduction seems to be essential for 
optimal management of UPSC, overcoming upstaging with improvement of recurrence rates and 
survival outcome. In light of the significant upstaging often required when comprehensive staging 
was not performed, it is reasonable to postulate that this ‘stage migration’ explains the previously 
reported poor survival rates of 35–50% for stage I–II UPSC patients. Maximum cytoreduction will 
enhance response to adjuvant therapy and provides a favorable survival rate. Even though optimal 
treatment for UPSC remains elusive, external RT seems not to be of any significant value for survival 
and is often accompanied by severe toxicities. Brachytherapy has been demonstrated to be of minor 
importance for OS, although it does improve local control and PFS and thus should be considered. 
CT has been shown to be beneficial in all (sub)stages of UPSC disease, reducing local and distant 
recurrences. Combinations of platinum with paclitaxel have shown the most promising survival 
outcome. 
Five-year view 
Comprehensive staging with maximal cytoreduction followed by adjuvant CT seems more and more 
warranted in UPSC patients. However, most data on the clinical management of UPSC patients are 
based on small, retrospective, single-institution studies that are plagued by the usual biases and 
confounders. In 2006, an inter national prospective clinical trial (Post Operative Radiotherapy for 
Endometrial Carcinoma [PORTEC]-3) was initiated to study the effect of RT alone compared with RT 
with the addition of adjuvant CT in endometrial carcinoma.102 However, despite the fact that UPSC 
patients are included in this prospective clinical trial, we argue that this study will not reveal the 
optimal adjuvant treatment option specifically for UPSC patients, because 1) It is not mandatory to 
perform a comprehensive staging procedure after which UPSC patients can be included in this study; 
2) There is an ethical dilemma since UPSC patients will be ran domized and thus can end up in the RT 
arm of the study, most likely not the most effective treatment modality at present; and 3) The number 
of included UPSC patients will be relatively low owing to its rarity, resulting in a lack of power to 
perform sta tistical analysis in both treatment arms on survival outcome specifically in these patients. 
Therefore, we feel there is an urgent need for a prospective ran domized clinical trial with international 
collaboration, specifically for UPSC patients. In this trial, we suggest that all patients should be 
comprehensive surgically staged, with maximum cytoreductive surgery, followed by randomization 
in one of the two following arms of adjuvant therapy: standard treatment (observation only or RT, 
depending on stage of disease) compared with CT (in all stages of UPSC disease, including stage IA). 
This trial should mainly focus on stage I and II UPSC patients since these patients will possibly benefit 
most from using CT.
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INTRODUCTION
Uterine papillary serous carcinoma (UPSC) is a highly malignant subtype of endometrial 
adenocarcinoma, representing only 10% of all uterine carcinomas. However, it accounts for up to 
40% of all endometrial cancer deaths and was therefore recognized as an unusually aggressive 
tumor.1,2 Unlike its endometrioid adenocarcinoma counterpart, UPSC patients commonly present 
with advanced stage of disease. UPSC has a high propensity for lymphovascular space invasion and 
metastasis, even when diagnosed without myometrial invasion.3-5 UPSC shows a similar behavior 
and spread pattern as serous papillary carcinoma of the ovary and morphologically these two 
entities are identical.2,6 The highly malignant potential of UPSC is also indicated by a 5-year overall 
survival of only 18-45%.5,7 Typically, 55-87% of the women with UPSC will have disease spread 
outside of the uterus (i.e. extra-uterine disease) at time of diagnosis and approximately 40-70% of 
clinical stage I UPSC are therefore upstaged at the time of surgery.8-11 
A particularly troublesome feature of UPSC has been the inability to predict extra-uterine spread 
of disease based on the primary diagnostic dilatation & curettage specimen. In addition, tumor 
grade is of no prognostic value and sensitivity of CT and MRI for detecting extra-uterine disease 
is limited.8,12,13 Comprehensive surgical staging instead of classical staging has been suggested 
to more reliably determine extra-uterine spread of disease in UPSC patients.6,11,14,15 This staging 
procedure should include hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, 
bilateral pelvic lymph node dissection with para-aortic lymph node sampling and omental biopsy 
or omentectomy. Investigators already showed that 21-42% of the UPSC patients had metastatic 
disease in their sampled omentum or lymph nodes, in some cases even as the only evidence of 
metastasis and otherwise missed when no comprehensive staging was performed.10,15,16 However, 
this comprehensive staging procedure requires more surgical expertise and is associated with higher 
complication rates. A preoperative test or tumor marker that can reliably discriminate between early 
and advanced stages of UPSC would therefore be helpful in the clinical management and planning, 
and possibly in prognostication.  
The tumor-associated antigen CA-125 level has proven its utility in epithelial ovarian cancer (EOC). 
Many prospective trials have validated the use of CA-125 in EOC patients as a prognostic marker, 
for monitoring the clinical response to treatment and for the detection of recurrent disease.17-19 
However, serum CA-125 levels were not predictive for the presence of advanced stage of disease 
in EOC patients.17-19 The utility of preoperative serum CA-125 measurement in endometrial cancer 
patients has also been investigated. Preoperative serum CA-125 elevations in endometrial cancer 
patients were first described in patients with recurrent and advanced carcinoma of the uterine 
corpus.20 Several studies have shown elevated preoperative CA-125 levels being associated 
with different clinicopathologic risk factors, extra-uterine tumor spread and reduced actuarial 
survival.21-24 However, most of these studies included different histological tumor types and lacked 
proper review by an experienced gyneco-pathologist. Furthermore, very few studies addressed the 
utility of preoperative CA-125 measurement solely in UPSC patients.25-26
ABSTRACT
Objective
We determined the clinical utility of preoperative serum CA-125 as predictor of 
extra-uterine disease and as prognosticator for survival in patients with uterine 
papillary serous carcinoma (UPSC).
Methods
Patients diagnosed with UPSC, identified between 1992 to 2009, and with 
preoperative CA-125 measurement were included. A receiver operator 
characteristic (ROC) curve was used to quantify marker performance. Overall 
and progression free survival were analyzed using the Kaplan-Meier method. 
Regression analyses were used to investigate the association of preoperative 
CA-125 levels and other clinicopathologic variables with the presence of extra-
uterine disease and for the effects on survival.
Results
66 patients met the study criteria. Using ROC, 45 U/mL as cut-off level provided 
the best sensitivity and specificity (75% and 74%, respectively) for extra-uterine 
disease, with a positive predictive value of 86%. Survival was significantly longer 
in patients with preoperative CA-125 ≤ 45 U/mL (p < 0.001). Only preoperative 
CA-125 > 45 U/mL remained significantly associated with extra-uterine 
disease (OR 6.30, 95% CI 1.93 – 20.62). Furthermore, advanced FIGO stage 
(HR 4.53, 95% CI 1.50 – 13.62) and preoperative CA-125 > 45 U/mL level 
(HR 3.12, 95% CI 1.13 – 8.73) were associated with decreased survival.
Conclusion
Preoperative elevated serum CA-125 is an independent predictor for the 
presence of extra-uterine disease and an independent risk factor for survival in 
UPSC patients.
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The purpose of this study was to determine the utility of preoperative serum CA-125 as a predictor 
of extra-uterine disease and as a prognostic factor for survival in patients diagnosed with UPSC.
MATERIALS & METHODS
Patient selection 
A retrospective multi-centre study was started by identifying all UPSC patients between January 
1992 and December 2009. A total of 141 patients were identified which had primary surgery at 
one of the five participating hospitals in the eastern region of the Netherlands (Radboud University 
Nijmegen Medical Centre, Rijnstate Hospital Arnhem, Gelderse Vallei Hospital Ede, Canisius 
Wilhelmina Hospital Nijmegen and Maas Hospital Boxmeer). Pathological, medical and operative 
records of all 141 patients were retrieved from the hospitals involved. 
All histopathological slides were reviewed by an expert gyneco-pathologist (JB) verifying the 
diagnosis pure or mixed UPSC. The tumor was considered pure UPSC when the serous component in 
the carcinoma comprised >75% of the total carcinoma and denoted as mixed UPSC when the serous 
component comprised between 10-75% of the total carcinoma. When the serous component did 
not comprise a significant proportion of the tumor (<10%), the carcinoma could not be designated 
as mixed UPSC according to previously published criteria 27, and these patients were excluded 
from this study (N = 26). In the participating hospitals, serum CA-125 was similarly measured with 
immunoassay’s on the AxSym analyzer, Abbott Diagnostics. For the preoperative workup of UPSC 
patients it has never been mandatory to include CA-125 measurement and therefore 49 patients 
had to be excluded since preoperative serum CA-125 levels were unknown. Thus a total of 66 
patients were included in this study.
All patients underwent surgical treatment, except for 5 patients because of serious comorbidity 
(N = 4) or because the patient refused treatment (N = 1). Three out of these five patients had stage 
IV disease based on metastases in liver (N = 1), brain (N = 1) and lung (N = 1), the other two had 
stage III disease based on cervical and vaginal involvement without further evidence of metastatic 
disease. These 5 patients remained to be included in our study to determine the preoperative 
marker performance of serum CA-125, however these patients did not receive optimal surgical and 
adjuvant treatment and were excluded from our further analyses on survival. Patients were staged 
according to the 2009 FIGO surgical staging system. Surgical treatment included peritoneal washing, 
total abdominal hysterectomy and bilateral salpingo-oophorectomy, with/without pelvic and para-
aortic lymph node sampling or lymphadenectomy and omentum sampling. Clinicopathological 
data were collected regarding preoperative serum CA-125, age, parity, BMI, FIGO stage, mixed 
versus pure serous histology, lymphovascular space invasion, myometrial invasion, tumor diameter 
and extra-uterine disease. Tumor diameter was analyzed as both a continuous and categorical 
variable, whereas extra-uterine disease was defined as spread of disease outside the uterine corpus, 
excluding direct growth into the cervix.
Statistical methods 
To quantify the marker performance of CA-125 for the detection of extra-uterine spread of disease 
and to analyze the sensitivity, specificity and the positive and negative predictive values of 
preoperative serum CA-125 levels at different cut-off values, a receiver operator characteristic (ROC) 
curve was constructed. The optimal cut-off value of preoperative CA-125 in relation to extra-uterine 
disease was determined using the Youden’s J index.28 Note that this index is based on the principle 
of  equal costs of misclassification, because the loss or gain in sensitivity and specificity is weighted 
equally. Furthermore, univariable logistic regression analysis was performed to investigate the 
association of different clinicopathologic variables with the presence of extra-uterine disease 
at the time of diagnosis. Variables reaching a level of statistical significance were entered into a 
multivariable logistic regression model with stepwise selection procedures to identify variables that 
independently predict the presence of extra-uterine disease. A significance level of 0.05 was used 
to remain in this model.
Length of overall survival (OS) was calculated from the date of initial surgery to the date of death 
or of last contact, whereas surviving patients were censored at the date of last contact. Progression 
free survival (PFS) was defined as the time in months from initial surgery to the date of recurrence. 
Overall and progression free survival estimates were plotted utilizing the Kaplan-Meier method. 
To examine the effects of various clinicopathogical variables on PFS and OS, univariable analyses 
were performed using a Cox proportional hazard method. Variables reaching a level of statistical 
significance in univariable analysis were valid for entry into a multivariable Cox proportional hazards 
model with stepwise selection procedures. Using a significance level of 0.05 to remain in the model, 
this multivariable Cox proportional hazards model was used to identify independent risk factors 
for survival. All statistical analyses were performed using SPSS version 16.0 for Windows (SPSS, Inc, 
Chicago, IL). P < 0.05 was considered statistically significant.
RESULTS
Demographic and histopathologic characteristics of the 66 UPSC patients included are presented 
in Table 1. The median age at diagnosis was 70 years, with a range from 51 to 87. Eighteen patients 
(27.2%) had stage I disease, 5 (7.6%) had stage II disease, 14 (21.2%) had stage III disease and 
29 (43.9%) had stage IV disease. Twenty-four out of these 29 stage IV patients already had gross 
macroscopic disease at the time of surgery. In 30 UPSC patients lymph nodes were sampled: all 30 
patients received a pelvic lymphadenectomy, whereas 13 UPSC patients received both a pelvic and 
para-aortic lymphadenectomy. Among these 30 patients with lymph nodes sampling, 15 (50.0%) 
had nodal metastases. To note, among patients without proper lymph node sampling, 26 out of 36 
patients (72.2%) had obvious disseminated disease based on macroscopic tumor deposits, bone or 
lung metastases or peritoneal disease. Furthermore, lymphovascular space invasion was present in 
34 women (54.8%), tumor invasion >50% of the myometrium was present in 32 patients (52.5%), and 
the median diameter of the tumor was 4.0 cm (range 0.5 – 15.0). Histology was verified as pure UPSC 
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in 42 patients (63.6%), while 24 patients (36.4%) had a mixed UPSC. Markedly, 47 patients (71.2%) 
had extra-uterine disease at the time of primary surgery after staging and pathologic evaluation. 
Twenty-three UPSC patients (34.8%) did not receive adjuvant treatment after surgery, whereas 23 
patients (34.8%) received adjuvant radiotherapy and 20 patients (30.4%) adjuvant chemotherapy. 
Among patients not receiving adjuvant treatment, five did not receive surgery due to serious 
comorbidity or patient refusal. Of those patients treated by surgery only, 10 of 18 patients had stage 
I-II disease and 8 of 18 patients had stage III-IV disease. To note, most of the stage III-IV patients 
refused further adjuvant treatment, and had disseminated disease with spread to mediastinum, 
lungs, or peritoneal disease, with a dismal prognosis.
Table 1: Patient characteristics of the total study population (N = 66).
Variables  Median (range) / N (%)
Age at diagnosis (years) 70 (51 - 87)
Follow-up (months) 17.5 (1 - 163)
BMI (kg/m2) 27.0 (18.8 - 35.8)
Parity (number) 2 (0 - 7)
Preoperative CA-125 (U/mL) 55.5 (2.0 - 13.000)
Menopausal state
    Premenopausal 4 (6.1%)
    Postmenopausal 62 (93.9%)
FIGO Stage‡
     I 18 (27.2%)
     II 5 (7.7%)
     III 14 (21.2%)
     IV 29 (43.9%)
Peritoneal Cytology
    Negative   25 (43.1%)
    Positive 33 (56.9%)
    Not sampled 8
Para-aortic and/or Pelvic Lymph nodes
    Negative 15 (50.0%)
    Positive 15 (50.0%)
    Not sampleda 36
Extra-uterine spreading
    No 19 (28.8%)
    Yes 47 (71.2%)
           Cervix involvement / Total sampled 27/63 (42.9%)
           Vagina involvement / Total sampled 4/66 (6.1%)
           Ovaries and fallopian tube involvement / Total sampled 25/63 (39.7%)
Table 1 (continued)
Variables  Median (range) / N (%)
Lymphovascular invasion
    No 28 (45.2%)
    Yes 34 (54.8%)
    Unknown 4
Histology
     Pure UPSC 42 (63.6%)
     Mixed UPSC 24 (36.4%)
Myometrial invasion
     ≤1/2 myometrium 29 (47.5%)
     >1/2 myometrium 32 (52.5%)
     Unknown 5
Diameter of tumor (cm) 4.0 (0.5 - 15.0)
Adjuvant treatment
     None 23 (34.8%)
     Radiotherapy 23 (34.8%)
     Chemotherapy 20 (30.4%)
aLymph node status assigned from inspection/palpation at laparotomy or from imaging; ‡Stage of disease was adapted according to 
the 2009 FIGO surgical staging system; FIGO: International Federation of Obstetrics and Gynecologists; UPSC: uterine papillary serous 
carcinoma.
Preoperative serum CA-125 and extra-uterine disease 
The median preoperative serum CA-125 level was 55.5 U/mL with a range of 2.0 - 13.000 U/mL. In 
patients with extra-uterine disease the median preoperative serum CA-125 level was significantly 
higher (median 124.0 U/mL; 25th-75th quartiles 28.0 - 433.9 U/mL) compared to patients without 
extra-uterine disease (median 17.5 U/mL; 25th-75th quartiles 10.1 – 28.5 U/mL) (p < 0.001). We set 
out to determine whether preoperative serum CA-125 levels were able to distinguish extra-uterine 
disease from local disease in our UPSC population. Preoperative CA-125 measurement as predictor 
for extra-uterine disease had an area under the curve (AUC) of 0.76 (95% CI, 0.64-0.88) in ROC analysis. 
The cutoff value was chosen to be 45 U/mL based on the equal costs of misclassification principle 
(Table 2). This resulted in a sensitivity and specificity for predicting extra-uterine disease of 75% and 
74% respectively, with a positive predictive value of 86%. Table 2 shows sensitivity, specificity, PPV 
and NPV at different CA-125 cut-off levels.
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Table 2: The sensitivity, specificity and the positive and negative predictive values at different cut-off values of 
preoperative CA-125 levels for detection of extra-uterine disease in UPSC patients.
CA-125 Cut-off (U/mL) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
35 75 47 78 43
40 75 63 85 51
45 75 74 86 52
50 72 74 87 52
55 68 84 94 51
PPV: positive predictive value; NPV: negative predictive value.
Lymphovascular invasion and preoperative serum CA-125 > 45 U/mL were both significantly 
associated with the presence of extra-uterine disease in univariable analysis (OR 4.04 (95% CI, 1.28 – 
12.81); and OR 6.32 (95% CI, 1.96 – 20.33) respectively) (Table 3). Importantly, age at diagnosis, BMI, 
pure or mixed histology, depth of myometrial invasion and tumor diameter (both as continuous or 
categorical variable) were not associated with extra-uterine spread of disease. Preoperative serum 
CA-125 > 45 U/mL remained significantly associated with the presence of extra-uterine disease in 
multivariable analysis. Adjusted for covariates, UPSC patients with a preoperative CA-125 level > 45 
U/mL have a 6.30 (95% CI, 1.93 -20.62) times greater risk for extra-uterine disease (Table 3).
Table 3: Crude and Adjusted Odds ratios (OR) with 95% confidence interval (CI) for the presence of extra-uterine 
disease by clinicopathological variable of UPSC patients, using uni- and multivariable logistic regression with 
selection procedure.
Univariable Multivariable
Variable N OR (95% CI) OR (95% CI)
Age at diagnosis (years) 66 0.96 (0.91 – 1.02) NS*
BMI (kg/m2) 59 1.06 (0.91 – 1.23) NS*
CA-125 
     ≤45 U/mL 25 1.00 (reference) 1.00 (reference)
     >45 U/mL 41 6.32 (1.96 – 20.33) 6.30 (1.93 – 20.62)
Histology
     Pure UPSC 42 1.00 (reference) NS*
     Mixed UPSC 24 0.52 (0.18 – 1.55)
Lymphovascular invasion
     No 28 1.00 (reference) NS*
     Yes 34 4.04 (1.28 – 12.81)
Myometrial invasion
     ≤1/2 myometrial 29 1.00 (reference) NS*
     >1/2 myometrial 32 0.99 (0.33 – 2.93)
Maximum tumor diameter
      ≤4cm 31 1.00 (reference) NS*
      >4cm 24 0.70 (0.22 – 2.24)
*NS: Not selected because it was dropped out during stepwise multivariable analysis.
Survival analysis 
Median follow-up was 17.5 months with a range of 1 to 163 months, while the median recurrence 
interval was 10 months with a range of 2 to 34 months. During the follow up period, 31 patients 
(47.0%) developed a recurrence and 17 patients (25.8%) suffered from progression of disease 
despite treatment. Forty-two patients (63.6%) eventually died of UPSC and 4 (6.1%) died of other 
causes. Figure 1A demonstrates Progression Free Survival (PFS) and Figure 1B Overall Survival (OS) 
when patients were grouped using preoperative serum CA-125 level of 45 U/mL as a cut-off. The 
median PFS for patients with preoperative CA-125 ≤ 45 U/mL was not reached during the duration 
of this study, whereas the median PFS for patients with CA-125 > 45 U/mL was 4 months (p < 0.001). 
In addition, OS was significantly shorter in the group of UPSC patients with preoperative CA-125 > 
45 U/mL (median 11 months) compared to the group with preoperative serum CA-125 ≤ 45 U/mL 
(median 28 months) (p < 0.001).
Figure 1: Kaplan-Meier estimates of A) Progression Free Survival (PFS) and B) Overall Survival (OS) of uterine 
papillary serous carcinoma patients with preoperative serum CA-125 ≤ 45 U/mL (N = 24, upper line) and 
patients with serum CA-125 > 45 U/mL (N = 37, lower line) (p < 0.001, for both PFS and OS). Vertical bars 
indicate patients with censored data. 
In a Cox proportional hazard model the clinicopathologic variables were analyzed for their 
association with PFS and OS. In univariable analyses, FIGO stage and CA-125 > 45 U/mL were 
significantly associated with PFS, whereas FIGO stage, CA-125 > 45 U/mL and lymphovascular 
invasion were significantly associated with OS (Table 4). In contrast, no significant associations 
were found between survival and the diameter of the tumor (as both a continuous or categorical 
variable), depth of myometrial invasion or pure versus mixed histology of the tumor. 
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Table 4: Crude hazard ratios (HR) with 95% confidence interval (CI) of Progression Free Survival (PFS) and Overall 
Survival (OS) by clinicopathological variable of UPSC patients, using univariable Cox regression.
PFS OS
Variable N HR (95% CI) HR (95% CI)
Age at diagnosis (years) 61 0.99 (0.95 - 1.02) 0.99 (0.95 - 1.02)
BMI (kg/m2) 55 1.01 (0.92 - 1.12) 1.02 (0.91 - 1.14)
CA 125 
     ≤45 U/mL 24 1.00 (reference) 1.00 (reference)
     >45 U/mL 37 3.81 (1.77 – 8.21) 5.20 (2.29 - 11.80)
FIGO Stage 
     I 18 1.00 (reference) 1.00 (reference)
     II 5 1.91 (0.48 – 7.65) 2.04 (0.51 – 8.20)
     III 12 1.79 (0.58 – 5.55) 1.76 (0.56 - 5.50)
     IV 26 6.02 (2.38 – 15.24) 8.86 (3.38 – 23.19)
Histology
     Mixed 23 1.00 (reference) 1.00 (reference)
     Pure UPSC 38 1.70 (0.83 – 3.51) 1.71 (0.82 - 3.54)
Lymphovascular invasion
     No 27 1.00 (reference) 1.00 (reference)
     Yes 34 1.82 (0.90 – 3.65) 2.07 (1.03 – 4.16)
Myometrial invasion
     ≤1/2 myometrial 29 1.00 (reference) 1.00 (reference)
     >1/2 myometrial 32 1.07 (0.54 - 2.09) 1.09 (0.55 – 2.14)
Maximum tumor diameter
      ≤4cm 31 1.00 (reference) 1.00 (reference)
      >4cm 24 0.89 (0.45 – 1.77) 1.17 (0.59 – 2.34)
Using multivariable survival analysis, both advanced FIGO stage and preoperative CA-125 > 45 U/mL 
were significantly and independently associated with both reduced progression free and reduced 
overall survival (Table 5). To note, inclusion of the 5 previously excluded patients not receiving 
optimal surgical and adjuvant treatment did not alter our results on survival significantly (data not 
shown).
Table 5: Adjusted hazard ratios (HR) with 95% confidence interval (CI) of Progression Free Survival (PFS) and 
Overall Survival (OS) by clinicopathological variable of UPSC patients, using multivariable Cox regression with 
selection procedure.
PFS# OS#
Variable N HR (95% CI) HR (95% CI)
CA 125
     ≤45 U/mL 24 1.00 (reference) 1.00 (reference)
     >45 U/mL 37 2.56 (1.08 – 6.43) 3.12 (1.13 - 8.73)
FIGO
     I 18 1.00 (reference) 1.00 (reference)
     II 5 2.10 (0.58 – 11.49) 1.83 (0.45 - 7.42)
     III 12 1.68 (0.76 – 7.61) 1.59 (0.51 – 4.95)
     IV 26 3.56 (1.23 – 9.59) 4.53 (1.50 – 13.62)
#FIGO stage, Serum CA-125, and LVSI were entered in the multivariable model.
DISCUSSION
A preoperative marker that can reliably discriminate between early and advanced stages of UPSC 
and can predict survival outcome would be helpful in the clinical management and prognostication 
of UPSC patients. In this largest study in literature evaluating the possible role of preoperative serum 
CA-125 level exclusively in UPSC patients, we demonstrated that preoperatively elevated serum 
CA-125 was the only studied factor significantly associated with extra-uterine disease. In addition, 
an elevated preoperative serum CA-125 level was, together with stage of disease, a significant 
independent predictor of decreased survival.
Unlike the typical endometrioid adenocarcinoma of the uterine corpus, UPSC commonly presents at 
an advanced stage and even when diagnosed without myometrial invasion it may be associated with 
disseminated disease.3,4 In the present study, 71% of the UPSC patients had extra-uterine disease at 
the time of diagnosis, consistent with previously reported data of 55-87% of the women having 
extra-uterine disease.8-10 Within the clinical setting, the assessment of serum CA-125 may be a useful 
test during the initial evaluation of a patient with UPSC. First, we demonstrated a strong association 
of serum CA-125 elevation with extra-uterine disease. More importantly, elevated CA-125 was the 
only studied preoperative factor significantly associated with disseminated disease. Although the 
management of all stages of UPSC should include surgical staging, preoperatively elevated serum 
CA-125 may prompt to use imaging to detect sites of metastatic disease that may not be clinically 
apparent. Moreover, the preoperative serum CA-125 establishes a baseline value that may be useful 
when interpreting the patient’s subsequent CA-125 levels during further treatment. 
Second, our multivariable survival analysis revealed that, together with stage of disease, preoperative 
serum CA-125 was a significant independent predictor of survival. In contrast to others4, our study 
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shows that lymphovascular invasion, myometrial invasion and tumor diameter are not associated 
with survival. These findings indicate that serum CA-125 may be a useful tool for prognostic purposes 
and disease assessment already in the preoperative setting, and could be helpful in counseling and 
informing patients about their prognosis. Furthermore, this could be relevant with regards to the 
choice of the appropriate surgeon to operate UPSC patients. In our participating hospitals UPSC 
patients have not always been operated by a gynecologic oncologist.29 As a result, UPSC patients 
possibly did not receive optimal treatment for their disease. Comprehensive staging with maximum 
cytoreduction has been associated with a significant survival benefit in UPSC patients.11,30,31 Although 
to our opinion all UPSC patients should be comprehensively staged, preoperative serum CA-125 
may help to triage a subgroup of women diagnosed with UPSC who need radical debulking surgery. 
Finally, preoperative serum CA-125 could possibly be helpful in selecting appropriate UPSC 
patients to investigate a novel treatment approach using neoadjuvant chemotherapy (NACT). 
UPSC commonly presents at an advanced stage of disease and despite the introduction of more 
aggressive surgical approaches and the use of adjuvant combination chemotherapy, the prognosis 
of UPSC has been dismal with a 5-year survival <50% for advanced stage (Stage III-IV) patients. At 
present, data are accumulating using NACT in advanced stages of epithelial ovarian cancer, with 3-4 
cycles of NACT prior to initial surgery, followed by additional adjuvant chemotherapy. This regimen 
reduces tumor burden, permitting less aggressive primary surgery. As a result, besides similar or even 
improved survival rates, associated postoperative complications and the requirement of intensive 
care unit admission and hospital stay are both reduced. Recently, also NACT prior to surgery of 
UPSC patients was investigated in a limited number of studies with promising results: reduction of 
disease prior to surgery was correlated with better survival outcome and improved quality of life by 
reduction of complications.32-33 Although further research will be necessary to validate the possibly 
beneficial role of NACT prior to primary surgery in the treatment of UPSC patients, preoperative 
serum CA-125 could possibly help in the triage selecting those UPSC patients who benefit most, 
since patients with elevated preoperative serum CA-125 most likely have advanced stage disease 
with a poor prognosis. To note, elevated preoperative CA-125 had a positive predictive value of 86% 
for the presence of extra-uterine disease.
We are aware UPSC patients were included over a long period of time (i.e. 18 years), in which 
treatment modalities have changed (e.g. comprehensive staging and adjuvant chemotherapy), 
which could have impacted on survival. To assess whether time of treatment had an influence on 
the outcome, we divided the UPSC population into two groups: group 1 were patients from 1992-
2000 (N = 32) and group 2 were patients from 2001-2009 (N = 34). Survival of the total group or by 
stage in group 1 was compared to survival of the total group or by stage in group 2. We found no 
difference in survival (data not shown). 
The present study has an important limitation being retrospective. Not all included UPSC patients 
were radically debulked or comprehensively staged, for reasons like massive spread of disease, 
morbid obesity or medical co-morbidities. However, most patients without proper comprehensive 
staging procedure already had obvious disseminated disease based on macroscopic tumor deposits, 
bone or lung metastases, or peritoneal disease. Furthermore, we found a relatively short median 
time of follow-up, inherent to the highly aggressive nature of UPSC and caused by the high number 
of stage IV UPSC patients included in our study. We also compared the groups of UPSC patients 
with (N = 66) and without (N = 49) preoperative CA-125 measurement and found no significant 
differences: all variables were equally distributed among the two groups (data not shown). The 
strengths of this multicentre study are that it comprises patients of five different institutions, with 
histology confirmed by a dedicated expert gyneco-pathologist. To date, it represents one of the 
largest series on patients with this rare histology in literature.
In conclusion, serum CA-125 could have potential clinical application in the management of UPSC 
patients. Serum CA-125 elevation is predictive for the presence of extra-uterine disease already in a 
preoperative setting. Furthermore, it can be used for prognostication since preoperative serum CA-
125 is a significant independent risk factor for survival. However, to warrant true clinical significance, 
a prospective study should be performed to evaluate serum CA-125 marker performance in UPSC 
patients.
Chapter 3 Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients
6160
Chapter
 3
REFERENCES 
1. Cirisano FD, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous 
and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000;77:55-65.
2. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial 
adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
3. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma. A morphologically diverse neoplasm 
with unifying clinicopathologic features. Am J Surg Pathol 1992;16:600-10.
4. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 
cases. Gynecol Oncol 2003;91:463-9.
5. Hamilton CA, Kapp DS, Chan JK. Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol 
2008;20:26-33.
6. Schwartz PE. The management of serous papillary uterine cancer. Curr Opin Oncol 2006;18:494-9.
7. Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged 
patients. Gynecol Oncol 1998;69:69-73. 
8. Cirisano FD, Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear 
cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999;74:385-94.
9. Dunton CJ, Balsara G, McFarland M, et al. Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv 
1991;46:97-102.
10. Geisler JP, Geisler HE, Melton ME, et al. What staging surgery should be performed on patients with uterine 
papillary serous carcinoma? Gynecol Oncol 1999;74:465-7.
11. Roelofsen T, van Ham MA, de Hullu JA, et al. Clinical management of uterine papillary serous carcinoma. Expert Rev 
Anticancer Ther 2011;11:71-81.
12. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the 
prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian 
carcinoma. Gynecol Oncol 1992;47:298-305.
13. Loubeyre P, Undurraga M, Bodmer A, et al. Non-invasive modalities for predicting lymph node spread in early stage 
endometrial cancer? Surg Oncol 2011;20:e102-8.
14. Bristow RE, Asrari F, Trimble EL, et al. Extended surgical staging for uterine papillary serous carcinoma: survival 
outcome of locoregional (Stage I-III) disease. Gynecol Oncol 2001;81:279-86.
15. Chan JK, Loizzi V, Youssef M, et al. Significance of comprehensive surgical staging in noninvasive papillary serous 
carcinoma of the endometrium. Gynecol Oncol 2003;90:181-5.
16. Gehrig PA, Groben PA, Fowler WC, et al. Noninvasive papillary serous carcinoma of the endometrium. Obstet 
Gynecol 2001;97:153-7.
17. Juretzka MM, Barakat RR, Chi DS, et al. CA125 level as a predictor of progression-free survival and overall survival in 
ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation 
therapy. Gynecol Oncol 2007;104:176-80.
18. Fayers PM, Rustin G, Wood R, et al. The prognostic value of serum CA 125 in patients with advanced ovarian 
carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. 
Int J Gynecol Cancer 1993;3:285-92.
19. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according 
to serum CA 125. J Clin Oncol 1996;14:1545-51.
20. Niloff JM, Klug TL, Schaetzl E, et al. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, 
and endocervix. Am J Obstet Gynecol 1984;148:1057-8.
21. Hsieh CH, ChangChien CC, Lin H, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy 
in surgical staging of endometrial cancer? Gynecol Oncol 2002;86:28-33.
22. Jhang H, Chuang L, Visintainer P, et al. CA 125 levels in the preoperative assessment of advanced-stage uterine 
cancer. Am J Obstet Gynecol 2003;188:1195-7.
23. Sood AK, Buller RE, Burger RA, et al. Value of preoperative CA 125 level in the management of uterine cancer and 
prediction of clinical outcome. Obstet Gynecol 1997;90:441-7.
24. Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 
2005;50:585-90.
25. Gupta D, Gunter MJ, Yang K, et al. Performance of serum CA125 as a prognostic biomarker in patients with uterine 
papillary serous carcinoma. Int J Gynecol Cancer 2011;21:529-34.
26. Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, et al. Utility Utility of pre-operative serum CA-125 in the management 
of uterine papillary serous carcinoma. Gynecol Oncol 2008;110:293-8.
27. Gynecologic Oncology Group Pathology Manual: Neoplasia of the Corpus, page IV2, 2009.
28. Green MS, Evaluating the discriminatory power of a multiple logistic regression model. Stat Med 1988;7:519-24.
29. Roland PY, Kelly FJ, Kulwicki CY, et al. The benefits of a gynecologic oncologist: a pattern of care study for 
endometrial cancer treatment. Gynecol Oncol 2004;93:125-30.
30. Memarzadeh S, Holschneider CH, Bristow RE, et al. FIGO stage III and IV uterine papillary serous carcinoma: impact 
of residual disease on survival. Int J Gynecol Cancer 2002;12:454-8.
31. Rauh-Hain JA, Growdon WB, Schorge JO, et al. Prognostic determinants in patients with stage IIIC and IV uterine 
papillary serous carcinoma. Gynecol Oncol 2010;119:299-304.
32. Despierre E, Moerman P, Vergote I, et al. Is there a role for neoadjuvant chemotherapy in the treatment of stage IV 
serous endometrial carcinoma? Int J Gynecol Cancer 2006;16-S1:273-7.
33. Vandenput I, Van CB, Capoen A, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in 
patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J 
Cancer 2009;101:244-9.
Chapter 4
Cervical cytology in serous and endometrioid 
endometrial cancer
Thijs Roelofsen#, Yvette P. Geels#, Johanna M.A. Pijnenborg, Maaike A.P.C. van Ham, 
Saskia F. Zomer, Johanna M. Wiersma van Tilburg, Marc. P.M.L. Snijders, 
Albert G. Siebers, Johan Bulten, Leon F.A.G. Massuger
Accepted in Int J Gynecol Pathol, 2012
# T. Roelofsen and Y. Geels contributed equally to this work
Cervical cytology in serous and endometrioid endometrial cancer
65
Chapter
 4
ABSTRACT
Objective
To determine the frequency of abnormal cervical cytology in preoperative 
cervical cytology of patients diagnosed with uterine papillary serous carcinoma 
(UPSC) and endometrioid endometrial carcinoma (EEC). Additionally, 
associations between abnormal cervical cytology and clinicopathological 
factors were evaluated.
Methods
Multicentre study in which EEC patients diagnosed at two hospitals from 1999-
2009, and UPSC patients diagnosed at five hospitals from 1992-2009, were 
evaluated. Revision of the histological slides was performed systematically 
and independently by three gyneco-pathologists. Cervical cytology within 
six months before histopathological diagnosis of endometrial carcinoma was 
available for 267 EEC and 80 UPSC patients. Cervical cytology with atypical, 
malignant, or normal endometrial cells in post-menopausal women was 
considered as abnormal cytology, specific for endometrial pathology.
Results
Abnormal cervical cytology was found in 87.5% of UPSC patients, compared to 
37.8% in EEC patients. 
In UPSC, abnormal cytology was associated with extra-uterine spread of disease 
(p = 0.043). In EEC, abnormal cytology was associated with cervical involvement 
(p = 0.034). In both EEC and UPSC patients abnormal cervical cytology was not 
associated with survival.
Conclusion
Abnormal cervical cytology was more frequently found in UPSC patients. It 
was associated with extra-uterine disease in UPSC patients, and with cervical 
involvement in EEC patients. More prospective research should be performed 
to assess the true clinical value of preoperative cervical cytology in endometrial 
cancer patients.
INTRODUCTION
Endometrial cancer is the most frequent malignancy of the female genital tract in the western world.1 
The majority of patients with endometrial cancer are diagnosed with endometrioid endometrial 
carcinoma (EEC), typically presenting at an early stage with an excellent prognosis; five-year overall 
survival rates of 70-80% have been reported.2,3 In contrast, uterine papillary serous carcinoma (UPSC) 
represents only 10% of endometrial cancers, but accounts for up to 39% of all endometrial cancer 
deaths. UPSC is therefore recognized as an aggressive tumor.4 Unlike its EEC counterpart, UPSC 
commonly presents with advanced stage disease and poor prognosis, indicated by a five-year 
survival rate of only 18-45%.4,5
The treatment of endometrial cancer is primarily based on surgery, consisting of hysterectomy 
and bilateral salpingo-oophorectomy (BSO). There is no worldwide consensus whether pelvic and/
or para-aortic lymphadenectomy should be performed as part of the staging procedure.6,7 For EEC 
patients the extensiveness  of surgery depends on the presence of risk factors for metastatic disease, 
like high tumor grade, deep myometrial invasion, and cervical involvement.7 However, preoperative 
assessment of these factors remains a challenge. After histopathologic examination, only 8-13% 
of the EEC patients have cervical involvement, and about 7% will have extra-uterine disease  at 
the time of diagnosis.8,9 In contrast, in UPSC patients 55-87% have microscopic or macroscopic 
metastases outside the uterus at the time of diagnosis.10,11 For these patients, debulking surgery and 
comprehensive surgical staging (including hysterectomy, BSO, bilateral pelvic lymph node dissection 
with para-aortic lymph node sampling and omental biopsy or omentectomy) have been suggested 
to more reliably determine stage of disease, to guide adjuvant treatment, and to improve survival.12-14
In asymptomatic women, cervical cytology appeared to be a poor screening tool for endometrial 
carcinoma because of its low sensitivity.15,16 However, when normal or atypical endometrial cells are 
found in cervical cytology of postmenopausal women, it is predictive for endometrial pathology.15,17,18 
Furthermore, cervical cytology has shown to be of additional value for the prediction of cervical 
stroma involvement and lymph node metastases.19-21 In addition, in patients with endometrial cancer, 
cervical cytology with atypical or malignant endometrial cells was associated with advanced stage of 
disease, high tumor grade and deep myometrial invasion.22-26
In patients with endometrial cancer, the frequency of atypical or malignant endometrial cells in 
preoperative cervical cytology varies from 31-50%.22,24,25 It has been reported though, that in UPSC 
patients cervical cytology is more likely to contain atypical or malignant endometrial cells.27 However, 
cervical cytology has only been investigated in cohorts with limited numbers of UPSC patients, and 
evidence for associations with poor prognostic factors in UPSC patients is lacking.25,27-30 
The aim of this study was to evaluate the presence of shedded atypical endometrial cells in cervical 
cytology during the diagnostic and/or preoperative workup of patients with UPSC as compared to 
patients with EEC. Possible associations between abnormal cervical cytology and clinicopathological 
variables were studied in both cohorts. Furthermore, we evaluated whether the presence of atypical 
endometrial cells in preoperative cervical cytology has prognostic significance for survival in UPSC 
and EEC patients.
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MATERIALS & METHODS
Patient selection
The nationwide network and registry of histo- and cytopathology in the Netherlands (Pathologisch 
Anatomisch Landelijk Geautomatiseerd Archief: PALGA)31 was used to search for all patients 
with primary EEC, diagnosed and treated at the Radboud University Nijmegen Medical Centre 
or the Canisius Wilhelmina Hospital in the period between January 1999 and December 2009. 
Furthermore, this network was used to search for all patients diagnosed with UPSC in the same two 
hospitals and three additional hospitals (Rijnstate Hospital Arnhem, Gelderse Vallei Hospital Ede, 
and Maas Hospital Boxmeer) from January 1992 till December 2009. Patients were excluded in case 
of a second primary malignancy. Pathological, medical and operative records of all patients were 
retrieved from the hospitals involved. 
All histopathological slides from surgery specimens were reviewed systematically by three expert 
pathologists (SZ, AW and JB). Review included tumor histology, tumor grade, depth of myometrial 
invasion, and the presence of lymphovascular space invasion (LVSI). Per definition, UPSC was 
considered to be grade 3 carcinoma.32,33 Patients with UPSC were included when the carcinoma 
comprised at least 10% serous histology according to previously published criteria.32,34 The included 
UPSC cases were defined as pure UPSC, with the serous component comprising >75% of the total 
tumor, and mixed UPSC, with the serous component comprising 10-75% of the tumor. 
Revised UPSC and EEC patients were included when cervical cytology was taken for the diagnostic 
and/or preoperative workup because of clinical suspicion for malignancy, within a time frame of 
6 months prior to histopathological diagnosis. To note, all included patients had cervical cytology 
taken before endometrial biopsy or dilatation and curettage. In case multiple cervical smears were 
taken during this 6 months time interval, the smear with the most severe diagnosis was used for our 
analyses. 
Cervical Cytology
PALGA was used to retrieve the complete cervical cytology history of each EEC and UPSC patient. This 
database has nationwide coverage from 1991 onwards, showing all surgical specimens and cervical 
cytology ever taken from each patient, both by the general practitioner and medical specialist.31 
Within our study period, cervical cytology was obtained using both conventional cytology and the 
more recently introduced liquid based cytology.35 Liquid based cytology was introduced between 
1996 and 2003 at the different pathology laboratories. Cervical cytology was screened and classified 
by cytotechnologists and approved by a pathologist according to the CISOE-A classification system, 
of which results are easily translatable to the various Bethesda 2001 subcategories.36 CISOE-A 
explicitly specifies the presence of normal and abnormal endometrial cells. Cervical cytology was 
classified as normal if there were no endometrial cells present. Atypical or malignant endometrial 
cells that were diagnosed in diagnostic or preoperative cervical cytology was considered as an 
abnormal cytological result, indicating endometrial pathology. Cervical cytology showing normal 
endometrial cells was considered abnormal only in postmenopausal women. To note, atypical 
squamous or atypical glandular / endocervical cells were not considered as abnormal cytology.
Because of the retrospective study design, patients were staged according to the 1988 FIGO surgical 
staging system.37 All patients underwent primary surgical treatment, except for four UPSC patients 
because of serious comorbidity (N = 3) or because the patient refused treatment (N = 1). These four 
patients remained to be included in our study to investigate the frequency of abnormal endometrial 
cells in preoperative cervical cytology and their relationship with various clinicopathological 
variables. However, these four UPSC patients did not receive optimal surgical and/or adjuvant 
treatment and were therefore excluded from further analyses on survival. Clinicopathological 
data were collected regarding age, body mass index (BMI), FIGO stage, peritoneal cytology, lymph 
node metastases, cervical involvement, extra-uterine disease, histology, and tumor diameter. 
Extra-uterine spread of disease was defined as cervical involvement, nodal involvement, positive 
peritoneal cytology, and/or disease at any other site outside the uterus.
Statistical analysis
To analyze the correlation between different clinicopathological variables with abnormal cervical 
cytology, univariable analyses were performed, with χ2 or Fisher’s exact test analyses for categorical 
variables, independent T-test for continuous variables, and univariable logistic regression analyses 
when appropriate. Furthermore, to examine the effects of various clinicopathogical variables on 
progression free survival (PFS), univariable analyses were performed using the Cox proportional 
hazard method. PFS was defined as the time in months from initial surgery to the date of recurrence. 
In case of no recurrence, the date of last contact or death was used for censoring. All statistical 
analyses were performed using SPSS statistical software for windows, version 18.0 (SPSS, Inc, 
Chicago, IL). P < 0.05 was considered statistically significant. 
RESULTS
Records of 141 UPSC patients and 353 EEC patients were retrieved from the hospitals involved. 
In the UPSC-group, 26 patients were excluded because the serous component within the tumor 
comprised less than 10%, whereas 19 EEC patients were excluded because of (partly) non-
endometrioid histology. Furthermore, from 35 UPSC patients and 67 EEC patients cervical cytology 
was either not taken for diagnostic/preoperative workup within 6 months prior to diagnosis, or 
unsatisfactory for diagnosis, and these patients were excluded. Thus, a total of 80 UPSC and 267 EEC 
patients comprised our study population.
Demographic and histopathological characteristics of the UPSC and EEC patients are presented in 
Table 1. For UPSC patients, the median age at diagnosis was 72 years (range from 47 to 86), whereas 
the median age at diagnosis for EEC was 63 years (range from 38 to 92). Forty-three (53.7%) UPSC 
patients were diagnosed with advanced stage (III-IV) disease, compared to 30 (11.2%) EEC patients. 
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In 52 (65.0%) UPSC patients extra-uterine spread of disease was found, compared to 52 (19.5%) of the 
patients with EEC. UPSC patients, compared to EEC patients, more often had LVSI (46.1% and 21.1% 
respectively), cervical involvement (40.3% and 12.4% respectively) deep myometrial invasion (52.0% 
and 40.4% respectively), and a larger median tumor diameter (4.0 and 2.5 respectively). In 36 UPSC 
patients (45%) lymphadenectomy was performed of whom 36.1% had positive pelvic or para-aortic 
lymph nodes. To note, among UPSC patients without proper lymph node sampling, the majority 
had obvious disseminated disease based on macroscopic tumor deposits, bone or lung metastases 
or peritoneal disease. In EEC patients, lymph node sampling was omitted in cases without clinical 
suspicion of FIGO stage II or more, as recommended by the Dutch guidelines for endometrioid 
endometrial cancer treatment. Thirty-five EEC patients (13.1%) underwent lymphadenectomy of 
whom 8.6% had positive lymph nodes. The median follow-up time for UPSC patients was 19 months 
(range 1 - 163 months) and 47 months (range 0 - 126 months) for EEC patients. Thirty-seven UPSC 
patients (48.7%) and 34 EEC patients (14.8%) had recurrence of disease, resulting in a five-year PFS 
of 40.2% and 90.8% respectively. 
Table 1: Clinical and pathological characteristics of patients with UPSC and EEC.
UPSC patients (N = 80) EEC patients (N = 267)
Variables  Median (range) / N (%) Median (range) / N (%)
Age at diagnosis (years) 72 (47-86) 63 (38-92)
BMI (kg/m2) 27.0 (18.0-41.0) 28.3 (18.4-53.6)
FIGO Stage
     I 28 (35.0%) 215 (80.5%)
     II 9 (11.3%) 22 (8.2%)
     III 21 (26.3%) 18 (6.7%)
     IV 22 (27.4%) 12 (4.5%)
Peritoneal Cytology
    Negative   42    (63.6%) 189 (91.7%)
    Positive 24 (36.4%) 17 (8.3%)
    Not sampled 14 61
Para-aortic and/or Pelvic Lymph nodes
    Negative 23 (63.9%) 32 (91.4%)
    Positive 13 (36.1%) 3 (8.6%)
    Not sampleda 44 232
Extra-uterine disease
    No 28 (35.0%) 215  (80.5%)
    Yes 52 (65.0%) 52 (19.5%)
Table 1 (continued)
UPSC patients (N = 80) EEC patients (N = 267)
Variables  Median (range) / N (%) Median (range) / N (%)
Cervical involvement
    No 46 (59.7%) 234  (87.6%)
    Yes 31 (40.3%) 33 (12.4%)
    Unknown 3 0
LVSI
    No 41 (53.9%) 202 (78.9%)
    Yes 35 (46.1%) 54 (21.1%)
    Unknown 4 11
Histology
     Pure histology 62 (77.5%) NA$
 Mixed histology 18 (22.5%)     
Tumor Grade
    1 0 (0.0%) 115 (43.0%)
    2 0 (0.0%) 110 (41.2%)
    3 80 (100.0%) 42 (15.7%)
Myometrial invasion
     ≤1/2 myometrium 36 (48.0%) 159 (59.6%)
     >1/2 myometrium 39 (52.0%) 108 (40.4%)
     Unknown 5 0
Diameter of tumor (cm) 4.0 (0.5 - 10.0) 2.5  (0.2-8.0)
Median time of follow-up (months) 19 (1-163) 47 (0-126)
aLymph node status assigned only by inspection/palpation at laparotomy or from imaging; FIGO: International Federation of Obstetrics 
and Gynecologists; LVSI: lymphovascular space invasion; UPSC: uterine papillary serous carcinoma; EEC: endometrioid endometrial 
carcinoma. $Not available: the variable ‘histology’ is a constant in EEC patients.
Preoperative cervical cytology
The cervical cytology findings in both UPSC and EEC patients are listed in Table 2. The median time 
interval between initial cervical cytology and final histopathological diagnosis for endometrial 
carcinoma was 1 month (range 0-6 months) for UPSC patients and 1.5 month (range 0-6 months) for 
EEC patients. In the group with 80 UPSC patients, 20 patients (25.0%) had atypical endometrial cells 
and 50 (62.5%) had malignant endometrial cells in their cervical cytology. Seven patients (8.8%) had 
normal cervical cytology preoperatively, and three patients (3.7%) had abnormal cervical cytology 
not specific for endometrial pathology: two cases with atypical glandular / endocervical epithelial 
cells and one case with atypical squamous epithelial cells. In total, 70 UPSC patients (87.5%) had 
abnormal cervical cytology, specific for endometrial pathology preoperatively (Table 2). 
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Within the group of 267 EEC patients, in 48 patients (18.0%) atypical endometrial cells were 
found in cervical cytology. In four patients (1.5%) normal endometrial cells were found, these 
four patients were postmenopausal. Forty-nine patients (18.4%) had malignant endometrial 
cells in their preoperative cervical cytology. In 163 EEC patients (61.0%) normal cervical cytology 
was found preoperatively, and three patients (1.1%) had abnormal cytology findings not specific 
for endometrial pathology: two with atypical squamous cells, and one with atypical glandular / 
endocervical cells. In total 101 EEC patients (37.8%) had abnormal cervical cytology, specific for 
endometrial pathology, prior to their diagnosis.
Table 2: Preoperative cervical cytology findings within six months prior to diagnosis of UPSC or EEC.
UPSC patients (N = 80) EEC patients (N = 267)
Pathology in cervical cytology N (%) N (%)
Normal endometrial cells in smear 0     (0%) 4 (1.5%)
Atypical endometrial cells in smear 20 (25.0%) 48 (18.0%)
Malignant endometrial cells in smear  50 (62.5%) 49 (18.3%)
Total abnormal cervical cytology 70 (87.5%) 101 (37.8%)
Cervical cytology without pathology 7 (8.8%) 163 (61.1%)
Other# pathology in smear 3 (3.7%) 3 (1.1%)
Total normal cervical cytology 10 (12.5%) 166 (62.2%)
UPSC: uterine papillary serous carcinoma; EEC: endometrioid endometrial carcinoma; #Atypical squamous epithelial cells, or atypical 
glandular / endocervical epithelial cells.
Associations of abnormal cervical cytology with clinicopathological findings
In UPSC patients, only extra-uterine spread of disease (p = 0.043) was significantly associated with an 
increased frequency of abnormal cervical cytology (Table 3). Using univariable logistic regression, 
extra-uterine disease remained the only factor associated with abnormal cervical cytology (OR 5.11, 
95% CI 1.02 – 28.36; data not shown). Advanced stage of disease was not associated with abnormal 
cervical cytology; 23 of 28 UPSC patients (82.1%) with stage I disease already had abnormal cervical 
cytology. In addition, patients lacking poor prognostic factors, like negative peritoneal cytology, 
absence of lymph node metastases, or no cervical involvement, had abnormal cervical cytology in 
37 of 40 (92.5%), 20 of 21 (95.2%), and 41 of 46 (89.1%) cases, respectively. There was no significant 
difference in frequency of abnormal cervical cytology among pure UPSC and mixed UPSC patients. 
Other well known prognostic factors such as myometrial invasion, LVSI, and tumor diameter, were 
also not associated with abnormal cervical cytology in UPSC patients. 
In EEC patients abnormal cervical cytology was significantly associated with cervical involvement (p 
= 0.034). All other clinicopathological variables were not associated with abnormal cervical cytology 
in EEC patients (Table 3). Cervical involvement was the only variable associated with abnormal 
cervical cytology in EEC patients using univariable logistic regression (OR 1.61, 95% CI 1.14 – 4.88; 
data not shown). 
Table 3: Associations preoperative cervical cytology findings with clinicopathological variables in patients with 
UPSC and EEC.
Cervical cytology in UPSC patients‡ Cervical cytology in EEC patients‡
Variable Normal Abnormal p-value Normal Abnormal p-value
Mean Age (years) 75.7 70.5 0.140# 64.6 63.4 0.270#
Mean BMI (kg/m2) 26.7 27.0 0.872# 28.9 30.5 0.092#
FIGO Stage
    I 5 (71.4%) 23 (32.8%) 0.151∞ 139 (83.7%) 76 (75.3%) 0.392
    II 0 (0.0%) 7 (10.0%) 12 (7.3%) 10 (9.9%)
    III 0 (0.0%)  20 (28.6%) 9 (5.4%) 9 (8.9%)
    IV 2 (28.6%) 20 (28.6%) 6 (3.6%) 6 (5.9%)
Peritoneal Cytology
    Negative 3 (60.0%) 37 (62.7%) 0.904∞ 125 (92.6%) 64 (90.1%) 0.543
    Positive 2 (40.0%) 22 (37.3%) 10 (7.4%) 7 (9.9%)
Para-aortic and/or Pelvic Lymph nodes
    Negative 1 (50.0%) 20 (62.5%) 0.724∞ 20 (100.0%) 12 (80.0%) 0.070∞
    Positive 1 (50.0%) 12 (37.5%) 0 (0.0%) 3 (20.0%)
Extra-uterine spread
    No 5 (71.4%) 23 (32.9%) 0.043∞ 139 (83.7%) 76 (75.2%) 0.089∞
    Yes 2 (28.6%) 47 (67.1%) 27 (16.3%) 25 (24.8%)
Cervical involvement
    No 5 (83.3%) 41 (60.3%) 0.265∞ 151 (91.0%) 83 (82.2%) 0.034
    Yes 1 (16.7%) 27 (39.7%) 15 (9.0%) 18 (17.8%)
LVSI
    No 3 (42.9%) 36 (54.5%) 0.556∞ 129 (81.6%) 73 (74.5%) 0.173
    Yes 4 (57.1%) 30 (45.5%) 29 (18.4%) 25 (25.5%)  
Histology
     Pure histology 5 (71.4%) 56 (80.0%) 0.594∞ 166 (100.0%) 101 (100.0%) NA$
     Mixed histology 2 (28.6%) 14 (20.0%) 0 (0.0%) 0 (0.0%)
Tumor Grade
    1 0 (0.0%) 0 (0.0%) NA* 78 (47.0%) 37 (36.6%) 0.274
    2 0 (0.0%) 0 (0.0%) 65 (39.2%) 45 (44.6%)
    3 7 (100.0%) 70 (100.0%) 23 (13.8%) 19 (18.8%)
Myometrial invasion
     ≤1/2 myometrium 2 (33.3%) 32 (48.5%) 0.477∞ 98 (59.0%) 61 (60.4%) 0.826
     >1/2 myometrium  4 (66.7%) 34 (51.5%) 68 (41.0%) 40 (39.6%)
Mean Diameter of tumor (cm) 3.1 4.0 0.343# 2.9 2.6 0.236#
‡Adjusted for abnormal cytology specific for endometrial pathology; #Independent T-test was used for continuous variables; ∞Fisher’s 
exact test; *Not available: the variable ‘tumor grade’ is a constant in UPSC patients. $Not available: the variable ‘histology’ is a constant in 
EEC patients. LVSI: lymphovascular space invasion; UPSC: uterine papillary serous carcinoma; EEC: endometrioid endometrial carcinoma.
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Survival analysis
In a Cox proportional hazard model clinicopathological variables including preoperative cervical 
cytology were analyzed for their association with progression free survival (PFS). In univariable 
analyses in UPSC patients, FIGO stage, extra-uterine disease, lymph node metastases, and LVSI were 
significantly associated with PFS (Table 4). Abnormal cervical cytology was not associated with 
PFS in UPSC patients. In addition, no associations were found between PFS and age, BMI, cervical 
involvement, myometrial invasion, tumor diameter, or the composition of the tumor (pure or 
mixed UPSC). In EEC patients, FIGO stage, tumor grade, extra-uterine disease, cervical involvement, 
LVSI, myometrial invasion, and tumor diameter were significantly associated with PFS (Table 4). 
However, also in EEC patients abnormal cervical cytology specific for endometrial pathology was 
not associated with PFS.
Table 4: Crude hazard ratios (HR) with 95% confidence interval (CI) of Progression Free Survival (PFS) by 
clinicopathological variable in UPSC and EEC patients, using univariable Cox regression.
PFS - UPSC PFS - EEC
Variable N HR (95% CI) N HR (95% CI)
Age at diagnosis (years) 76 1.00 (0.96 – 1.03) 283 1.03 (0.99 - 1.06)
BMI (kg/m2) 68 0.93 (0.86 – 1.01) 242 0.99 (0.93-1.05)
FIGO Stage
    I – II 37 1.00 (reference) 251 1.00 (reference)
    III – IV 39 6.87 (3.22 – 14.67) 32 9.66 (4.91 - 19.01) 
Histology
     Pure 58 1.00 (reference) NA$
     Mixed 18 0.79 (0.36 – 1.73)
Tumor Grade
    Low (grade 1 - 2) NA* 242 1.00 (reference)
    High (grade 3) 41 5.82 (2.95 - 11.48)
Extra-uterine disease
     No 28 1.00 (reference) 212 1.00 (reference)
     Yes 48 6.67 (2.75 – 16.16) 51 6.75 (3.39 - 13.43)
Cervical involvement
     No 46 1.00 (reference) 230 1.00 (reference)
     Yes 29 1.84 (0.95 – 3.55) 33 3.29 (1.53 - 7.10)
Para-aortic and/or Pelvic Lymph nodes
    Negative 21 1.00 (reference) 32 NA#
    Positive 12 3.96 (1.40 – 11.20) 3 NA#
Table 4 (continued)
PFS - UPSC PFS - EEC
Variable N HR (95% CI) N HR (95% CI)
LVSI
     No 41 1.00 (reference) 219 1.00 (reference)
     Yes 35 2.56 (1.34 – 4.92) 53 4.57 (2.27 - 9.18)
Myometrial invasion
     ≤1/2 myometrial 36 1.00 (reference) 172 1.00 (reference)
     >1/2 myometrial 39 1.76 (0.92 – 3.37) 111 2.42 (1.22 - 4.78)
Maximum diameter  tumor 63 1.13 (0.95 – 1.35) 103 1.05 (1.01 - 1.10)
Cervical cytology
    Normal 10 1.00 (reference) 180 1.00 (reference)
    Abnormal 66 1.73 (0.61 – 4.89) 103 1.41 (0.72 - 2.77)
*Not available: the variable ‘tumor grade’ is a constant in UPSC patients. $Not available: the variable ‘histology’ is a constant in EEC 
patients. LVSI: lymphovascular space invasion; UPSC: uterine papillary serous carcinoma; EEC: endometrioid endometrial carcinoma. 
Not available: the number of EEC patients with proper lymph node sampling was insufficient.
DISCUSSION
In this study a high frequency of abnormal cervical cytology was found in UPSC patients compared 
to EEC patients (87.5% and 37.8% respectively). In UPSC patients, abnormal cervical cytology was 
significantly associated with extra-uterine disease, whereas in EEC patients an association was found 
with cervical involvement. Abnormal cervical cytology specific for endometrial pathology was not 
associated with survival in either UPSC or EEC patients. 
The possible prognostic and diagnostic role of cervical cytology in patients with the suspicion of 
endometrial cancer has gained little attention so far. It was shown that cervical cytology may provide 
additional preoperative diagnostic information when normal, suspicious or malignant endometrial 
cells are detected. The presence of atypical endometrial cells has a significant correlation with 
the presence of endometrial cancer.15,17,18,39 In addition, in endometrial cancer patients abnormal 
cervical cytology has been associated with unfavorable prognostic, clinical, and pathological 
parameters.19,20,22,24,25,38 However, in none of these studies a difference was made between patients 
with EEC and UPSC.
The most striking finding in this study was the very high frequency of abnormal cervical cytology 
(87.5%) in UPSC patients relative to EEC patients. At present, there have only been a few studies with 
a limited number of patients on cervical cytology in UPSC patients, and frequencies of abnormal 
cervical cytology among UPSC patients have varied from 72-88%.25,27-30 It has been suggested 
previously that cervical cytology of UPSC patients is more likely to contain suspicious or malignant 
endometrial cells, probably due to the papillary architecture of the tumor and the propensity 
to exfoliate.38,40 Although the molecular biology to account for this observation has not been 
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thoroughly investigated, we and others propose there is a relation with change of expression of 
cell adhesion molecules such as CD44, integrin, e-cadherin, β-catenin and L1-CAM.39-41 In addition, 
involvement of the endocervix by the serous uterine tumor is more prevalent when compared to 
EEC and hence could explain the high rate of positive cervical cytology.40,42
We showed that in UPSC patients extra-uterine disease was significantly associated with abnormal 
cervical cytology. Markedly, UPSC patients who lacked poor prognostic factors still had abnormal 
cervical cytology in most cases. This was illustrated by patients with negative peritoneal cytology 
or absence of lymph node metastases who had abnormal cervical cytology in 92.5% and 95.2% of 
the cases respectively. In EEC patients, we found an association of abnormal cervical cytology with 
cervical involvement. The prognostic impact of other clinicopathologic factors was in concordance 
with literature.1,17 We did not find a prognostic impact of BMI in our analyses, probably due to our 
separate analyses of the EEC and UPSC cohort. Furthermore, the number of EEC patients might not 
be sufficient to find a prognostic impact of BMI.
Investigators have studied whether preoperative cervical cytology is an independent prognostic 
factor for survival in endometrial cancer patients. Although in one study by Fukuda and co-workers 
an association was found in univariable analyses24, cervical cytology never was an independent 
prognosticator for survival. In concordance, we found no association between cervical cytology 
and progression free survival in both UPSC and EEC patients independently. The fact that abnormal 
cervical cytology was associated with extra-uterine disease but not with PFS in UPSC patients may 
be explained by the very large number of UPSC patients with advanced stage of disease with a 
dismal prognosis.
It was shown by some investigators that preoperative cervical cytology with atypical glandular / 
endocervical cells, especially in patients over 50 years of age, was associated with endometrial 
pathology in 5-25% of cases.43,44 In our UPSC cohort two patients had atypical glandular cells, and 
in the EEC cohort one patient had atypical glandular cells. When these smears were considered 
as abnormal cytology, results of the analyses were not different. In the UPSC group extra-uterine 
spread of disease remained the only variable significantly associated with an increased frequency 
of abnormal cervical cytology (OR 5.33, 95% CI 1.12 – 29.54; data not shown), whereas cervical 
involvement remained the only variable significantly associated with abnormal cervical cytology in 
EEC patients (OR 5.67 95% CI 1.07-30.09; data not shown). Furthermore, abnormal cervical cytology 
was still not associated with PFS in both cohorts (data not shown).
It is of great importance to identify UPSC already in the preoperative setting, because of UPSC’s 
aggressive behavior and different surgical and adjuvant treatment approach compared to its EEC 
counterpart, including radical debulking surgery, comprehensive staging and chemoradiation 
therapy.14,45 Biopsy of the endometrium using either outpatient biopsy techniques or dilatation 
and curettage has been the standard of care procedure to obtain a preoperative histopathological 
diagnosis.6 However, diagnosis of the histological type made on these biopsies or curettage 
specimen can be challenging, with up to 20% of the diagnoses of histological type being changed 
after surgery.46 Preoperative cervical cytology might give an indication to suspect a more aggressive 
uterine tumor.
There are some limitations to this study, being retrospective as most important issue. In only a small 
portion of included EEC patients lymphadenectomy or lymph node sampling was performed, and 
not all UPSC patients were radically debulked and comprehensively staged for reasons like massive 
spread of disease, morbid obesity or medical co-morbidities. In addition, there was a change from 
conventional to liquid based cytology at different time points in the different laboratories involved. 
The sensitivity for the detection of endometrial cancer appears to be higher when liquid based 
cytology is used compared to conventional techniques.47 However, we cannot comment on the 
difference in detection rate in the current study, since data on the cytology method are not available 
for all individual patients. Furthermore, we found a difference in median time of follow up between 
the EEC and UPSC cohort. However, this difference can be explained by the highly aggressive nature 
of UPSC, with its high mortality rate already soon after clinical presentation, and poor five-year overall 
survival rate compared to EEC patients. This multicentre study comprises patients of five different 
institutions, with UPSC and EEC histology confirmed by three dedicated gyneco-pathologists, and 
with a complete national coverage of cervical cytology history. Furthermore, in all included patients 
cervical cytology was taken before endometrial biopsy or dilatation & curettage, with a median time 
interval of 1-2 months prior to final histopathological diagnosis. To our knowledge this is the first 
study analyzing endometrial pathology in cervical cytology in two large cohorts of UPSC and EEC 
patients specifically. 
In conclusion, abnormal cervical cytology was more frequently found in UPSC patients. It was 
associated with extra-uterine disease in UPSC patients and with cervical involvement in EEC patients. 
More prospective research should be performed to assess the true clinical value of preoperative 
cervical cytology in endometrial cancer patients.
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ABSTRACT
Objective: 
To analyze whether mixed compared with pure uterine papillary serous 
carcinoma (UPSC) histology affects clinical outcome, and to assess UPSC for 
its association with the precursor lesion endometrial intraepithelial carcinoma 
(EIC).
Methods: 
A multi-institution observational study on stage I – IV UPSC patients was 
performed. Histopathologic slides were reviewed by four expert pathologists, 
with determination of the percentage serous histology within each tumor. The 
pre-existent endometrium was evaluated for the presence of EIC.
Results: 
We included 108 UPSC patients. Fifty-eight patients had mixed and 50 patients 
had pure UPSC histology. On multivariable analysis, advanced International 
Federation of Gynecology and Obstetrics (FIGO) stage (HR 3.15, 95%CI 1.57 – 
6.32), mixed UPSC histology (HR 0.35, 95%CI 0.19 – 0.66), and lymphovascular 
space invasion (HR 2.10, 95%CI 1.07 – 4.16) were significantly associated with 
recurrence. FIGO stage (HR 4.67, 95%CI 2.25 – 9.70) and mixed UPSC histology 
(HR 0.39, 95%CI 0.20 – 0.76) were significantly and independently associated 
with survival. EIC was identified in 83.9% of all cases, with no significant 
difference between mixed and pure UPSC patients. Atrophic or weakly 
proliferative endometrium was found in 90.7% of pure UPSC cases, whereas 
hyperplastic endometrium with atypia was more commonly found in 34.7% of 
patients with mixed UPSC (p = 0.004).
Conclusion:
Pure UPSC histology and FIGO stage are the most important risk factors for 
recurrence and survival in patients with UPSC. Adjusted for covariates, patients 
with pure UPSC had a 2.9 times greater risk for recurrence and a 2.6 times 
higher risk of death compared to patients with mixed UPSC. Furthermore, 
EIC was equally found among pure and mixed UPSC cases, whereas the 
nonneoplastic endometrium was atrophic or weakly proliferative in pure UPSC 
cases compared to more hyperplastic endometrium with atypia in mixed UPSC 
cases.
INTRODUCTION
Uterine papillary serous carcinoma (UPSC) is a highly aggressive subtype of endometrial cancer, 
disproportionally responsible for up to 39% of deaths due to endometrial cancer.1,2 Typically, 55-
87% of the UPSC patients have extra-uterine spread of disease at the time of diagnosis.5,6
UPSC often displays considerable morphologic heterogeneity, co-existing with at least one other 
subtype of uterine cancer, most often comprising an endometrioid or clear cell component.7,8 
However, it is largely unknown whether the percentage UPSC histology is predictive of recurrence 
rates or survival. It was proposed that patients with mixed UPSC had the same prognosis and risk for 
metastases as patients with pure UPSC.7-14 In contrast, others described a favorable survival outcome 
for mixed UPSC patients compared to pure UPSC.15,16 17
The natural history for endometrioid endometrial carcinoma has been fairly well characterized as 
progression from its precursor endometrial hyperplasia with atypia to an invasive carcinoma.18,19 
In contrast, the etiology of UPSC is not as well understood. Histopathologic studies suggest that 
the majority of uterine serous carcinomas develop from endometrial intraepithelial carcinoma 
(EIC), identified in 58-89% of uteri containing serous carcinoma.8,20-22 However, the presence of 
EIC as precursor in mixed UPSC cases is largely unknown. It can be argued that the etiology and 
pathogenesis of mixed UPSC may differ from that of pure UPSC 23, possibly also resulting in a 
different clinical behavior.
The purpose of this study was to estimate whether mixed versus pure UPSC histology affects clinical 
outcome, and to identify clinicopathologic factors predictive for recurrence and survival in stage 
I-IV UPSC patients. Furthermore, we assessed the uninvolved endometrium in both pure and mixed 
UPSC cases for their association with the precursor lesion EIC or (atypical) hyperplasia or both.
PATIENTS & METHODS
Patient selection
For this observational study the Research Ethics Committee of the Radboud University Nijmegen 
Medical Centre declared that the study protocol is in accordance with the applicable rules 
concerning the review of research ethics committees and informed consent. The nationwide 
Netherlands database of histo- and cytopathology (PALGA)24 was used to search for all patients with 
primary UPSC, diagnosed and treated at the Radboud University Nijmegen Medical Center, Rijnstate 
Hospital Arnhem, Canisius Wilhelmina Hospital Nijmegen, Gelderse Vallei Hospital Ede, and Maas 
Hospital Boxmeer, in the period between January 1992 till December 2009. Pathologic, medical and 
operative records were retrieved.
All histopathologic slides were independently reviewed by four expert pathologists (MB, JB, 
AW and SZ), on the basis of criteria outlined below. All pathologists were blinded to any clinical 
information. Review of the specimen included determination of tumor type and composition, 
depth of myometrial invasion, tumor diameter, and LVSI. Percentage histology was estimated by 
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each individual pathologist reviewing slides of the entire carcinoma using a low-magnification (50-
100x) field. Individual scoring was assessed and discrepancies were resolved in a consensus meeting 
with the four pathologists. Each tumor was measured along the widest diameter, irrespective of 
histological component within mixed cases, with rounding at 0.5 centimeter. Furthermore, grade 
of nuclear atypia, presence of hobnail cells, psammoma bodies, and the number of mitotic figures 
were scored. The pre-existent and/or adjacent endometrium was evaluated for the presence of EIC. 
When available, the cervix, fallopian tubes, ovaries, lymph nodes and other sites were examined for 
metastatic disease. Per definition, UPSC was considered to be high-grade.7,8
Women were included in which the carcinoma comprised at least 10% serous histology in their 
respective uterine pathologic specimen after review, according to previously published criteria: 
“an epithelial subtype must be at least 10% of the total volume to designate the tumor mixed”.7,13 
Patients were excluded in case of a second primary malignancy. In cases where tumor involved the 
ovaries, only those that did not form a discrete ovarian mass typical for a primary ovarian carcinoma 
were included. Cases in which the entire endometrium was replaced by invasive tumor were not 
excluded (N = 15). 
The diagnosis UPSC was based on earlier described criteria.7,8 In brief, the serous component of the 
carcinoma was characterized by a complex papillary growth pattern, although glandular and solid 
patterns may also occur, with numerous mitotic figures, psammoma bodies, fibrovascular micro-
papillae and large, branching glands lined by papillary tufts composed predominantly of cuboidal 
or hobnail cells. Marked nuclear atypia should always be present. 
The endometrium uninvolved by invasive tumor was classified as atrophic/weakly proliferative, 
hyperplastic with/without atypia, or EIC. Atrophic/weakly proliferative endometrium was defined 
as thin endometrium, composed of dense stroma in which there were widely spaced simple tubular 
glands lined by atrophic-appearing epithelium in which there were few mitotic figures, or by more 
columnar and pseudostratified mitotically inactive epithelium.20,22
Endometrial hyperplasia was characterized by an increase in glandular density relative to the 
adjacent endometrial stroma. Hyperplastic endometrium, when present, was classified as simple 
with or without atypia, or complex with or without atypia.8,20
EIC was characterized by the replacement of benign surface endometrial epithelium or endometrial 
glands by a layer of markedly atypical cells resembling UPSC, usually adjacent to atrophic/weakly 
proliferative epithelium.20,21 The lesion can be very small and both focal or multifocal, and is often 
present in a polyp. Cytologically, the cells show marked nuclear membrane irregularities, mitotic 
figures including abnormal forms, and apoptotic bodies. By definition, EIC is not characterized by 
proliferation of glands as in complex hyperplasia with atypia. Both on the surface and in partially 
affected glands, there is a sharp demarcation between the morphologically malignant and atrophic/
weakly proliferative epithelium.20,22
Stage of disease was assigned based on the 2009 International Federation of Gynecology and 
Obstetrics (FIGO) endometrial cancer criteria.25 Surgical treatment with intent to achieve maximal 
cytoreduction included total abdominal hysterectomy and bilateral salpingo-oophorectomy, 
with/without pelvic and para-aortic lymph node sampling or lymphadenectomy, and omentum 
sampling. In case of incomplete surgical staging, stage was assigned on the basis of available 
operative and pathology findings. UPSC histology was analyzed both as a continuous variable 
and categorically as mixed UPSC (10-90% serous component) versus pure UPSC (100% serous 
component). Subgroup analyses of patients with 10-40% and 50-90% UPSC histology were also 
performed. Clinicopathological data were collected regarding age, menopausal state, presenting 
symptom, FIGO stage, peritoneal cytology, lymph node metastases, and tumor diameter. Tumor 
diameter was analyzed as both a continuous and categorical variable (≤ 4.0cm versus > 4.0cm).
Patient demographic and histopathologic characteristics were compared between mixed UPSC 
and pure UPSC patients, tested for statistical significance using one-way ANOVA for continuous 
variables. For categorical variables the Pearson’s chi-square (χ2) test or Fisher’s exact test was used 
when appropriate. Univariable proportional hazards models were used to examine the influence of 
various clinicopathological variables on recurrence and survival. Recurrence was defined as the first 
evidence of disease or death of disease after a six months disease-free interval after initial surgery. 
Length of overall survival (OS) was calculated from the date of initial surgery to the date of death 
or of last contact, whereas surviving patients were censored at the date of last contact. Progression 
free survival (PFS) was defined as the time in months from initial surgery to the date of recurrence. 
Multivariable proportional hazards models with a stepwise forward selection procedure were used 
to examine recurrence, OS, and PFS, while adjusting for demographic and tumor variables. Only 
variables with a p-value < 0.10 on univariable analyses were entered in the multivariable regression 
model. Furthermore, OS and PFS estimates were plotted utilizing the Kaplan-Meier method and 
compared between mixed-UPSC and pure UPSC using Log-rank statistics. We also performed sub-
group analyses for FIGO stage (stage I-II compared to III-IV). All statistical analyses were performed 
using SPSS statistical software, version 18.0 for windows (SPSS, Inc, Chicago, IL, USA). P < 0.05 was 
considered statistically significant.
RESULTS
Records of 141 patients were retrieved from the hospitals involved. Twenty-six patients were 
excluded because the serous component comprised <10% of the tumor. All patients underwent 
primary surgical treatment, except for seven UPSC patients because of serious comorbidity (N = 5) 
or because the patient refused treatment (N = 2). These seven patients were also excluded. Although 
UPSC is considered high-grade, 13 cases (12%) showed low-grade nuclear atypia. Serous carcinoma 
may show considerable cytologic variability throughout the tumor 26, and as the tumors with low-
grade nuclear atypia further showed the typically serous architecture, we included these cases as 
true UPSC. A total of 108 UPSC patients met the inclusion criteria.
Patient demographic and clinical characteristics were analyzed among mixed UPSC and pure UPSC 
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cases (Table 1). Mean age at diagnosis was 70.9 and not significantly different among the two 
groups. For the total cohort, 48.1% had stage III-IV disease, and distribution of stage of disease was 
not significantly different among mixed versus pure UPSC cases. In addition, menopausal state, BMI, 
and main presenting symptom were not different between the groups. Furthermore, no significant 
differences in adjuvant treatment were found among mixed and pure UPSC patients, with 39.7% 
and 36.0% receiving no adjuvant treatment, respectively. Forty-seven percent of all patients were 
not fully comprehensively staged, though this was not significantly different among mixed and pure 
UPSC cases (46.6% and 48.0%, respectively). To note, sub-analyses using completely staged patients 
only revealed similar results among pure and mixed UPSC cases (data not shown). Mean follow-up 
for the total study cohort was 29 months. The mean follow-up period differed significantly among 
the sub-groups, with 34.7 months (median 24.0 months, range 1-163) for mixed UPSC versus 21.8 
months (median 15.5 months, range 0-132) for pure UPSC cases (p = 0.026). 
For the total UPSC cohort, per case a median number of 5 slides (range 2-20) of the uterine specimen 
were reviewed. Histopathologic tumor characteristics by sub-group are presented in Table 1. We 
found 50 patient cases (46.3%) with pure UPSC histology (100% serous component) whereas 
58 cases (53.7%) had mixed UPSC histology (10-90% serous component). Of the 58 mixed UPSC 
cases, 45 (77.6%) had concurrent endometrioid adenocarcinoma, 8 patients (13.8%) had clear cell 
carcinoma, and 5 patients (8.6%) had a concurrent component of undifferentiated carcinoma. To 
note, the endometrioid component within mixed UPSC cases was most often low grade. In the 
mixed cases, the deepest areas of invasion were usually composed of UPSC histology, and 20 of 
45 (44.4%) mixed endometrioid-UPSC cases had extra-uterine disease consisting predominantly of 
the serous component. Typically, the total UPSC cohort showed LVSI and deep myometrial invasion 
in 53 (49.1%) and 51 (47.7%) cases, respectively. Thirty-eight patients (35.2%) had both LVSI and 
deep myometrial invasion. Tumor diameter, carcinoma confined to an endometrial polyp, positive 
LVSI, and deep myometrial invasion were not significantly different among mixed versus pure UPSC 
cases. In addition, the serous component of mixed UPSC resembled the pure UPSC: marked nuclear 
atypia, the presence of psammoma bodies and/or hobnail cells, and the amount of mitotic figures 
did not differ significantly between the two sub-groups (Table 1). 
In 15 cases, the serous carcinoma invaded all the endometrium available for review. In the remaining 
93 patients, the precursor lesion EIC was identified within the uterine specimen in 78 cases (83.9%). 
EIC was equally distributed among the sub-groups: in 41 (83.7%) mixed UPSC cases EIC was 
identified, compared to 37 (84.1%) in pure UPSC cases (Table 1). Even in mixed carcinoma consisting 
of 10-40% UPSC histology, EIC was present in 9 of 10 cases (90.0%) (data not shown). In addition, EIC 
was most commonly identified adjacent to the serous carcinoma (79.5%), whereas it was present at 
distant sites only in 20.5%. EIC was multifocal in 52 of 78 cases (66.7%), with a median number of two 
EIC lesions per case (range 1 – 10). The distribution of EIC with respect to the serous carcinoma and 
the number of multifocal EIC lesions was not significantly different among the sub-groups (Table 1 
and data not shown). 
Table 1: Demographics, clinical and histopathological characteristics of pure versus mixed uterine papillary 
serous carcinoma patients (N = 108).
Mixed UPSC (N = 58) Pure UPSC (N = 50)
Variables  N (%) / Mean (SD) N (%) / Mean (SD) p-value
Mean age at diagnosis (years) 70.8 (+/- 9.1) 70.9 (+/- 8.7) 0.956#
Menopausal state
       Premenopausal 3 (5.2%) 2 (4.0%) 0.772
       Postmenopausal 55 (94.8%) 48 (96.0%)
BMI (kg/m2)
      ≤30 34 (72.3%) 33 (82.5%) 0.262
      >30 13 (27.7%) 7 (17.5%)
Main presenting symptom
      Blood loss 53 (91.4%) 44 (88.0%) 0.629
      Abdominal pain 2 (3.4%) 4 (8.0%)
      Other 3 (5.2%) 2 (4.0%)
FIGO stage
        I + II 33 (56.9%) 23 (46.0%) 0.258
        III + IV 25 (43.1%) 27 (54.0%)
Adjuvant treatment
       OBS 23 (39.7%) 18 (36.0%) 0.167
       RT 25 (43.1%) 18 (36.0%)
       CT +/- RT 10 (17.2%) 14 (28.0%)
Mean follow-up (months) 34.7 (+/- 32.6) 21.8 (+/- 25.3) 0.026#
Histology of other component
      Endometrioid 45   (77.6%) NA$
      Clear cell 8   (13.8%)
      Undifferentiated 5   (8.6%)
Nuclear atypia
       Slight 0 (0.0%)* 2 (3.8%) 0.578
       Moderate 7 (12.5%)* 4 (7.7%)
       Severe 49 (87.5%)* 46 (88.5%)
Hobnail-cells
       No 22 (37.9%) 13 (26.0%) 0.187
       Yes 36 (62.1%) 37 (74.0%)
Mitoses (per HPF)
      0-9 21 (36.2%) 18 (36.0%) 0.252
      10-24 15 (25.9%) 7 (14.0%)
      >24 22 (37.9%) 25 (50.0%)
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Table 1 (continued)
Mixed UPSC (N = 58) Pure UPSC (N = 50)
Variables  N (%) / Mean (SD) N (%) / Mean (SD) p-value
Psammoma bodies
      No 44 (75.9%) 32 (64.0%) 0.178
      Yes 14 (24.1%) 18 (36.0%)
Mean tumor diameter (cm) 3.9 (+/- 2.7) 4.0 (+/- 1.7) 0.836#
Tumor in polyp 
       No 38   (65.5%) 34   (68.0%) 0.785
       Yes 20   (34.5%) 16   (32.0%)
LVSI
       No 32   (55.2%) 23   (46.0%) 0.342
       Yes 26   (44.8%) 27   (54.0%)
Myometrial invasion
     ≤1/2 myometrium 34   (59.6%) 22   (44.0%) 0.106
     >1/2 myometrium 23   (40.4%) 28   (56.0%)
EIC present@
      No 8   (16.3%) 7   (15.9%) 0.956
      Yes 41   (83.7%) 37   (84.1%)
EIC in relation to UPSC
      Adjacent only 21 (51.2%) 13 (35.1%) 0.159
      At distance only 9 (22.0%) 7 (18.9%)
      Adjacent & at distance 11 (26.8%) 17 (46.0%)
Uninvolved endometrium€
      Atrophic / weakly  proliferative 32   (65.3%) 39   (90.7%) 0.004
      Hyperplasia with atypia 17   (34.7%) 4   (9.3%)
UPSC: uterine papillary serous carcinoma; SD: standard deviation; FIGO: International Federation of Obstetrics and Gynecologists; BMI: 
body mass index; OBS: observation only after surgery; RT: radiotherapy; CT +/- RT: Chemotherapy +/- radiotherapy; $NA: Not available, 
no other histological component present in pure UPSC cases; *Assessed in the serous component within mixed UPSC cases; LVSI: 
lymphovascular space invasion; HPF: high power field; EIC: endometrial intraepithelial carcinoma; @ In 15 cases, the serous carcinoma 
invaded all the endometrium available for review; € In one case, the entire endometrium was replaced by EIC and UPSC; #One-way 
ANOVA was used for continuous variables.
The endometrium was atrophic/weakly proliferative in 71 of 92 cases (77.2%), and showed 
hyperplasia in 21 cases (22.8%). Six of these cases consisted of simple atypical hyperplasia and 
15 cases consisted of complex atypical hyperplasia. The aspect of the uninvolved endometrium 
differed significantly among the two groups, with 4 of 43 (9.3%) pure UPSC cases having hyperplastic 
endometrium with atypia, of which two in an endometrial polyp without carcinoma, compared to 
17 of 49 (34.7%) mixed UPSC cases (p = 0.004). In 15 of these 17 cases (88.2%) the hyperplastic 
endometrium with atypia was adjacent to an endometrioid component within mixed UPSC (data 
not shown). Never hyperplastic endometrium with atypia was identified in close resemblance 
to UPSC or EIC. Atrophic or weakly proliferative endometrium was found in 90.7% of pure UPSC 
cases, compared to 65.3% in mixed UPSC cases. In 19 cases, both EIC and atypical hyperplasia were 
identified. In 14 of these 19 cases EIC was adjacent to UPSC, whereas hyperplastic endometrium 
with atypia was more commonly found at a distance from UPSC (data not shown). To note, 16 of 19 
cases involved mixed UPSC. In a sub-group analysis, no association was found for higher BMI and 
endometrial hyperplasia with atypia (p = 0.195, data not shown).
Table 2: Crude and adjusted hazard ratios (HR) with 95% confidence interval (CI) for disease recurrence by 
clinicopathological variable of uterine papillary serous carcinoma patients (UPSC), using uni- and multivariable 
Cox regression with selection procedure.
Univariable Multivariable
Variable N HR (95% CI) p-value N HR (95% CI) p-value
Age at diagnosis 82 1.00 (0.97 – 1.03) 0.980 NS*
FIGO stage#
     I – II 54 1.00 (reference) < 0.001 44 1.00 (reference) 0.001
     III – IV 28 3.47 (1.87 – 6.46) 26 3.15 (1.57 – 6.32)
Histology#
     Pure UPSC 32 1.00 (reference) 0.009 26 1.00 (reference) 0.001
     Mixed UPSC 50 0.44 (0.24 – 0.82) 44 0.35 (0.19 – 0.66)
LVSI#
     No 50 1.00 (reference) 0.001 42 1.00 (reference) 0.032
     Yes 32 2.89 (1.55 – 5.39) 28 2.10 (1.07 – 4.16)
Myometrial invasion
     ≤1/2 myometrial 48 1.00 (reference) 0.162 NS*
     >1/2 myometrial 34 1.55 (0.84 – 2.86)
Tumor diameter# 70 1.16 (0.99 – 1.36) 0.074 NS*
Uninvolved endometrium
     Atrophic / weakly proliferative 52 1.00 (reference) 0.253 NS*
     Hyperplasia with atypia 20 0.62 (0.27 – 1.41)
UPSC: uterine papillary serous carcinoma; LVSI: lymphovascular space invasion; #Variables entered in multivariable model; *Not 
selected because it was dropped out during stepwise multivariable analysis.
In a Cox proportional hazard model the clinicopathologic variables were analyzed for their 
association with progression free and overall survival. In univariable analyses, FIGO stage, mixed 
UPSC histology (analyzed both as continuous and categorical variable), LVSI, tumor diameter 
(analyzed both as continuous and categorical variable), and hyperplastic endometrium with atypia 
were significantly associated with both PFS and OS (Table 3). In contrast, no significant associations 
were found between survival and age at diagnosis, myometrial invasion, tumor in a polyp, or with 
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other histopathologic characteristics (hobnail cells, psammoma bodies, number of mitoses, nuclear 
atypia) (Table 3 and data not shown).
Table 3: Crude hazard ratios (HR) with 95% confidence interval (CI) of Progression Free Survival (PFS) and Overall 
Survival (OS) by clinicopathological variable of uterine papillary serous carcinoma patients, using univariable 
Cox regression.
PFS OS
Variable N HR (95% CI) p-value HR (95% CI) p-value
Age at diagnosis 108 1.00 (0.97 – 1.03) 0.834 1.00 (0.98 - 1.03) 0.812
FIGO stage 
     I – II 56 1.00 (reference) < 0.001 1.00 (reference) < 0.001
     III - IV 52 5.02 (2.76 – 9.13) 5.04 (2.78 – 9.15)
Histology
     Pure UPSC 50 1.00 (reference) < 0.001 1.00 (reference) 0.001
     Mixed UPSC 58 0.37 (0.21 – 0.64) 0.37 (0.21 – 0.66)
LVSI
     No 55 1.00 (reference) 0.001 1.00 (reference) < 0.001
     Yes 53 2.64 (1.52 – 4.61) 2.92 (1.68 – 5.08)
Myometrial invasion
     ≤1/2 myometrial 57 1.00 (reference) 0.117 1.00 (reference) 0.141
     >1/2 myometrial 51 1.54 (0.90 – 2.63) 1.50 (0.88 – 2.55)
Tumor diameter 93 1.24 (1.08 – 1.42) 0.002 1.28 (1.13 – 1.45) < 0.001
Uninvolved endometrium
      Atrophic / weakly proliferative 71 1.00 (reference) 0.023 1.00 (reference) 0.024
      Hyperplasia with atypia 21 0.34 (0.13 – 0.86) 0.34 (0.13 – 0.87)
UPSC: uterine papillary serous carcinoma; LVSI: lymphovascular space invasion.
On multivariable survival analysis, both FIGO stage (HR 4.81, 95%CI 2.34 – 9.89) and mixed UPSC 
histology (HR 0.35, 95%CI 0.18 – 0.67) were significantly and independently associated with PFS, 
whereas FIGO stage (HR 4.67, 95%CI 2.25 – 9.70), mixed UPSC histology (HR 0.39, 95%CI 0.20 – 0.76), 
and tumor diameter (both as continuous and categorical variable) (HR 1.21, 95%CI 1.02 – 1.43) were 
independently associated with OS (Table 4). Adjusting for covariates, patients with pure UPSC had a 
2.6 times greater risk of death compared with mixed UPSC patients.
Finally, survival outcomes of mixed versus pure stage I-IV UPSC patients were estimated using the 
Kaplan-Meier method. Figure 1A demonstrates Progression Free Survival (PFS) and Figure 1B Overall 
Survival (OS), divided by sub-group. The PFS for mixed UPSC patients was 24 months, compared 
to 9 months for pure UPSC patients (p < 0.001, Log-rank test). In addition, the OS was significantly 
shorter in the group of pure UPSC patients (18 months) compared to mixed UPSC patients 
(74 months) (p < 0.001, Log-rank test). Furthermore, we also performed sub-analyses in 
relation to survival using 100% UPSC histology (N = 50), compared to 10-40% UPSC histology 
(N = 15), and 50-90% UPSC histology (N = 43). Again, 10-40% UPSC and 50-90% UPSC had a 
favorable outcome compared to 100% UPSC for both PFS (28, 23, and 9 months, respectively) 
(p = 0.001, Log-rank test) and OS (78, 67, and 18 months, respectively) (p = 0.002, Log-rank test).
Table 4: Adjusted hazard ratios (HR) with 95% confidence interval (CI) of Progression Free Survival (PFS) and 
Overall Survival (OS) by clinicopathological variable of uterine papillary serous carcinoma patients, using 
multivariable Cox regression with selection procedure.
PFS# OS#
Variable N HR (95% CI) p-value HR (95% CI) p-value
FIGO stage 
     I - II 41 1.00 (reference) < 0.001 1.00 (reference) < 0.001
     III - IV 40 4.81 (2.34 – 9.89) 4.67 (2.25 – 9.70)
Histology
     Pure UPSC 36 1.00 (reference) 0.002 1.00 (reference) 0.006
     Mixed UPSC 45 0.35 (0.18 – 0.67) 0.39 (0.20 – 0.76)
Tumor diameter 81 NS* 1.21 (1.02 – 1.43) 0.028
UPSC: uterine papillary serous carcinoma; #FIGO stage, histology, LVSI, tumor diameter, and uninvolved endometrium were entered in 
the multivariable model; *Not selected because it was dropped out during stepwise multivariable analysis.
Figure 1: Kaplan-Meier estimates of A) progression free survival and B) overall survival of patients with 
uterine papillary serous carcinoma, showing pure uterine papillary serous carcinoma histology (100% serous 
component; N = 50, lower line) and patients with mixed UPSC histology (10–90% serous component; N = 58, 
upper line). Log-rank test p < 0.001 for both panels. Vertical bars indicate patients with censored data.
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DISCUSSION
In the current study, we identified pure UPSC histology and FIGO stage as most important prognostic 
risk factors for recurrence and survival in UPSC patients. Furthermore, the precursor lesion EIC was 
equally found among pure and mixed UPSC cases, whereas the non-neoplastic endometrium was 
predominantly athrophic/weakly proliferative in pure UPSC cases compared to more hyperplastic 
with atypia in mixed UPSC cases.
It has been suggested that even when a minor part of the endometrial carcinoma is composed of 
serous histology, the patient has the same prognosis and risk for metastases as patients with pure 
UPSC.6,8-11,13,14,27-29 The current study of 108 extensively reviewed stage I-IV UPSC patients shows that, 
besides an effect of stage of disease on recurrence risk and survival rate, mixed UPSC histology 
had an independent and favorable impact on the risk of recurrence and survival. There were no 
significant differences in demographic, clinical, or pathologic variables among mixed versus pure 
UPSC cases. To compare our findings with previous studies, we performed survival sub-analyses for 
mixed versus pure UPSC histology in both early (stage I-II) and advanced (III-IV) stage of disease. 
Importantly, in both early and advanced stage, mixed UPSC cases had a favorable outcome 
compared to pure UPSC for both PFS (p < 0.001, Log-rank test) and OS (p < 0.001, Log-rank test) 
(data not shown). In addition, we performed a sub-analysis among mixed UPSC cases whether the 
other component had an impact on survival outcome. There was a trend for a favorable outcome in 
mixed endometrioid-UPSC cases compared to mixed clear-cell-UPSC and mixed undifferentiated-
UPSC cases, although not significant (data not shown). 
Histopathologic studies with limited number of UPSC patients have suggested that the majority 
of serous carcinoma develop from a distinctive precursor lesion termed EIC.21-23 We confirm this 
finding in our cohort of UPSC patients with EIC clearly identifiable and present in 83.9% of the cases.
However, the role of EIC in the development of mixed UPSC has been largely unclear, and it could 
be expected that the etiology and pathogenesis of mixed UPSC may differ from that of pure UPSC. 
Interestingly, in the present study we show the incidence of EIC was similar in both pure and mixed 
UPSC cases. Endometrioid endometrial carcinoma is known to arise in a background of hyperplastic 
endometrium. In the present study, the endometrium adjacent to the carcinoma was mostly 
atrophic/weakly proliferative in cases with pure UPSC histology, in contrast to more hyperplastic 
endometrium with atypia in mixed UPSC cases, especially in mixed endometrioid-UPSC cases. This 
is in concordance with previous smaller studies.22,27 Others suggested that mixed endometrioid-
UPSC may begin as endometrioid carcinomas that arise from atypical hyperplasia, and that serous 
differentiation develops secondarily through a process of dedifferentiation and clonal evolution.23 
However, the hyperplastic endometrium with atypia and the serous carcinoma in both pure and 
mixed UPSC cases were usually topographically unrelated and appeared distinct. Together with 
the high incidence of EIC also in mixed UPSC cases, most often multifocally present and in direct 
continuity with the serous tumor, we suggest these findings do not support the etiology of mixed
UPSC arising from atypical hyperplastic endometrium via an endometrioid carcinoma within the 
uterine corpus.
Several limitations of our study have to be acknowledged. First, this was a retrospective cohort 
analysis. Not all UPSC patients were radically debulked and comprehensively staged for reasons 
like massive spread of disease, morbid obesity or medical co-morbidities. However, we found 
no difference in the percentage fully staged patients among mixed versus pure UPSC patients. 
In addition, similar results for clinicopathological variables were found when analyzing only 
completely staged pure versus mixed UPSC cases. In this study UPSC patients were included over 
a long period of time (i.e. 18 years), during which treatment modalities have changed, facts that 
could have impacted on risk for relapse and survival. We divided the UPSC population into 2 groups: 
group 1 included patients from the years 1992-2000 (N = 49) and group 2 included patients from 
the years 2001-2009 (N = 59). We found no significant differences in recurrence rate or survival (data 
not shown). A significant difference in follow-up period was found between pure versus mixed 
UPSC cases. This difference can be explained by the more aggressive nature of pure UPSC, with its 
higher mortality rate, and worse survival rate compared to mixed UPSC patients. The strengths of 
this multicentre observational study are that it comprises patients of five different institutions, with 
histopathology confirmed by four dedicated expert gyneco-pathologists. In the literature to date, 
most studies on UPSC were conducted using histopathology reports on initial diagnosis without 
review. To put this into perspective, within our study the number of mixed UPSC cases (10-90% 
serous component) increased from 38.1%, based on the initial histopathology report, to 53.7% after 
extensive review. 
In conclusion, pure UPSC histology, together with stage of disease, are the most important 
prognosticators for recurrence risk and survival in serous carcinoma of the uterine corpus. Although 
our data show differences in recurrence risk and survival in pure compared to mixed UPSC, we 
suggest any endometrial carcinoma with serous differentiation must still be regarded as having 
high metastatic potential and should be surgically staged. Furthermore, EIC as precursor was found 
in both pure and mixed UPSC cases, suggestive for its role in the carcinogenesis of both types of 
serous endometrial carcinoma. Further histopathologic and molecular studies are needed to 
address whether or not pure and mixed UPSC are true different entities, with their own etiology and 
pathogenesis.
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ABSTRACT
Objective
A precursor lesion for ovarian carcinoma, serous tubal intraepithelial carcinoma 
(STIC), has been identified in BRCA-mutation carriers undergoing prophylactic 
bilateral salpingo-oophorectomy (pBSO). Other lesions were also identified 
in fallopian tubes, but different terminology, interpretation, and lack of 
knowledge of normal epithelium, have hampered to unravel their possible role 
in carcinogenesis. The aim of this study is to classify tubal epithelial lesions in 
BRCA-mutation carriers and controls to enable comparison of prevalence, area 
of localization, and possible malignant potential.
Methods
Two hundred twenty-six BRCA1/2-mutation carriers were included; ovaries 
and fallopian tubes, embedded completely, were reviewed. Controls included 
105 women who underwent BSO for non-malignant reasons. Tubal epithelial 
lesions included the following categories: hyperplasia, minor epithelial atypia, 
STIC, and invasive carcinoma.
Results
Tubal neoplasia was identified in 7.1% (invasive carcinoma, 0.9%; STIC, 6.2%) of 
BRCA-mutation carriers compared to none in controls (p = 0.004). Hyperplasia 
and minor epithelial atypia were identified in 41.6% BRCA-mutation carriers 
and compared to 58.1% in controls (p = 0.005). Invasive carcinoma and STIC 
showed preference for the fimbrial ends (p = 0.027), while hyperplasia and 
minor epithelial atypia displayed more variation in localization. 
Conclusions
Invasive tubal carcinoma and STIC were limited to BRCA-mutation carriers, 
whereas hyperplasia and minor epithelial atypia were commonly found in both 
BRCA-mutation carriers and controls. It is suggested that hyperplasia and minor 
atypia represent variations of normal tubal epithelium instead of premalignant 
lesions. Furthermore, total salpingectomy is strongly recommended as most 
but not all STIC occurred in the fimbriae.
INTRODUCTION
Ovarian carcinoma is a highly aggressive disease which is most often diagnosed in an advanced 
stage. The majority of cases exhibit serous histology which can either be ovarian, fallopian tube, or 
peritoneal in origin.1 Until now these three localizations of serous carcinomas are considered as a single 
disease entity (“ovarian carcinomas”) with respect to treatment and prognosis. Over the last decades 
the pathogenesis of ovarian carcinoma has been subject to debate. The traditional view of ovarian 
carcinogenesis assumes that ovarian carcinoma originates from the ovarian surface epithelium 
(mesothelium), which invaginates into the underlying stroma, resulting in epithelial inclusion cysts 
that eventually undergo malignant transformation.2 However, these epithelial inclusion cysts were 
invariably present in both high risk cases and controls.3-5 Recently, a predisposition for ovarian 
carcinoma was discovered in the fallopian tubes of women with a germline BRCA-mutation.6,7 
Prophylactic bilateral salpingo-oophorectomy (pBSO) is performed in the majority of BRCA-mutation 
carriers, which reduces the risk of ovarian carcinoma by 80%.8,9 Incidental findings of occult invasive 
carcinoma and precursor lesions such as serous tubal intraepithelial carcinoma (STIC) were found in 
prophylactically removed fallopian tubes from women with a BRCA-mutation.6,7 Recent studies have 
established that STIC is present in 1-17% of these women.10-17
Histopathological investigation of fallopian tube specimens of women diagnosed with serous ovarian 
carcinomas reported the presence of STIC in up to 50% of these women.11,18,19 Recent morphologic 
and molecular genetic studies provided compelling evidence that a proportion of primary serous 
ovarian tumors actually arise from these precursor lesions; unique and identical p53 mutations 
were found in both the serous ovarian carcinoma and corresponding STIC, indicating a monoclonal 
relation.20-22 It is hypothesized that (pre)malignant cells of the tubal epithelium may exfoliate into the 
tubal lumen and migrate by retrograde flow to the abdominal cavity; implantation of these cells onto 
the peritoneum or ovarian surface might result in the development of serous carcinomas.8,20,23 
Histological entities other than STIC were also described in the tubal epithelium, for which various 
terminologies were used such as dysplasia, atypical hyperplasia or mucosal epithelial proliferations.15 
Because of difficulties in interpretation it is still unclear whether all these subtypes have a causal 
role in the development of tubal or ovarian carcinoma. Furthermore, because most studies did not 
include a proper control group of healthy women without a BRCA-mutation, knowledge of normal 
tubal epithelium is poor. This knowledge of tubal epithelial lesions in the general population is 
essential to enable differentiation of true premalignant lesions from lesions representing variants of 
normal tubal epithelium.
In this study, we report on tubal epithelial lesions in the largest cohort to date of women with a 
confirmed BRCA 1/2 mutation who underwent pBSO, in comparison to a large control group 
of women that underwent BSO for non-malignant reasons. Identified prevalences and areas of 
localization in the tubes will be compared between both groups to enable identification of lesions 
representing possible premalignancies and lesions that are most likely variations of normal tubal 
epithelium. In addition, a scheme for classification of tubal epithelial lesions is suggested. 
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MATERIALS & METHODS
Clinical data
Between January 1996 and December 2009, all women with a known germline BRCA1/2 mutation 
opted for pBSO at the Radboud University Nijmegen Medical Centre (RUNMC), The Netherlands, 
were identified. Patients with surgery for preoperatively suspected ovarian or tubal lesions were 
not included in this study. The Dutch nation-wide pathology database (PALGA) was used to identify 
a control group of women who underwent BSO at the RUNMC between 1999 and 2009. The 
control group included specimens of 105 women who underwent hysterectomy and/or salpingo-
oophorectomy with a non-malignant diagnosis: uterine leiomyomatosis (N = 42), mucinous 
cystadenoma (N = 19), serous cystadenoma (N = 14), fibroma (N = 6), endometrial hyperplasia with 
or without atypia (N = 6), mature teratoma (N = 5), ovarian torsion (N = 4), endometriosis (N = 3), 
uterovaginal prolapse (N = 3) or gynecological complaints such as meno- or metrorhagia without a 
distinct histopathologic diagnosis (N = 3).
Clinical and histopathological data were collected for each patient using a standardized form. Data 
collected included the BRCA-mutation status, age, menopausal status, presence of earlier breast 
carcinoma and management of the breast carcinoma. On behalf of the research ethics committee 
of the RUNMC, the study has been carried out in accordance with the applicable rules concerning 
the review of research ethics committees and informed consent. 
Pathology
All pBSO specimens of BRCA-mutation carriers were completely embedded, according to standard 
protocol. The fallopian tubes were cross sectioned at 3 mm interval, except for the fimbrial ends that 
were sectioned longitudinally to enable maximum exposure of the tubal plicae. One haematoxylin 
& eosin stained section was produced from each paraffin block. Fallopian tube specimens of 
control cases were not completely embedded. From these fallopian tubes representative sections 
of the fimbria, ampulla and/or isthmus were selected and embedded for histological examination. 
All available tubal sections were reviewed by two pathologists (MB, JB) with ample experience 
in gynecological pathology, being blinded for clinical patient characteristics. Tubal or ovarian 
epithelial lesions and their locations were recorded. Consensus was reached concerning the criteria 
for tubal epithelial lesions before the start of the present study. In case of discrepant diagnoses 
consensus was reached between both pathologists. In the present study, the following entities were 
distinguished in the fallopian tubes: benign epithelium, hyperplasia, minor epithelial atypia, STIC 
(tubal intraepithelial carcinoma, non invasive severe dysplasia and carcinoma in situ), and (occult) 
tubal invasive carcinoma.
Benign fallopian tube
The normal fallopian tube is lined by non stratified epithelium with a mixture of three cell types 
(Figure 1). Ninety percent of the tubal mucosa is layered by secretory and ciliated cells. The third cell 
type is the intercalated cell, which is inconspicuous and considered to be a secretory cell as well. 
Figure 1: Benign fallopian tube epithelium with secretory and ciliated cells (level of magnification: 200×; 
level of magnification of inset: 400×).
Hyperplasia
Tubal hyperplasia is defined as cellular crowding, stratification, occasional tufting of cells, some loss 
of nuclear polarity, but the absence of nuclear atypia. Cellular crowding is visible when the number 
of secretory cells exceeds the number of ciliated cells (Figure 2A).
Minor epithelial atypia
Features for histological diagnosis of minor epithelial atypia are slightly enlarged, rounded nuclei 
with irregular cell membrane outlines, slightly enlarged nuclear/cytoplasm ratio, nuclei with slight 
loss of polarity and inconspicuous nucleoli (Figure 2B). Minor epithelial atypia is not visible at low 
power magnification. It comprises epithelial lesions that fulfill some but not all of the criteria for 
STIC.
Tubal intraepithelial carcinoma (STIC) 
Tubal intraepithelial carcinoma is identifiable at low power magnification, displaying a row of 
dark and thickened epithelium. It is characterized by disorganized cellular crowding and nuclear 
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stratification, and consists of secretory cells in absence of ciliated cells. Other features include mitotic 
figures, high nuclear/cytoplasm-ratio, nuclear pleomorphism with loss of polarity and prominent 
nucleoli (Figure 2C). 
Tubal invasive carcinoma
Histological features of tubal invasive carcinoma are identical to STIC, but with the addition of an 
invasive component (Figure 2D).
Figure 2: Tubal epithelial lesions (level of magnification: 200×). A) Fallopian tube epithelium with hyperplasia, 
showing cellular crowding, but without atypical nuclei (arrow: mitotic figure). B) Minor epithelial atypia in 
the fallopian tube showing cellular crowding, slight cellular atypia and nuclei with small nucleoli, but without 
loss of polarity of the epithelial cells (arrows). C) Tubal intraepithelial carcinoma (STIC) with cellular crowding, 
stratification of nuclei, loss of polarity and severe atypia of the nuclei. D) Fallopian tube carcinoma, including 
overlying atypical epithelium.
Statistical analysis
Pearson’s chi square and, if appropriate, the Fisher’s exact test were used to test associations between 
categoric variables. The Kruskal-Wallis and Mann-Whitney U test were used to compare medians 
between different independent samples. All statistical analyses were performed using SPSS software 
version 18.0 (SPSS Inc, Chicago, IL) and p < 0.05 (two-sided test) was considered statistically significant.
RESULTS
Clinical findings
A total number of 226 women with a confirmed BRCA-mutation were included in the current study 
(149 BRCA1 and 77 BRCA2 mutations). Also, 105 controls were included. Women with a BRCA-
mutation had a median age of 44 years (range 24-70) compared to controls with a median age of 
48 years (range 22-60) (p = 0.04, Table 1). The median age specified for type of BRCA-mutation was 
42 years for the BRCA1 mutation carriers and 48 years for the BRCA2 mutation carriers. Distribution 
of menopausal status was comparable for both groups; 40% of the BRCA-mutation carriers were 
postmenopausal and 32% of the controls (85 of 212 vs 33 of 103; p = 0.17, Table 1). Median number 
of parity was two for both BRCA-mutation carriers and controls, but the BRCA-mutation carriers had 
more often three or more children compared to controls (Table 1). Breast carcinoma prior to BSO 
was significantly more often diagnosed in BRCA-mutation carriers compared to controls (81 of 226 
(36%) vs 1 of 105 (1%); p < 0.001, Table 1). 
Table 1: Population characteristics of BRCA-mutation carriers (N = 226) and controls (N = 105).
BRCA 1/2 Controls
Population characteristics N (%) N (%) p-value
Median age (range) 44 (24-70) 48 (22-60) 0.04a
Menopausal status 0.17b
     Premenopausal 127 (60%) 70 (68%)
     Postmenopausal 85 (40%) 33 (32%)
     Missing 14 2 
Parity 0.001b
     No children 34 (16%) 23 (24%)
     1-2 children 110 (50%) 60 (62%)
     3+ children 75 (34%) 14 (14%)
     Missing 7 8 
History of breast carcinoma 81 (36%) 1 (1%) <0.001b
Sterilization 23 (10%) 17 (16%) 0.11b
aMann Whitney U test; bPearson chi square.
Tubal epithelial lesions
The median number of sections reviewed from the fallopian tubes was 17 (range 2-33) for BRCA-
mutation carriers and six (range 1-20) for controls (p < 0.001). Of the 226 women with a BRCA-
mutation, 116 (51%) were diagnosed with benign tubal epithelium and in 110 (49%) a tubal epithelial 
lesion was detected: 43 (19%) cases showed hyperplasia, 51 (23%) minor epithelial atypia, 14 (6%) a 
STIC, and two (1%) an invasive tubal carcinoma (Table 2). In seven cases STIC was identified bilaterally 
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and in another seven cases unilaterally. Of the seven cases with unilateral STIC, the contralateral 
tubal epithelium showed benign epithelium in three cases, hyperplasia in one, and minor epithelial 
atypia in three. Two cases were identified with invasive tubal carcinoma which occurred unilaterally 
with contralaterally benign tubal epithelium in one case and occult ovarian carcinoma in the other. 
In the control group the tubal epithelium was benign in 44 (42%) cases, showed hyperplasia in 37 
(35%) and minor epithelial atypia in 24 (23%) cases. No tubal neoplasia (STIC or invasive carcinoma) 
was found in controls, which was significantly different from the BRCA-mutation carriers (zero of 105 
vs 16 of 226 (7%); p = 0.004). The less severe lesions, hyperplasia and minor epithelial atypia, were 
commonly identified in both BRCA-mutation carriers and controls, although more often in  controls 
(94 of 226 (42%) vs 61 of 105 (58%); p = 0.005, Table 2). 
Table 2: Histopathologic findings in the epithelium of the fallopian tubes from both BRCA-mutation carriers and 
controls that received bilateral salpingo-oophorectomy.
BRCA1 (N = 149) BRCA2 (N = 77) BRCA1/2 (N = 226) Controls (N = 105)
Tubal Epithelium N (%) N (%) N (%) N (%)
Benign 80 (53.7%) 36 (46.8%) 116 (51.3%) 44 (41.9%)
Hyperplasia 29 (19.5%) 14 (18.2%) 43 (19.0%) 37 (35.2%)
Minor atypia 31 (20.8%) 20 (26.0%) 51 (22.6%) 24 (22.9%)
STIC 9 (6.0%) 5 (6.5%) 14 (6.2%) 0 (0.0%)
Invasive carcinoma 0 (0.0%) 2 (2.6%) 2 (0.9%) 0 (0.0%)
STIC: serous tubal intraepithelial carcinoma
Furthermore, severity of tubal epithelial lesions in women with a BRCA-mutation was significantly 
associated with higher age (p < 0.001, Table 3). Controls revealed no significant difference in age 
distribution for tubal epithelial lesions (Table 3).
Table 3: Tubal epithelial lesions in BRCA-mutation carriers and controls in relation to age.
BRCA 1/2 Controls
Tubal Epithelium N Median age (range) N Median age (range)
Benign 116 41.5 (24-70) 44 48.0 (28-59)
Hyperplasia 43 45.0 (36-70) 37 48.0 (35-60)
Minor atypia 51 48.0 (35-69) 24 51.0 (22-59)
STIC 14 53.0 (35-63) -
Invasive carcinoma 2 57.5 (55-60) -
p < 0.001$ p = 0.14$
STIC: serous tubal intraepithelial carcinoma
Topographic characteristics of tubal epithelial lesions
In the majority of cases, invasive tubal carcinoma and STIC were identified in the distal fimbria: 
invasive tubal carcinomas in 100% and STICs in 64% of the cases (Table 4). Tubal neoplasia (invasive 
carcinoma or STIC) was significantly more often localized in the fimbriae compared to hyperplasia 
and minor epithelial atypia (11 of 16 (69%) vs 62 of 155 (40%); p = 0.027, Table 4). As mentioned 
previously, invasive tubal carcinoma and STIC were only identified in BRCA-mutation carriers and 
not in the controls. In the BRCA-mutation carriers hyperplasia was seen in the fimbriae in 35% and 
minor epithelial atypia in 47%, versus 27% and 54% in the controls, respectively. Hyperplasia and 
minor epithelial atypia did not occur significantly more often in the fimbriae but displayed more 
variation in localization (39 of 94 (41%) vs 23 of 61 (38%); p = 0.64, Table 4). 
Ovarian occult carcinoma
An occult ovarian carcinoma of 5.8 mm was identified in a 60 year old woman with a BRCA2 
mutation, with an occult invasive carcinoma in one of the adjacent tubes. All other cases, from both 
the BRCA-mutation and control group, showed only benign ovarian pathology. 
Of BRCA-mutation carriers, 81 (36%) were diagnosed with breast carcinoma prior to pBSO. In these 
81 BRCA-mutation carriers STIC was present in 5% and invasive tubal carcinoma in 2%, compared 
to respectively 7% and 0% in the 133 BRCA-mutation carriers without prior breast carcinoma. 
The presence of tubal neoplasia (STIC and invasive carcinoma) was not significantly different for 
cases with or without a previous breast carcinoma (six of 81 (7%) vs nine of 133 (7%); p = 0.86). 
Treatment for breast carcinoma was surgery (36%), or in addition either adjuvant chemotherapy 
(49%) or adjuvant chemotherapy with tamoxifen (15%). No significant difference was seen between 
treatment management of breast carcinoma and prevalence of tubal neoplasia (tamoxifen, p = 0.58 
(0/12 vs 6/69); chemotherapy, p = 0.18 (2/52 vs 4/29)).
Table 4: Tubal epithelial lesions in BRCA-mutation carriers located in the fimbria or in the isthmus and ampullary 
region of the tube (non-fimbrial).
BRCA 1/2 Controls
Fimbrial (N = 50) Non-fimbrial (N = 59) Fimbrial (N = 23) Non-fimbrial (N = 38)
Tubal Epithelium N (%) N (%) N (%) N (%)
Hyperplasia 15 (34.9%) 28 (65.1%) 10 (27.0%) 27 (73.0%)
Minor atypia 24 (47.1%) 27 (52.9%) 13 (54.2%) 11 (45.8%)
STIC 9 (64.3%) 5 (35.7%) - - - -
Invasive carcinoma 2 (100.0%) 0 (0.0%) - - - -
STIC: serous tubal intraepithelial carcinoma
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DISCUSSION
Our study has identified significant differences in the prevalence and preferred localization of tubal 
epithelial lesions in a large cohort of 226 BRCA-mutation carriers versus 105 controls. Occult invasive 
tubal carcinoma and STIC were present in 7.1% of the BRCA-mutation carriers but were absent in 
control cases. In contrast, tubal hyperplasia and minor epithelial atypia were commonly identified 
in both BRCA-mutation carriers and controls, although more often in controls. An association was 
found between increasing age and the presence of more severe tubal epithelial lesions in BRCA-
mutation carriers. Furthermore, invasive tubal carcinomas and STICs had a marked preference for 
the distal fimbrial end, which was not seen for tubal hyperplasia and minor epithelial atypia. 
Our divergent results for the different categories of tubal epithelial lesions lead to the suggestion 
that hyperplasia and minor epithelial atypia do not represent precursor lesions of invasive 
carcinomas and/or STICs. Previously, it has been suggested that a stepwise epithelial carcinoma 
progression model can be applied to the tubes.11 According to this model, occult carcinoma and 
STIC are preceded by atypic and/or hyperplastic tubal lesions. However, according to the results 
of the present study the accurateness of this stepwise progression model seems controversial, as 
prevalence of the specific tubal lesions as well as areas of localization are different for BRCA-mutation 
carriers and controls. The association found between increasing age and severity of tubal epithelial 
lesions in BRCA-mutation carriers might be suggestive for the stepwise progression model, but as 
the less severe lesions are more often identified in controls it seems unlikely that they are part of 
the oncogenic pathway. It is more likely that the less severe tubal lesions, as hyperplasia, represent 
normal proliferation of the tubal epithelium. Tubal hyperplasia is more common in younger women, 
as was suggested by Norquist et al.24 The fact that invasive carcinomas and STICs were not identified 
in controls marks their uniqueness for women at high risk for ovarian carcinoma and therefore their 
suggested role in carcinogenesis, especially, since controls were older and therefore more STICs and 
carcinomas would be expected. In addition, histological findings of hyperplasia and minor atypia 
were not identified in close proximity with occult invasive carcinoma and STIC.25 
The incidence of invasive tubal carcinoma and STIC in BRCA-mutation carriers in the present study 
was comparable with other studies including relatively large populations, with a mean overall 
prevalence of 5.2% for STIC and 6.7% for tubal neoplasia (STIC and invasive carcinoma) (Table 5). 
Comparing the prevalence of hyperplasia and minor epithelial atypia with previous reports entails 
more obstacles. Various terminologies have been used by different authors, or only distinct lesions 
such as occult carcinoma and STIC were recorded. Some extent of tubal epithelial proliferation 
has been seen in women, mostly premenopausal, without an increased risk of ovarian or tubal 
carcinoma, and are considered within normal limits of epithelial variation.26 However, the extent 
of this normal variation is still somewhat unclear as most studies did not include a control group. 
The current study provided the first large control group consisting of patients that were operated 
for various non-malignant reasons. Only two previous studies on epithelial lesions of the fallopian 
tubes included a control group (Table 5).25,27 
The study of Shaw et al. included 64 controls who underwent BSO and reported STIC in 3% of their 
control cases.27 However, 22% of their controls underwent surgery for synchronously diagnosed 
carcinoma of the cervix or endometrium which could have biased their results.27 In our own control 
group all patients receiving BSO for malignancy were excluded to rule out possible intrusion. 
A limitation of the current study is its retrospective nature leading to less extensive sampling of tubal 
tissue of controls. Therefore, median number of tubal slides available for review in BRCA-mutation 
carriers versus controls differed, resulting in an inability of completely blinding the pathologist for 
BRCA status. Tubal epithelial lesions are quite small and the use of a pathological protocol to embed 
the fallopian tubes in toto is preferred in further prospective research in order not to overlook 
putative precursor lesions. One of the strengths of our study is that it included the largest cohort of 
both BRCA-mutation carriers and controls. Age distribution of the cohort was comparable with other 
studies12,17,27, both groups were identified in one single institution and all sections were reviewed 
by the same two gyneco-pathologists. Before starting this study, a classification scheme for tubal 
epithelial lesions was developed and consensus was reached on definitions of these epithelial tubal 
lesions.
Although various epithelial tubal lesions in women at high risk for ovarian carcinoma were described 
previously, the diagnosis of tubal epithelial lesions is still subject to many difficulties as outlined 
in a recent report by Visvanathan et al.28 They analyzed inter- and intraobserver reproducibility 
between gynecologic pathologist in diagnosing tubal epithelial lesions which showed to be fair to 
moderate for STIC, but poor for other tubal epithelial lesions.28 To bypass definition issues several 
reports combined terms as occult carcinoma and STIC in their reported incidence number, which 
further complicates comparison of studies.8,13,27 The difficulties in interpretation of results stresses 
the importance of a generally used morphologic classification for future research. Our proposed 
classification scheme could overcome these interpretation difficulties when generally used.
The BRCA-mutation carriers also have an increased risk of developing breast carcinoma which often 
occurs at an earlier age than ovarian carcinoma.29 Literature shows some controversy on the influence 
of prior breast carcinoma and the risk of identifying occult tubal carcinoma in pBSO tissue.8,16 In the 
current study prior breast carcinoma did not influence the presence of tubal epithelial lesions, nor 
did different treatment protocols for breast carcinoma.
It is recommended to perform a pBSO in women with a confirmed BRCA-mutation at the age of 
about 40 years, which is based on the increased prevalence of tubal or ovarian carcinoma in these 
women.30 This is supported by the present study as both identified invasive tubal carcinomas 
occurred at the age of 55 and 60, respectively. However, in the current study, the precursor lesion 
STIC was identified in two women before reaching the age of 40 years. The median age of STIC was 
53 years (range 35-63) and age distribution of identified STIC was shown in Table 6. Whether the 
identification of STIC before reaching the age of 40 years is a reason to perform pBSO at a younger 
age needs further investigation. 
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More research is needed on the prevalence of STIC before the age of 40, on the possibility of STIC 
metastasizing before developing towards carcinoma and, if so, if this is an indication for adjuvant 
treatment in these women. Recently, ‘radical fimbriectomy’ was suggested as an alternative solution 
for prevention of tubal or ovarian carcinoma instead of pBSO.31 However, our study contradicts that 
only fimbriectomy would be sufficient in preventing these malignancies. We identified only two-
thirds of STICs in the fimbrial end while one-third occurred in the ampulla or isthmus of the tubes. 
Removal of the total fallopian tubes after completion of childbearing with a second step removal 
of the ovaries at a higher age might be a more suitable alternative for pBSO that needs further 
investigation.32 In addition, this method could be more safely performed before the age of 40 years 
as recommended for pBSO, without the adverse effects of early menopause. 
Table 6: Age distribution of STIC in women with a confirmed BRCA-mutation.
BRCA1 (N = 149) BRCA2 (N = 77) BRCA 1/2 (N = 226)
Age category N (total N) N (total N) N (total N)
     <35 0 (9) 0 (1) 0 (10)
     35-40 2 (57) 0 (17) 2 (74)
     41-50 2 (42) 2 (26) 4 (68)
     50+ 5 (41) 3 (33) 8 (74)
In conclusion, the results of the present study emphasize the essence of removing the fallopian 
tubes in total, as one-third of the identified STICs did not occur in the fimbrial end. Furthermore, the 
classification scheme used in this study appears to be useful as it differentiates between equivocal 
tubal epithelial lesions (hyperplasia and minor epithelial atypia) that are commonly present in 
the general population, from premalignant lesions with an already established role in carcinoma 
development (STIC and invasive carcinoma). Occult invasive carcinoma and STIC were only 
identified in BRCA-mutation carriers, whereas hyperplasia and minor epithelial atypia were more 
often identified in controls. Therefore, it seems unlikely that hyperplasia and minor epithelial atypia 
are also precursor lesions of ovarian carcinoma. We suggest to interpret tubal hyperplasia and minor 
epithelial atypia as variants of normal tubal epithelial proliferation.
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ABSTRACT
Objective
The pathogenesis of serous ovarian carcinoma (SOC) is still unknown. Recently, 
endometrial intraepithelial carcinoma (EIC) was proposed to be the precursor 
lesion of SOC. This study examines the model of EIC as precursor for SOC. 
Methods
Cases of SOC with a noninvasive or superficially invasive serous lesion, a 
hyperplastic lesion with/without atypia, or EIC in the endometrium were 
selected for inclusion in this study. Tissue sections from both ovaries, the 
fallopian tubes, and the uterus were extensively reviewed by an expert 
gynecopathologist. For both EIC and SOC, immunostaining for p53, Ki-67, 
estrogen receptor, and progesterone receptor; TP53 mutation analysis; and in 
situ ploidy analysis were performed.
Results
Nine cases of SOC with concurrent EIC in the endometrium were identified. 
Immunostaining for p53, Ki-67, estrogen receptor, and progesterone receptor 
revealed almost identical expression patterns and similar intensities in each 
pair of EIC and coincident SOC. Identical TP53 mutations were found in SOC 
and coinciding EIC in 33% of the cases, suggesting a clonal origin. DNA ploidy 
analysis, as a marker for neoplastic progression, demonstrated an increased 
number of aneuploid nuclei in SOC compared to their corresponding EIC (p = 
0.039). In addition, the mean amount of DNA per nucleus in SOC was higher (i.e. 
more aneuploid) compared to EIC (p = 0.039).
Conclusion
This study provides a first indication of EIC as possible precursor lesion for SOC. 
This finding could have major clinical implications for future ovarian cancer 
management and underscores EIC as a possible target for early SOC detection 
and prevention. 
INTRODUCTION
Although ovarian cancer only comprises approximately 3% of all female malignancies, it accounts for 
a disproportionately high mortality number, making it the leading cause of death from gynecologic 
cancers. Serous ovarian carcinoma (SOC) comprises approximately 70% of all ovarian cancers. Its 
aggressive characteristics are caused by its propensity for serosal organ involvement, discovery at 
an advanced stage, and peritoneal spread. 
There has been an ongoing debate about the pathogenesis of SOC. Many studies have focused 
on the ovarian surface epithelium, mainly supported by epidemiologic findings: a reduction in 
the number of ovulations as a result of multiple pregnancies, breast feeding, and the use of oral 
contraceptives lead to a decreased risk for developing ovarian cancer.1,2 Constant ovulation-induced 
damage and repair of the ovarian surface was suggested as the source of malignant transformation 
of ovarian epithelium.3,4 However, experimental or histopathological evidence is lacking, and 
a precursor lesion was never identified in the ovary itself. Recently, evidence has accumulated 
supporting the model of origin for a subset of high-grade ovarian serous carcinoma in the distal 
fallopian tube.5,6 Several studies identified an early form of serous carcinoma in the fimbriated end 
of the fallopian tube of female BRCA-mutation carriers, and this precursor lesion was termed serous 
tubal intraepithelial carcinoma (STIC).7-9
We recently described an alternative hypothesis regarding the site of origin for SOC in which 
endometrial intraepithelial carcinoma (EIC) was proposed to be the precursor lesion.10 Endometrial 
intraepithelial carcinoma was originally designated as the precursor lesion of uterine papillary 
serous carcinoma (UPSC) and was found near or adjacent to UPSC in 50% to 90% of the cases.11,12 
Endometrial intraepithelial carcinoma is noninvasive, often multifocal in origin, and can also be 
found on the surface of the ovary and in the fallopian tube.11,13 It was presumed that coexistence 
of multifocal serous carcinoma of the ovaries and endometrium originated from a single rather 
than from multiple sites.14 Therefore, we postulate that transtubal migration of the loosely 
cohesive cells from EIC foci in the endometrium may be the basis for the development of any type 
of intraperitoneal serous carcinoma. This is strengthened by the observations that hysterectomy 
without oophorectomy and tubal ligation both have been associated with reductions in the risk 
for ovarian cancer; odds ratios have ranged from 0.03 to 0.8 for hysterectomy and from 0.2 to 0.9 
for tubal ligation.15-20 Mutation and altered expression of the tumor suppressor protein p53 may 
be involved in the development of EIC and SOC. TP53 gene mutation analysis revealed identical 
mutations in both EIC and the concordant serous pelvic or ovarian carcinoma in a small cohort of 
patients, supporting a clonal origin.21 In a different study, identical TP53 mutations were shown in 
tumor foci from patients with peritoneal dissemination and ovarian involvement in association with 
a noninvasive serous endometrial lesion.14 The present study aims to further clarify the possible 
relationship between SOC and the presence of concurrent EIC in the endometrium by performing 
protein expression analysis using immunohistochemistry, TP53 mutation analysis, and in situ DNA 
ploidy analysis.
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MATERIALS & METHODS
Case selection
Patients with unilateral or bilateral SOC, diagnosed and surgically treated at the Radboud University 
Nijmegen Medical Center during the period 1993 and 2009 were selected (N = 192). Without revision 
of the primary histology at this stage, cases were selected with (1) a  noninvasive or superficially 
invasive serous lesion, a hyperplastic lesion with/without atypia, or EIC in the endometrium described 
in the original pathology report, and (2) tissue from both ovaries, the fallopian tubes in toto, and the 
uterus were available for revision. Thirty-eight cases fulfilled these criteria, and hematoxylin-and-
eosin-stained sections of all tissues were extensively reviewed for the presence of EIC by an expert 
gynecopathologist (JB), using previously published criteria.11,22 A total of 9 cases with SOC and 
concurrent EIC were identified and included in this study. For each case, patients’ demographics and 
clinicopathological findings were determined from our institution’s medical and operative records, 
including age, International Federation of Gynecology and Obstetrics (FIGO) stage, and the extent 
of the ovarian carcinoma, lymphovascular space invasion (LVSI), and the number of endometrial 
slides reviewed.
Immunohistochemistry
For assessment of protein expression by immunohistochemistry, 4-µm tissue sections were prepared 
from archival, formalin-fixed, paraffin-embedded tissue of both SOC and EIC and processed using 
standard techniques. A p53 monoclonal antibody (clone DO-7, Neomarkers, Fremont, CA) was used 
at a dilution of 1:250. A monoclonal antibody for Ki-67 (clone MIB-1, Dako, Glostrup, Denmark) was 
used at a dilution of 1:200; and for estrogen receptor (ER; clone SP-1, Thermo Scientific/Lab Vision, 
Fremont, CA), a monoclonal antibody was used at a dilution of 1:100. A monoclonal antibody for 
progesterone receptor (PR; clone PgR636, Dako) was used at a dilution of 1:500. After the application 
of appropriate secondary antibodies, a standard streptavidin-biotin technique (Vector Laboratories, 
Burlingame, CA) with diaminobenzidine as chromogen was used. All slides were counterstained 
with hematoxylin. Protein expression was scored as both the percentage of positively stained cells 
and the intensity of staining (-, negative; +, slight; ++, moderate; and +++, strong). For Ki-67, the 
percentage of immunostaining was assessed by average of 5 high-power fields. All slides were 
analyzed by 2 independent observers (TR and LvK).
Analysis of p53 mutation status
Both the SOC and its concordant EIC were analyzed for TP53 mutations. In all cases, normal 
endometrium/myometrium and normal ovarian stroma served as reference tissue to allow the 
identification of possible somatic mutations. Tissue sections (7 µm) were mounted on glass-
foiled polyethylene naphthalate membrane-covered glass slides (Leica, Rijswijk, The Netherlands) 
and stained with cresyl violet (Applied Biosystems/Ambion, Austin, TX) according to suppliers 
instructions. After drying, sections were covered with PinPoint solution (ZymoResearch, Orange, CA). 
Laser-capture microdissection (LMD6000, Leica Microsystems, Wetzlar, Germany) was performed to 
isolate clusters of cells for genetic analysis. DNA isolation was performed as previously described.23 
Genomic DNA was amplified by polymerase chain reaction using M13-tailed primers designed 
to amplify exons 5 to 8 of TP53.23 Polymerase chain reaction products were sequenced from both 
strands using M13 primers. Data were analyzed using Chromas software (Version 1.45, Griffith 
University, Queensland, Australia). Candidate mutations found by the software were compared with 
a reference database for cancer-associated TP53 mutations (International Agency for Research on 
Cancer TP53 Database, http://www-p53.iarc.fr/). Samples were scored as TP53 mutation-positive 
only if an identical mutation was identified in both the forward and reverse sequences.
DNA ploidy assessment in tissue sections
Measurement of the DNA ploidy status was performed as described previously.24,25 In brief, 7-µm 
thick paraffin-embedded tissue sections were incubated with primary antibody directed against 
Ki-67 (clone MIB-1, Dako). Subsequently, nuclear DNA was stoichiometrically stained using 
DRAQ-5 (Biostatus Limited, Leicestershire, UK). For each case, representative areas were selected 
by an experienced gynecopathologist (JB) and consisted of the following: (1) areas classified 
histopathologically as EIC with (2) areas containing normal endometrium/myometrium as diploid 
reference tissue, and (3) areas containing SOC with (4) areas containing normal ovarian stroma 
as diploid reference tissue. Images of DRAQ-5 and Ki-67 were acquired simultaneously using 
fluorescence microscopy. Automated recognition of nuclei was performed, and if required, results 
of automatic segmentation were interactively corrected. For nuclei in EIC and SOC, DNA index (DI) 
values were calculated using the respective diploid reference tissues (DI = 1.00 means diploidy). To 
be able to differentiate between proliferating euploid cells and aneuploid cells, only Ki-67-negative 
nuclei were analyzed. Those nuclei in EIC and SOC with DI greater than 1.25 were considered 
aneuploid. From these, the percentage of aneuploid cells (extent of aneuploidy) and the average DI 
value (degree of aneuploidy) were calculated.
Statistics
All data analyses were performed using SPSS software (version 16.0, SPSS Inc, Chicago, IL). The 
Fisher exact test was used to calculate p-values for association of p53 expression between EIC and 
SOC. To compare the extent and degree of aneuploidy between EIC and SOC, the Sign test was used.
RESULTS
Clinical findings
Nine cases of previously diagnosed SOC fulfilling our criteria were identified. In each case, noninvasive 
or microinvasive EIC was confirmed in the uterine specimen, whereas none of the cases exhibited a 
STIC in their fallopian tubes after examination. In 2 of the 9 cases, EICs were partially microinvasive. 
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However, based on the total extensiveness of the EIC in the various histopathological slides in these 
2 cases, and after review by our expert gyneco-pathologist, the lesions in the endometrium did not 
meet the criteria for minimally invasive UPSC. Therefore, we denoted these lesions as microinvasive 
EIC. Table 1 summarizes the results of histopathological examination of the endometrium and 
fallopian tubes of the included patients. A median of 5 endometrial sections (range 2-10) of each 
uterus were evaluated. The mean age of the patients at presentation was 66.4 years (range 53-82 
years). Furthermore, SOC with coinciding EIC only present in an endometrial polyp was identified in 
1 case (case 6), whereas all patients with both EIC and concordant SOC had metastases to omentum, 
peritoneum, and/or serosa of the uterus and fallopian tubes.
Table 1: Patient characteristics and pathological findings in serous ovarian cancer patients with complete 
uterine and tubal examination (N = 9).
Case
Age
(years)
Ovarian 
carcinoma
histology
Adnexal
involvement
EIC 
present
Uterine 
LVSI
Endometrial 
sections 
evaluated
STIC 
present
1 59 Serous Bilateral Yes No 3 No
2 53 Serous Bilateral Yes No 10 No
3 62 Serous Bilateral Yes* Yes 7 No
4 66 Serous Unilateral Yes Yes 5 No
5 76 Serous Unilateral Yes No 4 No
6 70 Serous Bilateral Yes*,† No 2 No
7 53 Serous Bilateral Yes No 8 No
8 82 Serous Unilateral Yes Yes 4 No
9 77 Serous Bilateral Yes No 5 No
EIC: endometrial intraepithelial carcinoma; LVSI: lymphovascular space invasion; STIC: serous tubal intraepithelial carcinoma; *EIC: 
was micro-invasive in these cases, without myometrial invasion; †EIC: was only present in a polyp.
Immunohistochemical features
Immunohistochemical findings in both intrauterine EIC and its concordant SOC are summarized 
in Table 2. Immunostaining for the 4 protein markers (p53, Ki-67, ER, and PR) revealed almost 
identical expression patterns and similar intensities in each pair of EIC and coincident SOC. In 6 of 
the 9 cases, both EIC and its concordant SOC showed strong nuclear staining for p53. Interestingly, 
in the other 3 cases, p53 immunostaining was absent in both EIC and in SOC. The probability of 
these findings by chance is p = 0.012. Percentages of Ki-67 nuclear staining ranged from 5% to 90%, 
although the percentage of positive staining was almost identical in each pair of EIC and SOC. The 
same holds true for the steroid hormone receptors (ER and PR); although most cases showed no 
expression of PR in EIC and SOC, 2 of the 9 cases showed nuclear staining for both; whereas in 6 
cases, nuclear expression of ER was found in both coincident lesions. Two representative cases with 
their immunostaining pattern for both EIC and SOC are presented in Figure 1.
Table 2: Immunohistochemistry characteristics of endometrial intraepithelial carcinoma and its concordant 
serous ovarian carcinoma (N = 9).
p53 Ki-67 (%) ER PR
Case EIC SOC EIC SOC EIC SOC EIC SOC
1 - - 60% 70% + ++ - -
2 - - 20% 20% + + + +
3 +++ +++ 30% 50% + ++ - -
4 +++ +++ 80% 80% + - - -
5 +++ +++ 5% 5% - - - -
6 - - 50% 70% +++ +++ - -
7 +++ +++ 30% 30% - - - -
8 +++ +++ 70% 90% + ++ - -
9 +++ +++ 60% 80% ++ ++ + +
EIC: endometrial intraepithelial carcinoma; SOC: serous ovarian carcinoma; ER: estrogen receptor; PR: progesterone receptor. The 
intensity of staining was scored as; - (negative); + (slight); ++ (moderate); +++ (strong).
TP53 mutations in EIC and SOC
The similarities in p53 protein expression between EIC and coinciding SOC led us to investigate 
whether this was a result of TP53 mutations in exons 5 to 8 and whether these mutations were 
similar in EIC and coinciding SOC. In all 9 cases, we were able to successfully analyze exons 5 to 8 
of the TP53 gene in both the tumor and its concordant EIC. Identical TP53 mutations were found 
in both EIC and SOC in 3 of the 9 cases (33%; Table 3: cases 3, 7, and 8), and coincided with high 
p53 protein expression in these lesions (Table 2). The adjacent normal tissue in these cases did not 
contain mutated TP53, indicating that the mutations were EIC and tumor specific. Although the 
detected mutations were identical between EIC and the corresponding SOC, the type of mutations 
between cases was different. In 2 cases (cases 1 and 6), we found a TP53 mutation in EIC, whereas the 
corresponding SOC showed a wild-type TP53 sequence. In the 4 other cases, the sequencing data 
revealed no mutations in exons 5 to 8 in either the EIC or the ovarian carcinoma.
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Figure 1: Representative sections of endometrial intraepithelial carcinoma (EIC) and serous ovarian 
carcinoma (SOC) stained for different proteins by immunohistochemistry. Case numbers correspond to the 
cases summarized in Tables 1 & 2. HE: hematoxylin-eosin staining; ER: estrogen receptor; PR: progesterone 
receptor.
Table 3: TP53 mutation analysis of endometrial intraepithelial carcinoma (EIC) and its concordant serous ovarian 
carcinoma (SOC).
Case Tissue
Coding 
Description
Base
change
Codon Effect
Reported ovarian 
Carcinoma with 
this mutation
Total Citations 
for this 
mutation
1 EIC
Cntr Endometrium
SOC
Cntr Ovary
c.878G>A 
None
None
None
G > A 293 Missense 5 51
2 EIC
Cntr Endometrium
SOC
Cntr Ovary
None
None
None
None
3 EIC
Cntr Endometrium
SOC
Cntr Ovary
c.659A>G 
None
c.659A>G 
None
A > G
A > G
220
220
Missense
Missense 50 398
4 EIC
Cntr Endometrium
SOC
Cntr Ovary
None
None
None
None
5 EIC
Cntr Endometrium
SOC
Cntr Ovary
None
None
None
None
6 EIC
Cntr Endometrium
SOC
Cntr Ovary
c.696C>T 
None
None
None
C > T 232 Silent 2 71
7 EIC
Cntr Endometrium
SOC
Cntr Ovary
c.832C>G
None
c.832C>G 
None
C > G
C > G
278
278
Missense
Missense 20 303
8 EIC
Cntr Endometrium
SOC
Cntr Ovary
c.527G>A
None
c.527G>A
None
G > A
G > A
176
176
Missense
Missense 30 404
9 EIC
Cntr Endometrium
SOC
Cntr Ovary
None
None
None
None
EIC: endometrial intraepithelial carcinoma; SOC: serous ovarian carcinoma; Cntr: control tissue as reference; Data 
adapted (http://www-p53.iarc.fr/).
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In situ DNA ploidy analysis
The DNA ploidy status of both EIC and concordant SOC were analyzed for each case. For each patient, 
3 microscopic fields were measured for each lesion (EIC and SOC), with a mean of 57 nuclei measured 
per field (range 19-115). Both the percentage of aneuploid cells and the degree of aneuploidy were 
calculated. The degree of aneuploidy was expressed as the mean amount of DNA per cell (i.e. DI) 
compared to normal diploid endometrial and ovarian control tissue in nonproliferating Ki-67-
negative cells. DNA ploidy analyses of individual nuclei demonstrated an increase in the number 
of aneuploid nuclei in 8 of the 9 SOCs compared to their corresponding EIC (p = 0.039; Figure 2). 
In addition, the DI per nucleus in SOC was higher (i.e. more aneuploid) compared to EIC (in 8 of 
9 cases; p = 0.039). The combined probability of these findings by chance is p = 0.0015. When EIC 
contained aneuploid cells, the DNA content per cell in the associated tumor was at least comparable 
or higher. In one case (case 9; Figure 2), the EIC contained more aneuploid cells with a higher DNA 
index compared to its coinciding ovarian tumor.
DISCUSSION
The pathogenesis of SOC in women has been subject to extensive research and controversy. The 
traditional view holds that ovarian cancer arises from Müllerian epithelium on the ovarian surface or 
from intracortical inclusion cysts; however, evidence at the clinical, histopathological, or DNA level 
is lacking to prove this concept. Here, we provide support for our previously described hypothesis10 
that EIC is a likely precursor lesion for SOC based on immunohistochemical staining patterns, TP53 
mutation, and DNA ploidy analyses. 
Our immunohistochemistry data provide first evidence for a possible relation between EIC and 
coinciding SOC. We found that immunostainings for 4 proteins (p53, MIB-1, ER, and PR) revealed 
almost identical staining patterns and similar intensities for each pair of EIC and corresponding SOC. 
These findings are concordant with recently published data in which similar expression profiles 
were shown between EIC and extra-uterine deposits in the ovaries, fallopian tube, omentum, 
or peritoneum.22,26,27 Our histopathologic examination and immunohistochemical data alone 
cannot unequivocally distinguish between a monoclonal or multicentric origin. EIC in the uterine 
cavity, although without myometrial invasion, can be associated with extensive extra-uterine 
carcinomatosis.26,28-30
Figure 2: Scatterplot of in situ DNA ploidy analysis of endometrial intraepithelial carcinoma (EIC) and its 
concordant serous ovarian carcinoma (SOC). X-axis shows the percentage of aneuploid cells in the different 
tissues, whereas the Y-axis indicates the degree of aneuploidy for each individual tissue type, measured as 
the total amount of DNA in non-dividing Ki-67 negative cells. Normal diploid endometrial and ovarian tissues 
were used as reference tissues. Overall, the number of aneuploid cells and the degree of aneuploidy was 
significantly higher in SOC: compared to EIC: (p = 0.0015). DI: DNA index; cntr: control tissue.
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Several theories have been proposed to explain the relationship between intra-uterine disease 
and extra-uterine disease, including early lymphatic spread and synchronous primary tumors 
(multicentricity). EIC may present with focal LVSI and lymphovascular metastasis may explain their 
extra-uterine spread in some cases. However, only 3 of the 9 cases of EIC in this study with concordant 
SOC showed LVSI. Importantly, EIC can present with extensive peritoneal metastases. Shedding of 
the (pre)malignant tumor cells into the uterine cavity after which the cells are transported through 
the fallopian tube lumen onto the ovaries and other pelvic peritoneal surfaces is the most likely 
mechanism. This is also substantiated by infrequent findings of so-called intransit deposits of serous 
carcinoma cells in the fallopian tube. Alterations in cell surface adhesion molecule expression, 
including E-cadherin and β-catenin, is associated with the loosely cohesive nature of these (pre)
malignant cells resulting in implantation at distant sites.31-33 
The most widely accepted model of evolution of primary cancers to metastases is the clonal evolution 
model in which tumors develop by a process of linear clonal evolution driven by accumulation of 
somatic genetic alterations. Mutation of the TP53 tumor suppressor gene has been detected in a 
diverse array of tumor types and is the most commonly altered gene in human malignancies known 
to date.34 Although the TP53 gene consists of a total of 11 exons, approximately 90% of mutations 
occur in exons 5 to 8.34 Studies have already shown a high prevalence of TP53 mutations in UPSC 
and its precursor EIC: up to 90% and 80%, respectively.21,29 Importantly, molecular studies on a small 
number of cases have recently found identical TP53 mutations in EIC lesions and their corresponding 
extra-uterine tumor deposits, suggesting a clonal relationship.14,21,26 In the present study, we 
identified identical TP53 mutations in each pair of EIC and concordant SOC in 3 of the 9 cases (33%), 
highly suggestive for a clonal origin. In 2 cases, TP53 mutations were found in EIC and not in their 
corresponding SOC. However, both mutations have a relatively rare incidence in human tumors and 
more specifically in ovarian carcinoma (Table 3), and one of the mutations is a silent mutation (case 
6) not causing changes in the amino acid sequence of the p53 protein. We speculate that these 2 
mutations do not provide a major advantage for the malignant progression of EIC toward SOC. In 4 
other cases, mutation analysis revealed no TP53 mutations in exons 5 to 8 in EIC or SOC. In addition, 
we expected to find TP53 mutations in those cases with immunohistochemically negative staining, 
most likely based on frameshift mutations. However, although approximately 90% of human TP53 
mutations occur in exons 5 to 8, we cannot rule out the possibility of p53 function altering mutations 
within other exons of the TP53 gene, which were not investigated in this study. 
It can be argued that EIC found in the endometrium represents intraepithelial spread from serous 
peritoneal or ovarian carcinomas. This cannot entirely be refuted on purely morphologic and 
immunohistochemical characteristics. DNA aneuploidy, an aberrant chromosome number, has 
been suggested as a useful marker for neoplastic progression of premalignant lesions at different 
localizations, including esophagus, skin, head and neck, and colon.35,36 It has been demonstrated 
previously that most of ovarian carcinomas are aneuploid.37,38 Our finding of a greater-than-diploid 
DNA content in nondividing epithelial cells in both EIC and SOC indicates aneuploidy in both lesions. 
More importantly, the severity of DNA aneuploidy in SOC was higher compared to the associated 
EIC in 8 of the 9 cases, suggesting an accumulation of DNA aberration.
In conclusion, it should be emphasized that the data of this study are presented as a first indication 
for EIC as a possible precursor lesion for SOC, based on a retrospective analysis of the endometrium 
with a limited number of samples and markers. In contrast, the view of ovarian carcinogenesis 
has been challenged lately through evidence that SOC arises in the fimbriae of the fallopian 
tube.39,40 This most widely accepted concept at present originated with the discovery of STIC in 
the fimbriae of BRCA mutation carriers. Subsequently, STICs were reported in women with ovarian 
or peritoneal serous carcinomas, regardless of family history.41 Based on our findings, we propose 
that EIC is another credible source of SOC along with fallopian tube precursors. Total analysis of the 
endometrium has not been part of the routine workup in patients with ovarian cancer. In most cases, 
limited tissue blocks of the endometrium were available or only a minimal fragment was archived. 
Therefore, we expect that the incidence of coexisting EIC and SOC that we report in this study is 
a significant underestimation. Only a prospective in-depth analysis of the total endometrium will 
reveal its true incidence. Despite this pitfall of our study, our data support a new concept of the 
origin of SOC. With the endometrium as a possible origin of SOC, it is not difficult to understand 
the preventive effect of tubal ligation and hysterectomy. In addition, all mechanisms that lead to 
‘‘incessant’’ ovulation (pregnancy, breast feeding, and oral contraceptives) also have a clear impact 
on the endometrium and may thus interfere with the development of intrauterine premalignancies. 
Although the significance of the endometrium as a source of pelvic and ovarian serous carcinoma 
has to be further validated in a preferably larger longitudinal prospective study, these data could 
have clinical implications for ovarian cancer management in the future, as its precursor may reside 
in the endometrium.
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Uterine papillary serous carcinoma (UPSC) is an aggressive variant of endometrial cancer. It has 
a propensity to metastasize throughout the abdomen, similar to serous carcinoma of the ovary. 
At present, most clinicians are unfamiliar with the clinical aspects and management of UPSC. 
Unfortunately, to date little prospective evidence exists regarding how best to treat this subset of 
patients. 
THE NEED FOR A PROSPECTIVE CLINICAL TRIAL
In this thesis, we performed a review of literature to summarize the latest results of various clinical 
management options in the different sub-stages of UPSC (Chapter 2). Comprehensive surgical 
staging with maximal cytoreduction seemed to be essential for optimal management. In general, 
adjuvant radiation therapy is recommended to treat patients with endometrial carcinoma at high 
risk for recurrent disease. However, external radiation therapy seemed not to be of any significant 
value for survival in UPSC patients. Brachytherapy improved local control, whereas chemotherapy 
showed to be beneficial in all (sub)stages of UPSC reducing local and distant recurrences. 
Most data on the clinical management of UPSC patients are based on small, retrospective, single 
institution studies that are plagued by the usual biases and confounders. A proper prospective 
trial specifically including UPSC patients should be performed to determine the optimal adjuvant 
treatment strategy. At present, only a very few prospective trials have started to address this question 
(www.clinicaltrials.gov). Most prospective studies to date are non-randomized, only investigating 
the combination of pelvic radiation and adjuvant chemotherapy in a single arm setting, or testing 
a new biological in a fase-I or fase-II trial. Intriguingly, some randomized prospective trials do exist 
testing the efficacy of external pelvic radiation therapy, with or without the addition of combination 
chemotherapy using cisplatin and paclitaxel. However, in these trials, all subtypes of high-grade 
endometrial cancer patients or recurrent endometrial cancer patients are lumped together 
and randomized. Despite the fact that also UPSC patients will be included in these prospective 
clinical trials, we argue that these studies will not reveal the optimal adjuvant treatment strategy 
specifically for UPSC patients. The number of included UPSC patients will be relatively low due 
to its rarity, resulting in a lack of power to perform statistical analysis in both treatment arms on 
survival outcome specifically for this group. Furthermore, in these studies a comprehensive staging 
procedure is not mandatory for inclusion of endometrial carcinoma patients. This may undermine 
the effect of adjuvant therapy specifically in the UPSC group. 
Therefore we feel there is an urgent need for a prospective randomized clinical trial specifically 
for UPSC patients. To be adequately powered, international collaboration will be needed. In 
such a trial, inclusion criteria are a comprehensive surgical staging procedure with maximum 
cytoreduction, and UPSC histology (both pure and mixed) confirmed on final uterine specimen. 
Patients are randomized into two arms of adjuvant therapy: 1) standard treatment (observation 
only or pelvic radiation therapy with/without brachytherapy, depending on stage of disease), 
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compared to 2) pelvic radiation with/without brachytherapy and combination chemotherapy (in 
all stages of UPSC disease, including Stage IA). Although a prospective study with three arms would 
be even more informative (standard treatment versus combination chemotherapy versus radiation 
and combination chemotherapy), the number of patients with UPSC needed for this study to be 
adequately powered might not be feasible. Pending such a randomized controlled trial, we propose 
an algorithm which can be useful in the clinical management of UPSC patients (Figure 1).
Figure 1: UPSC management algorithm (adapted from Boruta et al.1).
DIFFICULTIES FOR THE GYNECOLOGIST REGARDING UPSC
To date, it remains difficult to predict extra-uterine disease, recurrence risk, and survival in a UPSC 
population. Traditional risk factors in endometrial carcinoma patients associated with recurrence 
and survival, such as myometrial invasion, lymphovascular space invasion (LVSI), age at diagnosis, 
tumor size, and DNA aneuploidy, were not associated with recurrence risk and survival in UPSC 
patients.2-6 In this thesis, we substantiated these findings even more (Chapter 3, Chapter 4, and 
Chapter 5). We and others were able to show that preoperatively elevated serum CA-125 is an 
independent predictor for the presence of extra-uterine disease and an independent risk factor 
for survival in UPSC patients (Chapter 3).7, 8 Serum CA-125 might have potential clinical application 
in the management of UPSC patients, although sensitivity and specificity ranged from 78-100%. 
More importantly, negative predictive values between 52-74% have been reported, obviously too 
low to consider a UPSC patient not having extra-uterine disease solely based on preoperatively 
non-elevated serum CA-125. In addition, others showed that preoperative CA-125 levels were not 
predictive of complete or suboptimal cytoreduction, and may not predict recurrence in the absence 
of other clinical findings.9, 10 
Because of the particularly troublesome feature of UPSC to predict extra-uterine spread of 
disease preoperatively, imaging might be considered prior to a surgical comprehensive staging 
procedure. However, the sensitivity of preoperative magnetic resonance (MR) imaging or computed 
tomography (CT) for diagnosis of lymph node metastases or extra-uterine disease in endometrial 
carcinoma was only 50-62%, with a specificity of 92-95%.11-13 The high number of false-negatives 
on cross-sectional imaging was explained by the high percentage of positive nodes measuring less 
than 10mm in diameter at pathological examination. Since microscopic metastases are below the 
detection limits of cross-sectional imaging modalities, both MR imaging and CT seem to have a 
limited value in the preoperative assessment of extra-uterine disease in UPSC patients. 
There is an urgent need for other preoperative tests or tumor biomarkers that can be used to 
assess disease status and/or that can reliably discriminate between early and advanced stages 
of UPSC. Investigators have been searching for other markers that can be used either alone or in 
combination with serum CA-125. One of the novel potential serum markers includes HE4, a soluble 
mesothelin-related peptide. This HE4 was elevated in all stages of endometrial cancer and was 
more sensitive in the detection of extra-uterine disease compared to serum CA-125.14, 15 Another 
potential marker might be YKL-40, a secreted glycoprotein. It was frequently elevated in all stages 
of endometrial cancer and may identify high-risk subsets of patients.16 Combining YKL-40 and CA-
125 measurements improved the sensitivity and specificity for detecting advanced stage of disease 
even more. However, to date none of these markers has been adequately evaluated in women with 
UPSC.
DIFFICULTIES FOR THE PATHOLOGIST REGARDING UPSC
Pathological examination has been the cornerstone for the diagnosis of UPSC, most often using 
endometrial biopsy or Dilatation & Curettage (D&C) specimen from the outpatient clinic. UPSC is 
known to arise in a background of atrophic/weakly proliferative endometrium or in endometrial 
polyps, often displays considerable morphologic heterogeneity, all associated with a reduced 
accuracy of the endometrial sampling.17, 18 In addition, in mixed UPSC cases distinction of serous 
histology from endometrioid histology may be challenging, with up to 20% of the diagnoses of 
histological type being altered after surgery.19-21 To put this into perspective, within our cohort of 
UPSC patients, preoperative endometrial biopsy or D&C specimen were available in 105 of 115 
cases. Without review of these histopathological slides, only in 54 of 105 cases (51.4%) UPSC was 
diagnosed preoperatively (data not shown). To note, 34 of the remaining 51 cases (66.7%) involved 
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mixed UPSC cases. Incorrect preoperative diagnosis has potential consequences, since UPSC 
patients should be treated differently and more aggressively compared to their more common 
endometrioid endometrial carcinoma (EEC) counterpart. In a small D&C or biopsy specimen of a 
high-grade carcinoma, we suggest it might be sufficient to indicate that a serous component 
cannot be excluded, which might encourage the gynecologist to perform a comprehensive staging 
procedure. This also illustrates the need for more specific tools or biomarkers to identify UPSC more 
adequately.
Although morphology will always remain the cornerstone in the evaluation of serous tumors 
(combined with clinical history, appropriate gross evaluation, and sampling), immunohistochemistry 
can be helpful, if interpreted in the right context, in establishing the correct diagnosis.22-24 This could 
be especially important for endometrial biopsy or D&C specimen in which the diagnosis remains 
inconclusive based on morphological criteria. At present, little is known about the biomarker 
profile and molecular pathogenesis of UPSC. Most commonly UPSC are hormone (estrogen and 
progesterone) receptor negative, have elevated Ki-67 proliferation indices, and show mutations in 
the TP53 tumor suppressor gene in up to 75-90% of the cases.25-27 In contrast, the more common EEC 
frequently display microsatellite instability, preservation of estrogen receptor (ER) and progesterone 
receptor (PR) status, and mutations in the PTEN and KRAS genes.28, 29 However, overlapping molecular 
profiles have been found in which poorly differentiated EEC lose hormonal receptors status and gain 
TP53 gene mutations, whereas UPSC retained hormone receptor expression.1, 26, 28 These overlapping 
profiles can make accurate diagnosis even more difficult, especially in very poorly differentiated 
tumors and mixed UPSC. 
Recently, investigators have been focusing on promoter methylation specifically in endometrial 
carcinoma, since this is a cancer type-specific epigenetic event that plays an important role in tumor 
development. It was shown that promoter methylation was more common in EEC than UPSC cases, 
and 90% of EEC and 70% of UPSC cases could be predicted using two promoter loci.30 Possibly a 
panel of methylation biomarkers could be useful to distinguish between these two subtypes of 
endometrial cancer in the near future. Furthermore, L1-CAM as a novel marker for endometrial and 
ovarian carcinomas was described.31 While L1-CAM staining was always positive in UPSC, EEC cases 
were negative.31, 32 Although the majority of mixed UPSC may be correctly diagnosed on routine H&E 
stained slides, cases with tiny foci of serous or clear cell types, or with large undifferentiated areas, 
are easily misdiagnosed. As mixed UPSC represents a large proportion of cases (Chapter 5), L1-
CAM staining might be very helpful for the detection of a serous component, allowing a conclusive 
diagnosis and avoiding false classification.
Although many investigators to date are searching for a highly sensitive and specific biomarker 
for the identification of UPSC histology, such a marker has not been identified yet. Despite the 
attenuation of immunophenotypic differences between serous and poorly differentiated EEC, most 
studies found that a panel of antibodies, including ER, PR, p53, p16, PTEN, and Ki-67, is useful in 
separating these two subtypes of endometrial carcinoma.33-35
In the search for other preoperative tools to identify UPSC more adequately, an interesting 
finding was the high frequency of atypical or malignant endometrial cells in preoperative cervical 
cytology of UPSC patients (Chapter 4). Cervical cytology is routinely performed in patients with 
abnormal vaginal bleeding to exclude cervical pathology. Although cervical cytology appeared 
to be a poor screening tool for endometrial carcinoma because of its low sensitivity36, normal or 
atypical endometrial cells found in cervical cytology of postmenopausal women were predictive 
for endometrial pathology, cervical stroma involvement and lymph node metastases.37-39 We found 
that 87.5% of UPSC patients had abnormal cervical cytology specific for endometrial pathology, 
and abnormal cytology was associated with extra-uterine disease (Chapter 4). This high frequency 
most probably is due to the papillary architecture of UPSC and the propensity to exfoliate, although 
the molecular biology to account for this observation has not been thoroughly investigated yet.40, 41 
More prospective research should be performed, though preoperative abnormal cervical cytology 
might give an indication to suspect a more aggressive uterine tumor. To further substantiate this, 
especially when endometrial biopsy or the D&C specimen is inconclusive, immunohistochemistry 
on cytology might be considered to identify high-grade malignant cells, e.g. serous, clear cell, or 
undifferentiated cells, from the more common endometrioid or squamous cells. We performed a 
pilot study using Ki-67 and p53 on cervical cytology as to differentiate between EEC and UPSC, 
however results were disappointing. 
THE METASTATIC POTENTIAL OF UPSC AND ITS PRECURSOR
UPSC is an aggressive form of endometrial carcinoma with a dismal prognosis. UPSC has a very 
close resemblance with serous ovarian carcinoma (SOC), fallopian tube cancer and other types of 
pelvic serous cancers. The malignant cell type is morphologically identical for all of these types 
of cancer and the dissemination of disease and its prognosis is very similar. Several studies have 
reported on the metastatic properties of UPSC, with a high incidence of pelvic (41,9%) and para-
aortic (43,3%) lymph node metastases and omental involvement (15-35%).42, 43 Typically, 55-87% 
of the patients have extra-uterine spread of disease at the time of diagnosis.43-45 The mechanisms 
proposed to explain the characteristic widespread intra-abdominal dissemination of UPSC include 
transtubal expulsion of malignant cells into the peritoneal cavity46, 47, vascular/lymphatic invasion47, 
48, and multifocal disease.47, 49-51 Although the molecular biology to account for these observations 
have not been thoroughly investigated, there might be a relation with change of expression of 
proteins such as integrin, e-cadherin, β-catenin and L1-CAM. Typically, UPSC demonstrates genetic 
instability at the chromosome level, resulting in a high level of aneuploidy. The proportion of non-
diploid karyotypes in UPSC ranged from 70-95%.52, 53 One of the primary genetic defects is believed 
to be mutation of the TP53 tumor suppressor gene, observed in 75-90% of tumors.54 The expression 
of the protein E-cadherin, generally considered as a suppressor of tumor progression, has been 
found to be reduced in UPSC cases. Down-regulation is believed to be a critical step in the epithelial-
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mesenchymal transition (EMT).55, 56 During metastatic progression, polarized epithelial tumor 
cells undergo a transition into motile mesenchymal cells, allowing them to invade the basement 
membrane, enter the blood vessels and disseminate to secondary organs. L1-CAM is highly 
expressed in UPSC cases, with emphasis on the leading edge of the tumor.32 L1-CAM leads to down-
regulation of ER/PR and E-cadherin, which is associated with malignant transformation. In addition, 
up-regulation of L1-CAM was associated with enhanced cell invasion, and enhances cell motility by 
up-regulation of integrin expression.57, 58 Therefore L1-CAM is an important component in serous 
tumor progression. Furthermore, expression of β-catenin, which plays a role in cell-cell adhesion, 
intracellular signaling, and maintenance of tissue architecture, is down-regulated in UPSC.59 Possibly 
decreased epithelial cell-cell adhesion contributes to the typical capability of serous tumor cells to 
exfoliate from the primary tumor and disseminate distantly. 
Although the carcinogenesis of UPSC is largely unknown, EIC has been described as the non-invasive 
precursor of UPSC.60 It was often multifocal, found adjacent to UPSC in >80% of cases (Chapter 5), 
and exhibits p53 mutations and cytologic features similar to that observed in UPSC.61, 62 Loss of 
heterozygosity (LOH) at the TP53 locus is consistently identified in UPSC, whereas most EIC contained 
only one mutated TP53 allele.27 Furthermore, concordant mutations were identified among EIC and 
UPSC lesions, and these observations suggest that UPSC develops from EIC and that TP53 mutation 
is an early change in tumor progression.27 EIC has rarely been reported as the initial diagnostic 
manifestation of non-invasive UPSC.61 Markedly, EIC without invasive carcinoma within the uterine 
corpus was found coinciding with metastases on ovaries, fallopian tube or peritoneum.62-65 Although 
lymphovascular metastasis may explain the extra-uterine spread of EIC in some cases, only a very 
few cases of EIC itself showed LVSI (Chapter 5). The loosely cohesive nature of these cells within 
EIC lesions, primarily based on similar changes in expression of cell-cell adhesion proteins as in 
UPSC, predisposes them to shed easily. Shedding of the (pre)malignant tumor cells into the uterine 
cavity after which the cells are transported through the fallopian tube lumen onto the ovaries and 
other pelvic peritoneal surfaces is the most likely mechanism. Baergen and colleagues were the first 
to show that EIC and concordant extra-uterine serous lesion were of clonal origin, based on TP53 
mutation analysis.66 In addition, identical TP53 mutations in noninvasive serous endometrial lesion 
or EIC and associated extra-uterine serous carcinoma deposits have been recently described.27, 67 
Interestingly, in patients with bilateral ovarian cancer the genetic change in the TP53 gene was 
identical in both ovarian tumors, highly speculative for a site of origin elsewhere.67 Furthermore, the 
TP53 data discussed above are inconsistent with the interpretation that EIC and extra-uterine serous 
carcinoma represent independent primaries. In contradiction to the multicentricity theory, the TP53 
gene mutation profiles of EIC or minimal invasive serous carcinoma were identical to those of their 
corresponding extra-uterine tumor deposits, consistent with a clonal, metastatic process.27, 64, 66, 67
CLINICAL MANAGEMENT OF EIC
In contrast to the usual behavior of conventional carcinoma in situ of other organs, patients with EIC 
may present with extra-uterine tumor spread in up to 45% of cases, leading to an advanced stage 
and a clinical prognosis similar to that of full-blown UPSC.63, 64 The inability to detect EIC preceding 
UPSC suggests that EIC acquires invasive and metastatic properties early in its development.68 For 
this reason, there is some controversy whether EIC should be classified as true precursor lesion. Such 
concern is further exacerbated by the fact that these patients without myometrial or lymphovascular 
invasion have an excellent prognosis if extra-uterine disease is excluded by staging. In contrast, the 
prognosis is poor if even minimal microscopic extra-uterine disease is found.63, 64 Meticulous staging 
is essential for EIC because the prognosis is excellent, even without adjuvant therapy, if extra-uterine 
disease can be excluded. Clinically, we therefore feel it’s prudent that a complete comprehensive 
staging procedure is performed, even if the lesion is limited to a polyp.
LESION OF ORIGIN FOR SEROUS OVARIAN CARCINOMA
The pathogenesis of serous ovarian carcinoma (SOC) in women has been subject to extensive 
research and controversy. The traditional view holds that ovarian cancer arises from Müllerian 
epithelium on the ovarian surface or from intracortical inclusion cysts, but evidence at the clinical, 
histopathological or DNA level has been lacking to prove this concept. In this thesis, we provided 
data as a first indication for EIC as a possible precursor lesion for SOC (Chapter 7). Analogous to the 
theory for the development of endometriosis, transtubal migration of the loosely cohesive cells from 
EIC foci in the endometrium may be the basis for the development of any type of intraperitoneal 
serous carcinoma, including SOC. Furthermore, implantation in the fallopian tube may explain 
part of the so-called in-transit deposits of serous carcinoma infrequently detected by several 
investigators in the fimbriated end of the tubes. In addition, cases of non-invasive serous lesions 
or EIC in the endometrium with peritoneal serous metastases have been described coinciding with 
STIC in the distal end of the fallopian tube.69 Immunohistochemical staining patterns were identical 
between EIC, STIC, and intraperitoneal serous lesions, and TP53 mutation analyses identified shared 
mutations at all sites.69 At present, whether EIC and STIC are truly related is far from clear. When 
multiple serous tumor sites are identified, specifically ovarian and tubal, the role of EIC or STIC as an 
initiating point, though attractive, is still controversial.69, 70 
Since most of ovarian carcinoma that are identified in BRCA mutations carriers are SOC, examination 
of prophylactic salpingo-oophorectomy specimens should theoretically reveal a precursor lesion in 
at least a subset of these patients. Recent studies of women with hereditary mutations in the BRCA1 
and BRCA2 genes have reported detecting early carcinoma in the fallopian tube in a significant 
percentage of cases; the frequency has varied though between 1-8% (Chapter 6).71-73 These lesions 
are typically identified in the distal portion of the fallopian tube, as a noninvasive carcinoma 
(STIC). Others have now showed that 35-70% of sporadic (nonhereditary) SOC or serous peritoneal 
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carcinoma classified as ovarian primaries showed mucosal tubal involvement and were associated 
with STIC.74 STIC frequently up-regulate oncogene products that are also overexpressed by SOC, 
and have relatively shorter telomeres compared with concurrent SOC.75, 76 Furthermore, STIC and 
SOC were clonally related as the same TP53 mutations were detected in both STIC and SOC.77-79 
Finally, a gene profiling study showed that serous carcinoma from the fallopian tube and ovary were 
indistinguishable, and the expression profile of SOC was more closely related to the fallopian tube 
than to ovarian surface epithelium.80 These studies suggest strongly that the distal fallopian tube 
is an important site for serous carcinogenesis. In addition, more and more investigators are now 
reporting on STIC being identified in a significant portion of serous cancers conventionally classified 
as primary peritoneal.74, 77, 81 The evidence developed over the last 5 years supporting a tubal origin 
for SOC is now much stronger than the cumulative data of several decades investigating ovarian 
inclusion cysts as the site of origin.  Although it is likely that both tubal and non-tubal sites of origin 
for SOC occur, the fallopian tube appears to be more common.
FUTURE PERSPECTIVES
The findings in this thesis offer new possibilities for further research. First, our results demonstrate 
that patients with mixed UPSC have a favorable prognosis and survival outcome compared to 
pure UPSC, in contrast to previously published data.3, 82, 83 Despite the better prognosis for mixed 
UPSC patients, we do suggest any endometrial carcinoma with serous differentiation must still 
be regarded as having high metastatic potential and should be surgically staged. At present, the 
pathogenesis of mixed UPSC remains unclear. The precursor lesion EIC was equally found among 
pure and mixed UPSC cases, suggestive for its role in the carcinogenesis of both types of serous 
endometrial carcinoma. Interestingly, the non-neoplastic endometrium was predominantly 
athrophic/weakly proliferative in pure UPSC cases compared to more hyperplastic with atypia in 
mixed UPSC cases. Since atypical hyperplasia is the well know precursor lesion for EEC, it would 
be interesting to study the role of atypical hyperplasia in the carcinogenesis of mixed UPSC. 
Immunohistochemical and genetic analyses might give further insights whether the endometrioid 
component within mixed UPSC cases originates from atypical hyperplastic lesions, or whether it is 
the result of dedifferentiation within the tumor environment. 
Second, another and intriguing question remains the origin of serous ovarian carcinoma (SOC). 
More and more data is now accumulating that STIC in the fallopian tube is the precursor lesion for 
most serous ovarian and pelvic carcinoma. However, this site of origin remains controversial, since 
epidemiological studies show that tubal ligation and hysterectomy are reducing the life-time risk for 
ovarian cancer by up to 50%. To note, in patients receiving one of these interventions, the ovaries 
and fallopian tubes remain in situ. Furthermore, a significant subset of SOC and serous peritoneal 
carcinoma are not associated with STIC. 
In this thesis, we proposed that EIC is another possible source of SOC along with the fallopian tube 
precursor (STIC). In addition, all mechanisms that lead to ‘incessant’ ovulation (pregnancy, breast 
feeding and oral contraceptives) also have a clear impact on the endometrium and may thus 
interfere with the development of intrauterine premalignancies. The number of serous ovarian or 
peritoneal carcinoma cases which truly reflect a distal fallopian tube (STIC) or endometrial (EIC) origin 
remains to be determined by much larger studies. In addition, in most recent retrospective studies 
the fallopian tubes were not embedded in toto and serially sectioned using the SEE-FIM protocol, 
likely resulting in an underestimation of the incidence of STIC in the distal tube. Furthermore, total 
histopathological review of the endometrium has not been part of the routine workup in serous 
ovarian and pelvic cancer patients, and limited amount of endometrium was sampled. Thus, 
the results of previous studies and of this thesis stress the importance of conducting a proper 
prospective in depth analysis of both the fallopian tubes and total endometrium of all serous 
ovarian and pelvic carcinoma patients to permit discovery of early serous cancers. Subsequently, 
immunohistochemical and genetic analyses should be performed to provide evidence for clonality 
among precursor lesions identified in the endometrium or fallopian tube and the concurrent full-
blown serous carcinoma.
If the fallopian tube is considered the site of origin for most SOC and serous peritoneal carcinoma, 
then preventive strategies become much more realistic.84, 85 Sparing the fallopian tubes during 
hysterectomy for benign uterine indications provides no clear physiological benefit, as the 
remaining tubes are completely devoid of any function in the aftermath of such a procedure, and the 
patients hormone profile is not altered by salpingectomy.86 If adnexal SOC are unequivocally shown 
to develop almost exclusively in the fimbria, salpingectomy alone would be sufficient to reduce 
the risk of serous ovarian and pelvic cancer while preserving ovarian function. Thus, an interesting 
prospective trial would be to include BRCA mutations carriers at risk for serous carcinoma, and to 
randomize these patients into two study arms: 1) perform a complete salpingo-oophorectomy as 
standard of care, or 2) perform a salpingectomy only. This study would need a long term follow-up 
comparing the prevalence of serous ovarian and pelvic cancers. Such a study may shed light on the 
hypothesis that SOC truly is not originating from the ovaries. However, whether SOC and serous 
peritoneal carcinoma have an endometrial or tubal origin still remains a question.
Ultimately, we believe SOC might not be ovarian in origin but rather is secondary. Characterization 
of putative precursor lesions is fundamental in elucidating the molecular pathogenesis of cancer 
and has profound implications for early detection, prevention and treatment.
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SUMMARY
Uterine papillary serous carcinoma (UPSC) is a highly aggressive subtype of endometrial cancer 
that is disproportionately responsible for up to 40% of all endometrial cancer-related deaths. 
UPSC resembles serous ovarian carcinoma (SOC) morphologically and also in its clinical behavior, 
characterized by high recurrence and mortality rates even in early stage of disease. Improving the 
care for patients with UPSC requires further understanding of the etiology and clinical behavior 
of the disease. Chapter 1 reviewed the history, epidemiology, clinical characteristics, preoperative 
assessment options, treatment modalities, and pathogenesis of UPSC and its precursor endometrial 
intraepithelial carcinoma (EIC) as an introduction to the studies performed and described in this 
thesis.
Due to its rarity, most clinicians are unfamiliar with the clinical aspects and management of patients 
with UPSC. Furthermore, little prospective evidence exists regarding how best to treat this subset 
of patients with endometrial cancer. Pending proper prospective randomized trials, in chapter 2 
we performed a review on the clinical aspects of UPSC with a focus on the effects of staging and 
adjuvant therapy on recurrence rate and survival outcome in the different (sub-) stages of UPSC. 
We found that the necessity of comprehensive surgical staging in patients with UPSC cannot be 
overemphasized, since many studies have demonstrated the propensity of UPSC for extra-uterine 
spread. Therefore, comprehensive surgical staging of all UPSC patients should be recommended, 
regardless of the clinical stage at presentation. Furthermore, maximum cytoreduction enhanced 
response to adjuvant therapy and provided a favorable survival rate. With respect to adjuvant 
therapy, external radiation therapy seemed not to be of any significant value for survival. 
Brachytherapy showed to be of minor importance for overall survival, although it did improve local 
control and progression free survival and thus should be considered. Chemotherapy showed to be 
beneficial in all (sub)stages of UPSC, even in stage I disease, reducing local and distant recurrences. 
A particularly troublesome feature of UPSC has been the inability to predict extra-uterine spread 
of disease. A preoperative test or tumor marker that can reliably discriminate between early and 
advanced stages of UPSC would be helpful in the clinical management and planning, and possibly 
in prognostication. In chapter 3 we determined the utility of preoperative serum CA-125 as a 
predictor of extra-uterine disease and as a prognostic factor for survival in patients diagnosed with 
UPSC. In patients with extra-uterine disease the preoperative serum CA-125 level was significantly 
higher (median 124.0 U/mL) compared to patients without extra-uterine disease (median 17.5 U/
mL). Preoperative serum CA-125 > 45 U/mL was significantly associated with the presence of extra-
uterine disease, and UPSC patients with a preoperative CA-125 level > 45 U/mL had a 6.30 times 
greater risk for extra-uterine disease. In addition, advanced FIGO stage and preoperative CA-125 > 
45 U/mL were associated with both progression free and overall survival. Our results showed that 
serum CA-125 elevation was predictive for the presence of extra-uterine disease, and preoperative 
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serum CA-125 was an independent risk factor for survival. Routine measurement of preoperative 
serum CA-125 might be considered in patients with UPSC.
In asymptomatic women, cervical cytology appeared to be a poor screening tool for endometrial 
carcinoma because of its low sensitivity. However, when normal or atypical endometrial cells were 
found in cervical cytology of postmenopausal women, it was predictive for endometrial pathology. 
In chapter 4 we evaluated the presence of shedded atypical endometrial cells in cervical cytology 
of patients with UPSC as compared to patients with EEC. In total, 87.5% UPSC patients had abnormal 
cervical cytology, specific for endometrial pathology preoperatively, in contrast to 37.8% EEC 
patients. Extra-uterine disease was associated with abnormal cervical cytology in patients with UPSC, 
whereas in patients with EEC abnormal cervical cytology was associated with cervical involvement. 
Abnormal cervical cytology specific for endometrial pathology was not associated with PFS in either 
UPSC or EEC patients. Our results showed that abnormal cervical cytology was associated with poor 
prognostic factors, although it cannot be used as prognosticator for survival. 
UPSC often displays considerable morphologic heterogeneity, co-existing with at least one 
other subtype of uterine cancer. It is largely unknown whether the percentage UPSC histology is 
predictive of recurrence rates or survival. Furthermore, histopathologic studies suggested that the 
majority of UPSC develop from endometrial intraepithelial carcinoma (EIC). In chapter 5 we studied 
whether mixed versus pure UPSC histology affected clinical outcome. Furthermore, we assessed 
the uninvolved endometrium in both pure and mixed UPSC cases for their association with EIC. We 
found 50 patient cases (46.3%) with pure UPSC histology, whereas 58 cases (53.7%) had mixed UPSC 
histology. Together with early stage of disease, mixed UPSC histology was associated with lower 
recurrence risk and favorable survival compared to pure UPSC. Both progression free and overall 
survival were significantly shorter in the group of pure UPSC patients compared to mixed UPSC 
(p < 0.001). Atrophic or weakly proliferative endometrium was found in 90.7% of pure UPSC cases, 
whereas hyperplastic endometrium with atypia was more commonly found in 34.7% of patients 
with mixed UPSC (p = 0.004). Our results showed that pure UPSC histology and FIGO stage were the 
most important risk factors for recurrence and survival in patients with UPSC. Furthermore, EIC as 
precursor was equally found in both pure and mixed UPSC cases in 84% of cases, suggestive for its 
role in the carcinogenesis of both types of serous endometrial carcinoma.
Recently, a predisposition for SOC was discovered in the fallopian tubes of women with a germline 
BRCA-mutation. Prophylactic bilateral salpingo-oophorectomy (pBSO) is performed in the majority 
of BRCA-mutation carriers, and incidental findings of occult invasive carcinoma and the precursor 
lesion tubal intraepithelial carcinoma (STIC) were found. Recent studies provided some compelling 
evidence that a proportion of primary SOC actually arised from these precursor lesions. In chapter 
6 we set out to identify tubal epithelial lesions in a large cohort of women with BRCA 1/2 mutation 
who underwent pBSO, in comparison to a large control group of women that underwent BSO for 
non-malignant reasons. A total number of 226 women with a BRCA-mutation and 105 controls 
were included. Of the women with a BRCA-mutation, 6% had a STIC, and 1% had an invasive tubal 
carcinoma in their BSO specimen, in contrast to no tubal neoplasia (STIC or invasive carcinoma) in 
controls (p = 0.004). In the majority of cases, invasive tubal carcinoma and STIC were identified in the 
distal fimbria. Our results showed that occult invasive tubal carcinoma and STIC were present in 7% 
of the BRCA-mutation carriers but were absent in control cases. The fact that invasive carcinomas 
and STICs were not identified in controls marked their uniqueness for women at high risk for SOC 
and therefore their suggested role in carcinogenesis.
At present, experimental or histopathological evidence is lacking for an ovarian origin for SOC, and 
a precursor lesion was never identified in the ovary itself. In chapter 7 we studied an alternative 
hypothesis regarding the site of origin for SOC in which endometrial intraepithelial carcinoma 
(EIC) was proposed to be the precursor lesion. We selected patients with SOC and coinciding 
EIC in the endometrium. Immunostaining for 4 protein markers (p53, Ki-67, ER, and PR) revealed 
almost identical expression patterns and similar intensities in each pair of EIC and coincident SOC. 
Furthermore, identical TP53 gene mutations were found in both EIC and SOC in 33% of cases. DNA 
ploidy analyses demonstrated an increase in the number of aneuploid nuclei in 8 of the 9 SOCs 
compared to their corresponding EIC (p = 0.039). In addition, the DNA index per nucleus in SOC was 
higher (i.e. more aneuploid) compared to EIC (p = 0.039). Our results support our hypothesis that EIC 
is a likely precursor lesion for SOC based on immunohistochemical staining patterns, TP53 mutation, 
and DNA ploidy analyses. With the endometrium as a possible origin of SOC, it is not difficult to 
understand the preventive effect of tubal ligation and hysterectomy.
In chapter 8 we summarized our main findings and discussed our results. We especially stressed 
the need for a prospective trial on the clinical management of patients with UPSC, and we provided 
an algorithm which can be useful in the clinical management pending such a trial. Furthermore, we 
discussed some difficulties regarding UPSC from the gynecologist and pathologist perspective. In 
addition, we discussed the metastatic potential of UPSC and its precursor EIC, and the possible role 
EIC and STIC might play in the pathogenesis of SOC. Finally, we postulated some ideas for future 
research.
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SAMENVATTING 
Kanker is de huidige doodsoorzaak nummer 1  in Nederland, met in 2010 ruim 42.000 overledenen. 
De ziekte is daarmee verantwoordelijk voor bijna een derde van de totale sterfte. Door 
bevolkingsgroei en vergrijzing neemt het aantal sterfgevallen door kanker al decennia geleidelijk 
toe. Binnen de gynaecologische oncologie, welke zich bezig houdt met kanker van het vrouwelijke 
voortplantingsstelsel, kennen we kanker van de baarmoederhals, baarmoeder, eileiders, eierstokken, 
vagina en vulva (omvat schaamlippen, clitoris, uitgang urinebuis, en opening vagina; figuur 1). 
Hiervan komt baarmoederkanker het meest voor, met ongeveer 1930 nieuwe gevallen per jaar in 
Nederland en ongeveer 425 sterfgevallen per jaar. Baarmoederkanker presenteert zich vaak met 
vaginaal bloedverlies gedurende de (post)menopauze. Dit is een alarmsignaal, waardoor in veel 
gevallen de diagnose reeds in een vroeg stadium kan worden vastgesteld. Meestal is hierbij geen 
sprake van uitzaaiingen (metastasen) en omvat de standaard behandeling het operatief verwijderen 
van de baarmoeder en eierstokken, in een aantal gevallen gevolgd door nabehandeling met externe 
röntgenbestralingen. De prognose van deze patiënten is vaak gunstig, met een gemiddelde 5-jaars 
overleving van ongeveer 70-80%.
Essentieel bij alle vormen van kanker, dus ook binnen de gynaecologische  oncologie, is het stellen 
van de juiste diagnose. Met andere woorden: om welke soort kanker (oftewel carcinoom) gaat het 
precies, welk histologisch type? Dit is cruciaal voor de verdere behandeling en prognose van de 
patiënte. Deze diagnose kan worden gesteld door de patholoog-anatoom. Dit doet hij door rel-
evante stukken weefsel uit het chirurgische preparaat te snijden. Met behulp van een microscoop 
wordt een histologische diagnose gesteld, op basis van cel-kenmerken, typische afwijkingen en 
specifieke kleuringen. Het meest vóórkomende histologisch subtype van baarmoederkanker is het 
endometrioïde type (ongeveer 80% van alle gevallen) en kent een goede prognose. 
Hoofdstuk 1 betreft een algemene inleiding op de studies zoals die zijn gedaan en beschreven 
in dit proefschrift. Binnen de verschillende vormen van baarmoederkanker kennen we een 
uitermate agressief histologisch subtype: het sereus carcinoom van de baarmoeder (uterus). 
Ondanks dat dit subtype maar ongeveer 10% van alle baarmoederkanker gevallen per jaar omvat, 
is het verantwoordelijk voor ongeveer 40% van alle overledenen met baarmoederkanker. Dit komt 
met name omdat ten tijde van diagnose sereus carcinoom van de uterus meestal al sprake is van 
vergevorderde ziekte: tussen 55-87% van de patiënten heeft reeds metastasen, met name in de 
buikholte. Deze patiënten hebben dan ook een uitermate slechte prognose, met een gemiddelde 
5-jaars overleving van slechts 18-45%. De standaard behandeling voor baarmoederkanker lijkt tot 
dusverre dan ook suboptimaal voor dit agressievere subtype. In dit hoofdstuk beschrijven we de 
mogelijke ontstaanswijze inclusief het voorloperstadium, de epidemiologie, tumorkarakteristieken 
en behandelingsopties van dit subtype baarmoederkanker. Een beter begrip is essentieel om de 
behandeling te kunnen verbeteren.
Figuur 1: het vrouwelijke voortplantingsstelsel.
Hoofdstuk 2 betreft een overzicht van de huidige literatuur omtrent het sereus carcinoom van de 
uterus. Er wordt gefocust op de klinische aspecten en behandeling, met een nadruk op welk type 
chirurgie en aanvullende therapie het beste kan worden toegepast. Door de relatieve zeldzaamheid 
zijn de meeste gynaecologen vrij onbekend met dit agressieve subtype baarmoederkanker. 
Daarnaast zijn op dit moment maar een zeer gelimiteerd aantal studies in de literatuur bekend die 
een uitspraak doen omtrent de best mogelijke behandeling. 
Het sereus carcinoom van de uterus is voor de patholoog-anatoom histologisch identiek aan het 
sereus carcinoom van de eierstok (ovarium). Ook in klinisch gedrag, potentieel tot metastaseren, 
prognose en overleving lijken ze sterk op elkaar. De behandeling verschilt echter. Het sereus 
carcinoom van het ovarium wordt behandeld door toepassing van uitgebreide specialistische 
chirurgie (debulking chirurgie met stadiëring genaamd), waarbij baarmoeder inclusief 
baarmoederhals, eierstokken, eileiders, vetschort, lymfeklieren zowel in het kleine bekken als 
hogerop langs de grote lichaamsslagader (aorta), en alle verdachte laesies zichtbaar ten tijde van 
de operatie worden weg genomen. Daarbij bestaat de nabehandeling van eierstokkanker bijna 
altijd uit aanvullende chemotherapie. In internationale literatuur werd recent gesuggereerd dat het 
sereus carcinoom van de uterus wellicht hetzelfde zou moeten worden behandeld als het sereus 
carcinoom van het ovarium.
Na analyse van de beschikbare literatuur kunnen we niet sterk genoeg benadrukken dat het zeer 
belangrijk lijkt om patiënten met een sereus carcinoom van de uterus inderdaad volledig chirurgisch 
te debulken, inclusief een stadiëring procedure. Het blijkt dat patiënten zonder klinische verdenking 
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voor gemetastaseerde ziekte toch in 21-42% wel degelijk (micro-) metastasen hebben, ontdekt 
door een stadiëring procedure. Deze metastasen zijn met name in lymfklieren en in het vetschort 
gelokaliseerd. Daarnaast is debulking chirurgie (het maximaal weghalen van alle macroscopisch 
zichtbare kanker) sterk geassocieerd met een verbeterde respons op aanvullende chemotherapie. 
Patiënten met sereus carcinoom van de uterus, waarbij debulking chirurgie gecombineerd wordt 
met een stadiëring procedure, hebben een significant betere overleving vergeleken met patiënten 
die op de conventionele manier chirurgisch worden behandeld.
Ondanks dat de standaard aanvullende behandeling voor baarmoederkanker externe röntgen-
bestralingen omvat, blijkt deze aanvullende therapie nauwelijks van waarde bij het sereus carcinoom 
van de uterus. Er worden nauwelijks verbeteringen gevonden in gezondheid, de kans op hernieuwde 
ziekte (recidief ), en overleving vergeleken met patiënten die niet worden nabehandeld. Daarbij 
ontstaan er ernstige neveneffecten en complicaties. Brachytherapie wordt ook wel toegepast. 
Bij deze vorm van therapie wordt een röntgen bestralingsbron vaginaal ingebracht zodat lokale 
behandeling kan worden gegeven. Deze manier van behandelen kent veel minder neveneffecten 
en wordt meestal goed verdragen door de patiënte. Ondanks dat het een efficiënte methode is 
om de kanker lokaal te beteugelen en de kwaliteit van leven te verbeteren, wordt er geen winst 
geboekt in overleving. Aanvullende chemotherapie blijkt de enige behandeling die significant de 
overleving van patiënten met sereus carcinoom van de uterus verbeterd, zelfs bij patiënten met een 
vroeg stadium (zonder metastasen) van de ziekte. Hiermee wordt ook de kans op het krijgen van 
een lokaal recidief danwel een recidief op afstand veel kleiner. In afwachting van grote prospectieve 
klinische studies lijkt het dus aan te bevelen om patiënten met sereus carcinoom van de uterus 
uitgebreid chirurgisch te behandelen met debulking chirurgie inclusief een stadiëring procedure, 
gevolgd door aanvullende chemotherapie.
In Hoofdstuk 3 wordt onderzocht of het bepalen van de tumormerkstof CA-125 in het bloed 
van waarde kan zijn om voor de operatie (pre-operatief ) gemetastaseerde ziekte te voorspellen 
bij patiënten met een sereus carcinoom van de uterus. Het is namelijk vaak moeilijk gebleken om 
pre-operatief adequaat gemetastaseerde ziekte bij deze patiënten te detecteren, terwijl dit erg 
belangrijk kan zijn in de planning van de (chirurgische) behandeling en in de informatievoorziening 
naar de patiënte toe: wat kan zij verwachten, wat is haar prognose?  
Sinds de ontdekking in 1983 is de tumormerkstof CA-125 in bloed uitgebreid bestudeerd in relatie 
tot allerlei ziekten en aandoeningen. Zo bleek het nuttig om CA-125 te bepalen bij patiënten 
met eierstokkanker, omdat patiënten met een pre-operatief verhoogd CA-125 in bloed vaak 
gemetastaseerde eierstokkanker hadden en daardoor een slechte prognose. Daarbij was CA-125 
van waarde gedurende de behandeling en follow-up van patiënten met eierstokkanker tijdens en 
na aanvullende behandeling: stijging van CA-125 in bloed gedurende de behandeling danwel na de 
behandeling duidde op respectievelijk inadequate (chemo)therapie en een recidief. De waarde van 
CA-125 bij het sereus carcinoom van de uterus is echter nooit onderzocht.
Uit deze studie blijkt dat patiënten met sereus carcinoom van de uterus met gemetastaseerde 
ziekte, een significant hoger pre-operatief CA-125 hebben (mediaan 124.0 U/ml) in vergelijking met 
patiënten met dit subtype baarmoederkanker zonder uitzaaiingen (mediaan 17.5 U/ml). Een pre-
operatieve waarde met een cut-off van CA-125 > 45 U/mL in het bloed is significant geassocieerd 
met de aanwezigheid van gemetastaseerde ziekte: patiënten met een pre-operatief CA-125 > 45 
U/mL hebben een 6.3 keer zo hoog risico op het hebben van gemetastaseerde ziekte. Verder blijkt, 
dat naast het stadium (de uitgebreidheid) van de ziekte, een pre-operatieve waarde van CA-125 
> 45 U/ml significant geassocieerd is met een slechtere overleving. Dit onderzoek toont aan dat 
een pre-operatief verhoogd CA-125 in bloed van een patiënte met sereus carcinoom van de uterus 
een goede voorspeller is voor de aanwezigheid van gemetastaseerde ziekte, en dat CA-125 een 
onafhankelijk risicofactor is met betrekking tot overleving. Het routinematig pre-operatief bepalen 
van CA-125 in bloed wordt dan ook aanbevolen in patiënten met sereus carcinoom van de uterus.
Notabene: CA-125 kan niet worden gebruikt om dit subtype van baarmoederkanker op te sporen 
(screening), omdat niet alle kankers het CA-125 produceren (lage sensitiviteit) en omdat er ook 
andere aandoeningen zijn waarbij CA-125 verhoogd is (lage specificiteit).
In Hoofdstuk 4 wordt de frequentie van sterk afwijkende cellen dan wel kankercellen specifiek 
komend vanuit de baarmoeder in uitstrijkjes van de baarmoederhals onderzocht. Dit wordt 
vergeleken in patiënten met baarmoederkanker van het agressieve sereuze subtype versus 
patiënten met het prognostisch gunstigere endometrioïde subtype. Tevens wordt bekeken of 
uitstrijkjes van de baarmoederhals kunnen worden gebruikt als voorspeller van de prognose bij 
baarmoederkanker patiënten. 
In Nederland werd in de jaren 70 van de 20e eeuw begonnen met een grootschalig 
bevolkingsonderzoek met behulp van een uitstrijkje ter preventie van baarmoederhalskanker 
(cervixcarcinoom). Het uitstrijkje is een simpele, doeltreffende en relatief goedkope manier om 
voorstadia van baarmoederhalskanker te detecteren. Het uitstrijkje kon niet worden gebruikt om 
vrouwen te screenen op baarmoederkanker, omdat de sensitiviteit van de uitstrijk hiervoor te laag 
lag. Echter, wanneer per toeval sterk afwijkende en daarom verdachte cellen, specifiek afkomstig 
vanuit de baarmoeder konden worden aangetoond in het uitstrijkje (abnormale uitstrijk), dan was 
dit een belangrijke voorspeller voor een ziekteproces in de baarmoeder. Bezien over de gehele 
populatie patiënten met baarmoederkanker wordt de frequentie van abnormale uitstrijkjes geschat 
op 25-35%.
Opvallend genoeg blijkt uit deze studie dat patiënten met het sereus carcinoom van de uterus 
in maar liefst 87.5% een abnormale uitstrijk hebben, specifiek duidend op een ziekteproces in de 
baarmoeder. Dit vergeleken met 37.8% abnormale uitstrijkjes bij patiënten met het endometrioïde 
carcinoom van de uterus. Verder blijkt dat een abnormale uitstrijk bij patiënten met een sereus 
carcinoom van de uterus geassocieerd is met de aanwezigheid van gemetastaseerde ziekte. In 
patiënten met het endometrioïde carcinoom van de uterus is een abnormale uitstrijk geassocieerd 
met baarmoederkanker zich uitbreidend tot de baarmoederhals. Echter, in beide populaties 
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patiënten (sereus en endometrioïde carcinoom van de uterus) wordt geen associatie gevonden 
tussen een abnormale uitstrijk en uiteindelijke overleving. Concluderend blijkt een abnormale 
uitstrijk geassocieerd met slechte prognostische factoren. Echter een abnormale uitstrijk, specifiek 
duidend op een ziekteproces in de baarmoeder, heeft geen prognostische waarde met betrekking 
tot overleving bij deze patiënten.
In Hoofdstuk 5 wordt onderzocht wat de invloed is van het percentage sereuze histologie binnen 
de gehele tumor in de baarmoeder op het klinische gedrag van de kanker, op de prognose voor 
de patiënte en op de kans op recidief. Hiervoor worden patiënten met baarmoederkanker geheel 
bestaand uit het sereuze subtype vergeleken met patiënten met baarmoederkanker bestaand uit 
gemixte subtypes (sereus met ander histologische subtype). Tevens wordt het baarmoederslijmvlies 
naast de kanker uitgebreid geanalyseerd om het voorloperstadium te detecteren en beter in kaart 
te brengen. 
Naast het feit dat het sereus carcinoom van de uterus een uitermate agressieve variant is van 
baarmoederkanker, is een ander bijzonder feit dat dit subtype baarmoederkanker vaak ook gemixt 
voorkomt met andere histologische subtypes. Met andere woorden, de patholoog-anatoom kan 
bij zijn microscopisch onderzoek specifiek twee (of soms zelfs drie) verschillende histologische 
subtypes van baarmoederkanker onderscheiden binnen het chirurgische preparaat. Ondanks 
dat het sereus carcinoom van de uterus mogelijk vaak gemixt voorkomt met bijvoorbeeld het 
prognostisch gunstiger geachte endometrioïde subtype, werd tot nu toe aangenomen dat dit 
gemixte sereuze type baarmoederkanker een even slechte prognose kent als het pure sereuze 
carcinoom, en dus even agressief zou moeten worden behandeld. 
Daarnaast bestaat er nog veel onduidelijkheid en onbekendheid omtrent het voorloperstadium 
van het sereus carcinoom van de uterus. Voor het prognostisch gunstigere en meer voorkomende 
endometrioïde subtype baarmoederkanker is wel een voorloperstadium beschreven: complexe 
hyperplasie met atypie (CHA). Langdurige blootstelling van het baarmoederslijmvlies aan 
het vrouwelijke geslachtshormoon oestrogeen kan leiden tot veranderingen in dit slijmvlies, 
tot bovenmatige vermeerdering van dit slijmvlies (hyperplasie) en uiteindelijk in abnormale 
weefselaangroei, CHA genoemd. Afhankelijk van de ernst van veranderingen in het voorloperstadium 
CHA hebben deze patiënten 20-40% kans op het ontwikkelen van baarmoederkanker. Minder is 
bekend omtrent de ontstaanswijze van het sereus carcinoom van de uterus. Slechts in een aantal 
kleine studies is een voorloperstadium beschreven, ‘endometrial intraepithelial carcinoma’ (EIC) 
genaamd. Het werd zelden in preparaten van baarmoederkanker met een ander histologisch 
subtype aangetoond. Het EIC zou ontstaan in een achtergrond van één cellaag dik (atrofisch) 
baarmoederslijmvlies en is per definitie non-invasief. Complexe hyperplasie met atypie (CHA) 
werd niet of nauwelijks gevonden rondom EIC en het sereus carcinoom van de uterus. Echter, er is 
nauwelijks iets bekend over de rol van EIC als voorloperstadium bij gemixte vergeleken met pure 
sereuze carcinomen van de uterus.
Uit deze studie blijkt dat het in 46.3% van alle gevallen van een sereus carcinoom van de uterus gaat 
om het pure sereuze type en in 53.7% om gemixte sereuze carcinomen. Binnen de groep gemixte 
sereuze carcinomen van de uterus betreft het in 77.6% een combinatie met het endometrioïde 
histologische subtype. Verder blijkt dat, behalve patiënten met een laag stadium (geen metastasen) 
van de ziekte, ook patiënten met een gemixt sereus carcinoom van de uterus een betere 
overlevingskans hebben en een lager risico op recidief. Patiënten met puur sereuze histologie 
hebben een 2.9x hogere kans op recidief en een 2.6x hoger risico op overlijden vergeleken met 
patiënten met een gemixt sereus carcinoom van de uterus. Het voorloperstadium EIC wordt 
aangetroffen in 84% van alle gevallen, zonder significant verschil in incidentie tussen de groep 
patiënten met puur versus gemixt sereus carcinoom van de uterus. Atrofisch baarmoederslijmvlies 
wordt aangetroffen in 90.7% van patiënten met een puur sereus carcinoom van de uterus, 
terwijl CHA wordt aangetroffen in 34.7% van alle patiënten met een gemixt sereus carcinoom (p 
= 0.004). Concluderend blijkt dat puur sereuze histologie van de baarmoederkanker samen met 
een vergevorderd stadium van de ziekte de belangrijkste risicofactoren bij patiënten met sereus 
carcinoom van de uterus zijn voor wat betreft de kans op recidief en uiteindelijke overleving. Verder 
wordt EIC met een zelfde frequentie aangetroffen in zowel pure als gemixte sereuze carcinomen, 
suggestief voor zijn rol als voorloperstadium in beide varianten van sereus carcinoom van de uterus. 
De rol van CHA bij gemixt sereus carcinoom van de uterus blijft echter nog onduidelijk.
Zoals reeds eerder vermeld is het sereus carcinoom van de uterus histologisch en in klinisch gedrag 
identiek aan het sereus carcinoom van het ovarium (eierstok). Eierstokkanker is één van de meest 
sluipende en meest agressieve vorm van kanker. Er zijn nauwelijks voortekenen en als het wordt 
ontdekt is het bijna altijd al te laat. Vandaar dat eierstokkanker ook wel de “silent lady killer” wordt 
genoemd. Het sereus carcinoom van het ovarium is het meest voorkomende subtype (70-80%) 
van eierstokkanker. Patiënten presenteren zich ten tijde van diagnose in 60-80% van de gevallen 
met gemetastaseerde ziekte en hebben een slechte prognose. Jaarlijks krijgen ongeveer 1100 
vrouwen in Nederland deze ziekte van wie er 1000 overlijden. Het ontdekken en diagnosticeren 
van eierstokkanker in een vroeg stadium, of zelfs van het voorloperstadium, zou de behandeling 
en prognose van deze groep patiënten beduidend kunnen verbeteren. Helaas is gebleken dat 
screening naar eierstokkanker met behulp van echografie, de tumormerkstof CA-125, of met andere 
biomarkers niet sensitief en effectief is. 
De huidige gedachte omtrent de ontstaanswijze van eierstokkanker werd door de Egyptische 
gynaecoloog Fathalla reeds in 1971 gepostuleerd en was met name gebaseerd op epidemiologische 
feiten. Zo bleek een reductie in het aantal eisprongen (ovulaties) gedurende het leven van de vrouw 
(veroorzaakt door multipele zwangerschappen, het geven van borstvoeding, en het gebruik van 
orale anticonceptiva) te leiden tot een verlaging van het risico op het ontwikkelen van eierstokkanker 
gedurende het verdere leven. Er werd gedacht dat toenemende schade aan de eierstok, die optreedt 
na elke maandelijkse ovulatie, een factor is in het uiteindelijk ontaarden in kanker van de eierstok. 
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Echter, het type cel waaruit de eierstok bestaat lijkt helemaal niet op het sereuze subtype kankercel 
zoals die wordt aangetroffen in eierstokkanker; dit type cel lijkt meer op de cellen van Müller, die 
zich vroeg in de embryonale fase ontwikkelen tot eileiders, baarmoeder en bovenste 1/3 van de 
vagina. Daarnaast is tot op heden nooit een voorloperstadium van eierstokkanker in de eierstokken 
zelf ontdekt.
In Hoofdstuk 6 wordt de incidentie onderzocht van een potentieel voorloperstadium van 
eierstokkanker in de eileiders (tubae). Hiervoor wordt een groep patiënten met een bewezen 
BRCA1/2 gen-mutatie waarvoor preventieve verwijdering van eierstokken en eileiders, vergeleken 
met een groep patiënten zonder erfelijke aanleg voor het ontwikkelen van eierstokkanker, waarbij 
om niet-kanker gerelateerde redenen de eierstokken en eileiders zijn verwijderd.
In de jaren ‘90 van de vorige eeuw werden twee genen, BRCA 1 en BRCA 2, geïdentificeerd die 
geassocieerd waren met een sterk verhoogde kans op het krijgen van borst- en eierstokkanker 
wanneer deze genen een DNA-verandering (mutatie) bevatten. Afhankelijk van welk van de twee 
BRCA genen gemuteerd is, is het risico op het krijgen van eierstokkanker 5-60%. Aangezien screening 
voor eierstokkanker tot nu toe niet effectief is gebleken wordt de meeste BRCA mutatiedraagsters 
geadviseerd rond hun 40ste levensjaar en na vervulling van hun kinderwens preventief de eierstokken 
met eileiders te laten verwijderen. Dit leidt tot een afname van het risico op kanker tot naar het 
gemiddelde bevolkingsrisico. 
Deze reductie in risico op eierstokkanker heeft ertoe geleid, gecombineerd met het feit dat nooit 
een voorloperstadium werd aangetroffen in de eierstok zelf, dat onderzoekers de laatste jaren 
nauwkeurig de eileiders van BRCA mutatiedraagsters zijn gaan analyseren en bestuderen. Recentelijk 
hebben een aantal studies een mogelijk voorloperstadium voor sereus ovariumcarcinoom 
beschreven in de eileiders (tubae), ‘serous tubal intraepithelial carcinoma’ (STIC) genaamd. Vanuit 
embryologisch perspectief gezien stammen cellen van de eileider af van de cellen van Müller, en 
ontaarding van deze cellen zou leiden tot een kankercel subtype zoals dat van het sereuze ovarium 
carcinoom. Aangenomen wordt dat voorloper kankercellen vanuit STIC loslaten en zich hierna 
hechten op de eierstok en/of elders in de buik (gemetastaseerde ziekte). Echter, de incidentie 
van STIC als voorloperstadium varieert sterk, tussen 0.6%-8%, en de reproduceerbaarheid van 
de diagnose STIC is matig tot slecht. Daarbij is nog nauwelijks iets bekend over de incidentie van 
STIC als voorloperstadium bij patiënten zonder BRCA mutatie en dus zonder erfelijke aanleg voor 
eierstokkanker. 
Voor deze studie worden 226 BRCA1/2 mutatiedraagsters en 105 vrouwen waar voor niet-kanker 
gerelateerde redenen de eierstokken en eileiders zijn verwijderd (controle groep) onderzocht. In 
de groep BRCA mutatiedraagsters wordt in 6% een STIC als voorloperstadium gevonden en bij 1% 
per toeval daadwerkelijk een vroeg stadium eierstokkanker, in tegenstelling tot de controle groep 
waar geen STIC of invasieve kanker wordt aangetroffen (p = 0.004). In veruit de meeste gevallen 
wordt het voorloperstadium STIC geïdentificeerd in het uiteinde van de eileiders (64.3%), dus in de 
nabijheid van de eierstok. Een gevonden afwijking (STIC dan wel kanker) blijkt geassocieerd met 
een hogere leeftijd van desbetreffende vrouw. Concluderend wordt in ongeveer 6% van de BRCA 
mutatiedraagsters een voorloperstadium van eierstokkanker gevonden, terwijl in de eileiders van 
de controle groep geen afwijkingen worden gevonden. STIC lijkt dus een uniek voorloperstadium 
voor het sereus ovarium carcinoom al wordt het in de minderheid van de gevallen geïdentificeerd.
In Hoofdstuk 7 wordt een alternatieve hypothese onderzocht waarbij in patiënten met 
eierstokkanker mogelijk een voorloperstadium aanwezig is in het baarmoederslijmvlies. Hiervoor 
wordt een groep patiënten met sereus ovarium carcinoom geselecteerd en van deze patiënten wordt 
het baarmoederslijmvlies uitgebreid geanalyseerd, op zoek naar een mogelijk voorloperstadium. 
Zoals reeds eerder vermeld is tot op heden nooit een voorloperstadium van eierstokkanker 
geïdentificeerd in de ovaria. Hoewel recentelijk steeds meer data in de richting wijzen van STIC 
in de tubae als mogelijk voorloperstadium van het sereuze subtype eierstokkanker, wordt in 
minder dan 10% van alle BRCA mutatiedraagsters dit voorloperstadium daadwerkelijk gevonden. 
Interessant feit is dat vrouwen die zijn gesteriliseerd of op jonge leeftijd hun baarmoeder operatief 
hebben laten verwijderen om niet-kanker gerelateerde redenen, een lager risico hebben op het 
ontwikkelen van eierstokkanker gedurende het verdere leven. Deze afname in het risico op het 
krijgen van eierstokkanker is zelfs 20-60%. Daarbij moet in ogenschouw worden genomen dat bij 
beide ingrepen zowel de ovaria als de tubae nog steeds in het lichaam van de vrouw aanwezig 
zijn. Wellicht een bijzonder feit wanneer men aanneemt dat een mogelijk voorloperstadium van 
eierstokkanker zich in de ovaria dan wel tubae zou bevinden.
‘Endometrial intraepithelial carcinoma’ (EIC) is het voorloperstadium van het sereuze carcinoom 
van de uterus en kan in 80-90% van de gevallen met dit subtype baarmoederkanker worden 
geïdentificeerd. EIC is per definitie non-invasief en ontstaat in een achtergrond van atrofisch 
baarmoederslijmvlies. Echter van EIC is beschreven dat het ook kan voorkomen op de ovaria, in de 
tubae, of elders in de buikholte, zonder dat hier verder sprake is van kanker. De hypothese in dit 
hoofdstuk is dat voorlopercellen, afkomstig van het EIC, loslaten en migreren via de eileiders richting 
eierstok en buikholte. Dit fysiologische migratie proces wordt bijvoorbeeld ook gezien tijdens 
een normale menstruatie van een vrouw, waarbij bloed en delen baarmoederslijmvlies behalve 
richting vagina uitgang ook via de eileiders richting buikholte bewegen. De kleine hoeveelheden 
bloed die daardoor in de buikholte terecht komen prikkelen het buikvlies en kunnen de typische 
menstruatiepijn in de (onder)buik geven. Ook worden bijvoorbeeld na gemeenschap de zaadcellen 
vanuit de baarmoeder naar de eileiders gedirigeerd.
Voor dit onderzoek wordt een groep patiënten met sereus ovarium carcinoom geselecteerd. 
Van deze patiënten wordt het baarmoederslijmvlies en eileiders uitgebreid geanalyseerd. In 9 
van de 38 gevallen wordt naast de eierstokkanker ook een mogelijk voorloperstadium in het 
baarmoederslijmvlies van deze patiënten geïdentificeerd, het EIC. In deze groep patiënten 
wordt geen STIC geïdentificeerd. Om een daadwerkelijke relatie te kunnen aantonen tussen de 
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eierstokkanker en het mogelijke voorloperstadium, wordt het eiwitprofiel onderling vergeleken 
en het DNA van beide afwijkingen geanalyseerd. Het blijkt dat voor vier verschillende eiwitten 
het profiel nagenoeg identiek is voor zowel het sereuze carcinoom van het ovarium als het EIC. 
Verder wordt in 33% van de gevallen een unieke en identieke DNA-mutatie aangetoond in beide 
afwijkingen. Tot slot blijkt dat de cellen van de eierstokkanker op DNA niveau sterker afwijkend 
zijn (p = 0.039), met sterk veranderde cellulaire processen (p = 0.039), vergeleken met cellen van 
EIC. Dit laatste is onwaarschijnlijk wanneer EIC geen voorloperstadium maar een metastase zou 
zijn van de eierstokkanker. Concluderend ondersteunen deze data voor het eerst de hypothese dat 
EIC in het baarmoederslijmvlies een mogelijk voorloperstadium is van het sereuze carcinoom van 
het ovarium. Met deze mogelijke oorsprong in de baarmoeder is ook het beschermende effect van 
sterilisatie dan wel operatieve verwijdering van de baarmoeder op het krijgen van eierstokkanker 
te verklaren. Ook hebben multipele zwangerschappen, het geven van borstvoeding, en het gebruik 
van orale anticonceptiva (allen factoren geassocieerd met een verlaging van het risico op het 
ontwikkelen van eierstokkanker) duidelijk een invloed op het baarmoederslijmvlies en dus mogelijk 
op het ontstaan van EIC in het slijmvlies.
In Hoofdstuk 8 worden de belangrijkste bevindingen van dit proefschrift samengevat en 
bediscussieerd. Met name het belang van het opzetten van een goede prospectieve klinische studie 
naar de juiste behandeling van het sereuze carcinoom van de uterus wordt hier onderstreept. In 
afwachting van een dergelijke studie wordt een algoritme geboden die kan helpen in de klinische 
besluitvorming. Verder worden de moeilijkheden en valkuilen voor zowel de gynaecoloog als de 
patholoog-anatoom met betrekking tot het sereuze carcinoom van de uterus bediscussieerd. Ook 
worden de rollen van EIC en STIC als mogelijke voorloperstadia van eierstokkanker besproken. Tot 
slot worden enige ideeën voor toekomstig onderzoek aangedragen. Zo wordt gesuggereerd dat een 
toekomstige prospectieve studie een studie zou kunnen zijn waarin BRCA mutatiedraagsters, met 
een verhoogd risico hebben op het krijgen van eierstokkanker, conventioneel worden behandeld 
door chirurgisch zowel eierstokken als eileiders te verwijderen, dan wel slechts alleen de eileiders te 
verwijderen. Hoewel controversieel,  een dergelijke studie zou voor het eerst daadwerkelijk kunnen 
bewijzen dat eierstokkanker niet vanuit de eierstok zelf ontstaat.
Uiteindelijk is de gedachte dat het sereuze subtype ovarium carcinoom mogelijk niet ontstaat 
vanuit de eierstok, maar een secundaire vorm van kanker is met een oorsprong in de eileiders dan 
wel het baarmoederslijmvlies.
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DANKWOORD
Het is dan zover: het boekje is af!! Hiermee is een eind gekomen aan één van de meest hectische, 
maar tegelijkertijd meest bijzondere en leerzame periodes in mijn leven. Dit was natuurlijk nooit 
gelukt zonder de hulp, steun en het vertrouwen van vele mensen om mij heen. Bedankt daarvoor! 
Een aantal mensen wil ik hieronder nog even speciaal benoemen.
Als eerste natuurlijk mijn “promotie-team”:
Mijn promotor Prof. Dr. Massuger, beste Leon, wij hadden inmiddels alweer 5 jaar geleden eigenlijk 
maar 2 gesprekken op een vrijdagmiddag nodig om te weten wat we allebei wilden, wat de 
bedoeling ging zijn, en hoe we het wilden aanpakken. Ik heb het wel eens “liefde op het eerste 
gezicht” genoemd, op het professionele vlak dan…  Jouw kracht om mensen te motiveren en 
te enthousiasmeren is erg bijzonder, en samen met een hoop intelligentie, mensenkennis, en de 
continue stroom aan ideeën maakt jou voor mij een hele goede en fijne promotor. Ik, door jou 
wel eens ‘jonge hond’ genoemd, heb veel van je mogen leren en niet alleen omtrent mijn eigen 
onderzoek. Ik heb onze gesprekken op de vrijdagmiddag/avond en in de weekenden altijd zeer 
gewaardeerd. Ohw, nog 1 ding: uiteraard wil ik nog steeds revanche voor die verloren pot squash! 
Mijn co-promotor, Dr. van Ham, beste Maaike, je kwam er iets later bij, maar je pakte het meteen 
goed op en wierp jezelf op als een soort beschermengel van mij. Jij hield een oogje in het zeil of ik 
niet teveel werkte, ik het allemaal wel trok, sociaal nog wel aan dingen toekwam, en je was er voor 
me op persoonlijk vlak wanneer het wel eens even wat minder met me ging. Het laagdrempelige en 
persoonlijke contact heb ik altijd gewaardeerd! Je bent een echte mensen-dokter.
Mijn andere co-promotor, Dr. Bulten, beste Hans, jij was een belangrijke spil in ons onderzoek. 
Dankzij jou konden we onderzoek doen op de afdeling pathologie en wat hebben we samen veel 
geleerd van het coupes kijken! Alleen wat waren het er veel, zelfs jij zag het soms even niet meer 
zitten. Op dat soort momenten liep ik natuurlijk graag even met je naar buiten, naar ‘jouw plekje’, 
voor de broodnodige sigaar. Ondanks soms wat strubbelingen omtrent afspraken (maken), heb je 
enorm veel werk verzet en heeft mijn boekje zoveel goede pathologische inhoud! Je bent een echte 
expert in de gynaeco-pathologie. 
In aansluiting hierop wil ik ook de pathologen S. Zomer (CWZ), A. Wiersma van Tilburg (Rijnstate) en 
M. Bol (UMC) benoemen. Beste Saskia, Anne, en Mijke, jullie hebben een monsterklus geleverd door 
alle coupes individueel te reviseren. Dat maakte onze database en onze pathologische bevindingen 
uiteindelijk ook zo sterk. Gelukkig werd dat recent ook beloond met goede publicaties. Ik denk dat 
we hier trots op mogen zijn!
Ook wil ik de mensen van het ‘epitheelclubje’, iedere maandag ochtend, bedanken. Onder leiding van 
Prof. P. Slootweg een groep mensen bij elkaar die in een geheel ander veld onderzoek deden, met 
als gemene deler epitheelcellen. Dit was voor mij altijd zeer leerzaam. Nieuwe ideeën ontstonden 
Appendices Dankwoord, Curriculum Vitae en Bibliography
163162
en samenwerkingen werden aangegaan. Met name Dr. van der Laak, beste Jeroen, wil ik bedanken 
voor zijn hulp met hoofdstuk 7, ongelooflijk hoe jij microscopen en software kunt gebruiken om de 
meest uiteenlopende zaken te automatiseren en te berekenen. Speciaal moet ik hier nog noemen 
Dr. van Kempen, beste Léon, jij hebt samen met mij in kort tijdsbestek volle bak gewerkt aan de 
data die hebben geleid tot hoofdstuk 7 van dit proefschrift. Doch controversieel zijn we erg trots 
op de bevindingen en zonder jouw visie en hulp was het me niet gelukt. Gezien jouw intelligentie, 
werklust, inzicht en open denk wereld verbaasde het me natuurlijk niets dat je naar Montreal, 
Canada, werd gehaald. Je hebt die goede positie verdiend. Drink daar maar een sinas op! ;)
Dr. Siebers, beste Bert, ondanks dat je officieel niet betrokken was bij mijn promotie heb je 
zoekvragen in PALGA voor me gedaan en een aantal manuscripten van mij gereviseerd en van 
uitstekend en kritisch commentaar voorzien. Daar werd het altijd zeker beter van, dank! 
Dr. van Goor, beste Harry, ook jou moet ik hier natuurlijk noemen, want als mijn persoonlijke mentor 
gedurende de studie geneeskunde was jij diegene met het idee: “Thijs, moet je geen promotie-
onderzoek gaan doen?” Onze gesprekken heb ik altijd zeer gewaardeerd en ik denk dat dit boekje 
laat zien dat inderdaad alles kan ;)
Beste, lieve collega’s, kantoortuin-bewoners, wat heb ik het altijd fijn gehad! Zowel in mijn parttime 
als fulltime periode waren jullie er voor de broodnodige koffie en lunches, maar misschien nog 
belangrijker voor de VriMiBo’s (VrijdagMiddagBorrels voor diegenen die daar niet aan doen), de 
ski-weekenden, de onderzoekersweekendjes, etc. En wat waren de internationale congressen in 
Belgrado, Praag, Milaan, Londen en Vancouver TOF (!!), euh leerzaam, met jullie!! ;) Wat mij betreft 
houden we het er allemaal in!
Ook ‘mijn’ studenten Irma, Anne, Dorus en Marjanka wil ik bedanken voor al hun energie en werk 
dat ze in ons onderzoek hebben gestoken. En Marjanka natuurlijk helemaal, want jij bent degene 
die vervolgens als promovenda het onderzoek heeft doorgezet en de onderzoekslijnen verder 
uitbouwt. Ik wens je daarbij nog heel veel succes.
Beste lieve collega’s uit het Rijnstate, de maatschap gynaecologen, arts-assistenten en klinisch 
verloskundigen, dank jullie wel voor het ‘warme bad’ waarin ik belandde toen ik afgelopen Januari 
bij jullie kon beginnen als ANIOS. Ondanks dat ik een groot aantal van jullie al (van gezicht op z’n 
minst) kende, kreeg ik wederom een warm welkom. Ik waardeer jullie laagdrempelige karakter 
en de goede en fijne (werk)sfeer. Het voelde als `thuis komen`, om met 1 van de gynaecologen te 
spreken. We gaan er hopelijk nog een fijne en leerzame tijd van maken samen!
“Vrienden krijg je door jezelf te geven”, en ik ben dan ook heel blij dat ik een grote groep vrienden 
om me heen heb. Ik vind het altijd heerlijk om bij jullie te zijn, van me af te kunnen praten, te 
ontspannen, borrelen, leuke dingen te doen. Ik hoop dat we dat nog lang blijven doen samen! Een 
paar mensen wil ik hier speciaal benoemen.
Allereerst ‘de Commissie’, Werner, Wout, Remy, Erik en Ernst. We kennen elkaar nu ongeveer 10 jaar. 
Begonnen als huisgenoten heb ik onze vriendschap altijd super gewaardeerd. Want ondanks dat we 
allemaal andere studies hebben gedaan en deels verschillende interesses hebben klikt het enorm 
goed. Ongeacht de grotere afstanden onderling zien we elkaar gelukkig nog steeds zeer regelmatig 
en gaan we jaarlijks een weekend weg. En tja, één van onze gemene delers zullen toch wel de 
biertjes zijn, met goede gesprekken afgewisseld met slap geouwehoer. Jullie zorgden voor mijn 
broodnodige ontspanning, of moet ik ‘inspanning’ zeggen…? Laten we dat nog lang blijven doen!
Mannen van ‘Thuis Thuis’, oftewel uit de Achterhoek, Lucas, Sander, Thijs, Roel, Glenn, Chris, Sjoerd, 
Bram, dankzij jullie is het toch altijd weer ‘oldewets’ thuis komen. Of het nou bij 1 van jullie thuis is, 
of in de kroeg. Sorry dat ik niet meer zo vaak bij jullie kan zijn, maar het eindresultaat mag er wezen 
toch? 
Lieve ‘geneeskunde’-vrienden en vriendinnen! In de afgelopen jaren zijn we een hecht clubje 
geworden die van alles met elkaar deelden, en die regelmatig ook samen de bloemetjes buiten 
zetten! Jullie verklaarden me wel eens voor gek als ik weer eens op een vrije onderwijsmiddag het 
UMC in liep om verder aan m’n onderzoek te werken ipv met jullie een terrasje te pakken. En eerlijk 
is eerlijk; die verleiding was vaak erg groot! Dank voor een luisterend oor zo nu en dan, en voor 
alle leuke en ontspannende momenten samen, met als hoogtepunten natuurlijk de spelletjes- en 
karaoke avonden en carnaval! Lieve Iris en Iris, jullie zijn me extra dierbaar. We hebben afgelopen 
jaren letterlijk alles gedeeld, we hebben samen gehuild en gelachen, ik geniet altijd enorm van jullie 
gezelschap en ik wil jullie nooit meer kwijt. Friends forever!
Lieve Refika, natuurlijk mag jij hier ook niet ontbreken! Als vlaamse schone kwam je destijds naar 
Nijmegen en al snel bloeide een hechte vriendschap tussen ons op. Daarmee ben ik bevoorrecht, 
gezien jouw attente, loyale en integere karakter, je staat altijd voor me klaar. Ik zie U heel erg graag 
Refika, of kwam het nou door jouw mediterrane look en het Vlaamse accent?  Zullen we afspreken 
dat we de onderlinge afstand, waar we ook wonen en werken, nooit parten laten spelen?
Mijn lieve paranimfen Remy en Charlotte,
Lieve Remy, als één van mijn beste maatjes ben ik heel blij dat jij mijn paranimf wilt zijn op deze 
belangrijke en bijzondere dag voor mij. We hebben eigenlijk altijd alles gedeeld en waren er voor 
elkaar wanneer het moest. Dat heb ik altijd enorm gewaardeerd, naast het feit dat we ons ook altijd 
prima samen kunnen amuseren, of dat nu in Amsterdam is, in Nijmegen, of in Rome! ;) 
Lieve Lot, we kennen elkaar vanuit het ziekenhuis waarna we al snel goede vrienden werden. Maar 
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het is veel meer dan dat. Je bent er altijd voor me, je bent altijd in voor iets nieuws, iets anders, en 
jouw humor en eigen willetje kan ik erg waarderen! Je bent niet meer weg te denken en hoop dan 
ook dat we nog lang als ‘broer & zus’ door het leven mogen gaan! ;)
Lieve Remy & Charlotte, ik ben heel blij en gelukkig dat jullie als paranimfen op Vrijdag 19 April naast 
me willen staan!
Natuurlijk mogen hier mijn ouders niet ontbreken. Lieve Pap en Mam, jullie hebben me altijd 
gesteund, buiten de school om, tijdens mijn studies, en op het financiële vlak. Jullie vroegen je wel 
eens af wat ik toch allemaal aan het doen was en hoe lang het nog ging duren. Ook vonden jullie 
dat “ik nooit de normale gangbare weg kon volgen, ik moest het me altijd zo moeilijk maken”. Maar 
ik weet ook hoe blij en trots jullie zijn nu zowel de studie Geneeskunde als mijn promotie onderzoek 
is afgerond. Soms zijn daar trouwens ook geen woorden voor nodig om dat te zien en merken. 
Uiteindelijk had ik dit allemaal nooit kunnen bereiken zonder jullie, bedankt!
Tot slot, mijn allerliefste Karin, we hebben een roerige tijd samen achter de rug, met pieken en 
dalen. Maar ik weet 1 ding zeker: ik ben nog nooit zo gek op en gelukkig met iemand geweest! Dank 
voor alle steun en hulp rondom dit boekje, maar nog meer voor dat je me laat stralen en genieten. 
Samen is alles gewoon veel leuker, fijner, beter!
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Chapter 1, figure 1: Uterine papillary serous carcinoma (UPSC). A) Overview of full-blown UPSC with invasive 
properties and complex papillary growth (level of magnification: 50x). B & C) The distinctive precursor 
lesion endometrial intraepithelial carcinoma (EIC) represents malignant transformation of atrophic surface 
endometrium without myometrial invasion, and is immediately adjacent to the invasive UPSC (level of 
magnification: 200x). D) In detail view of UPSC, with its complex papillary growth, numerous mitotic figures, 
and marked nuclear atypia (level of magnification: 400x).
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Chapter 6, figure 1: Benign fallopian tube epithelium with secretory and ciliated cells (level of magnification: 
200×; level of magnification of inset: 400×).
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Chapter 6. figure 2: Tubal epithelial lesions (level of magnification: 200×). A) Fallopian tube epithelium with 
hyperplasia, showing cellular crowding, but without atypical nuclei (arrow: mitotic figure). B) Minor epithelial 
atypia in the fallopian tube showing cellular crowding, slight cellular atypia and nuclei with small nucleoli, 
but without loss of polarity of the epithelial cells (arrows). C) Tubal intraepithelial carcinoma (STIC) with 
cellular crowding, stratification of nuclei, loss of polarity and severe atypia of the nuclei. D) Fallopian tube 
carcinoma, including overlying atypical epithelium.
Chapter 7, figure 1: Representative sections of endometrial intraepithelial carcinoma (EIC) and serous 
ovarian carcinoma (SOC) stained for different proteins by immunohistochemistry. Case numbers correspond 
to the cases summarized in Tables 1 & 2. Abbreviations: HE, hematoxylin-eosin staining; ER, estrogen receptor; 
PR, progesterone receptor.
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Chapter 9, figuur 1: het vrouwelijke voortplantingsstelsel.
